GENE DISCOVERY FOR DISEASE MODELS
ffirs01.indd i
1/12/2011 9:44:45 AM
GENE DISCOVERY FOR DISEASE MODELS Edited by
Weikuan Gu and Yongjun Wang
A JOHN WILEY & SONS, INC., PUBLICATION
ffirs02.indd iii
1/12/2011 9:44:45 AM
Copyright © 2011 by John Wiley & Sons, Inc. All rights reserved Published by John Wiley & Sons, Inc., Hoboken, New Jersey Published simultaneously in Canada No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permission. Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages. For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002. Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com. Library of Congress Cataloging-in-Publication Data: Gene discovery for disease models / edited by Weikuan Gu and Yongjun Wang. p. ; cm. Includes bibliographical references and index. ISBN 978-0-470-49946-7 (cloth) 1. Medical genetics. 2. Mutation (Biology) 3. Genomics. 4. Genetic disorders. I. Gu, Weikuan and Yongjun Wang. [DNLM: 1. Genetic Association Studies–methods. 2. Models, Genetic. 3. Mutation. QU 450] RB155.G3584 2011 616′.042–dc22 2010028355 Printed in Singapore. 10
ffirs03.indd iv
9
8
7
6
5
4
3
2
1
1/12/2011 9:44:45 AM
CONTENTS
Preface
vii
Acknowledgments
ix
Contributors
xi
1. Gene Discovery: From Positional Cloning to Genomic Cloning
1
Weikuan Gu and Daniel Goldowitz
2. High-Throughput Gene Expression Analysis and the Identification of Expression QTLs
11
Rudi Alberts and Klaus Schughart
3. DNA Methylation in the Pathogenesis of Autoimmunity
31
Xueqing Xu, Ping Yang, Zhang Shu, Yun Bai, and Cong-Yi Wang
4. Cell-Based Analysis with Microfluidic Chip
59
Wang Qi and Zhao Long
5. Missing Dimension: Protein Turnover Rate Measurement in Gene Discovery
83
Gary Guishan Xiao
6. Bioinformatics Tools for Gene Function Prediction
93
Yan Cui
7. Determination of Genomic Locations of Target Genetic Loci
111
Bo Chang
8. Mutation Discovery Using High-Throughput Mutation Screening Technology
139
Kai Li, Hanlin Gao, Hong-Guang Xie, Wanping Sun, and Jia Zhang
9. Candidate Screening through Gene Expression Profile
165
Michal Korostynski
10. Candidate Screening through High-Density SNP Array
195
Ching-Wan Lam and Kin-Chong Lau
11. Gene Discovery by Direct Genome Sequencing
215
Kunal Ray, Arijit Mukhopadhyay, and Mainak Sengupta v
ftoc.indd v
1/12/2011 9:44:46 AM
vi
CONTENTS
12. Candidate Screening through Bioinformatics Tools
235
Song Wu and Wei Zhao
13. Using an Integrative Strategy to Identify Mutations
261
Yan Jiao and Weikuan Gu
14. Determination of the Function of a Mutation
279
Bouchra Edderkaoui
15. Confirmation of a Mutation by Multiple Molecular Approaches
303
Hector Martinez-Valdez and Blanca Ortiz-Quintero
16. Confirmation of a Mutation by MicroRNA
343
Hongwei Zheng and Yongjun Wang
17. Confirmation of Gene Function Using Translational Approaches
371
Caroline J. Zeiss
18. Confirmation of Single Nucleotide Mutations
391
Jochen Graw
19. Initial Identification and Confirmation of a QTL Gene
403
David C. Airey and Chun Li
20. Gene Discovery of Crop Disease in the Postgenome Era
425
Yulin Jia
21. Impact of Genomewide Structural Variation on Gene Discovery
443
Lisenka E.L.M. Vissers and Joris A. Veltman
22. Impact of Whole Genome Protein Analysis on Gene Discovery of Disease Models
471
Sheng Zhang, Yong Yang, and Theodore W. Thannhauser
Index
ftoc.indd vi
531
1/12/2011 9:44:46 AM
PREFACE
The availability of an annotated mouse genome sequence now provides the most efficient tool yet in the gene hunter’s toolkit. One can move directly from genetic mapping to identification of candidate genes, and the experimental process is reduced to PCR amplification and sequencing of exons and other conserved elements in the candidate interval. With this streamlined protocol, it is anticipated that many decades-old mouse mutants will be understood precisely at the DNA level in the near future.
This paragraph, from Initial Sequencing and Comparative Analysis of the Mouse Genome (2002) by the Mouse Genome Sequencing Consortium, summarizes the historical transition in both the strategy and the direction of gene discovery. It describes the tremendous changes in our protocols for positional cloning and announces the evolution of positional gene cloning. Positional gene cloning no longer requires years of teamwork to achieve. In fact, it is now possible for just one laboratory to identify several genes within one year. This not only is an extraordinary milestone but also is an opportunity for a new starting point for better comprehending the biological function(s) of genes throughout the whole genome. The implication of such a statement should also have similar results with the identification of mutated genes from human diseases and animal models once genome sequencing is completed for them as well. More than half a decade has passed since that paragraph’s publication. We are pleased to prepare a book detailing a new set of concepts and protocols representing the current progress in gene discovery. One goal of this book is to provide readers with a comprehensive understanding of the new concepts and protocols implemented in gene discovery in the present post-genome era. The dramatic progress of gene discovery is built on tremendous resources, such as genome sequences, literature, and databases as well as technologies such as high-throughput gene expression platforms and mutation-screening systems. With the availability of whole genome sequences, molecular markers can be precisely located on the genome and within a particular region of interest. In addition, every genomic element can be obtained easily through genome databases. Online literature and databases for gene information allow a quick search for a specific gene’s function. Large databases on gene expression profiles created by microarray data provide information on both gene expression levels and the specificity of almost every gene vii
fpref.indd vii
1/12/2011 9:44:46 AM
viii
PREFACE
in humans and major organisms. High throughput mutation screening systems are capable of identifying mutations from hundreds of genes with a minimal time frame. This book not only provides a systematic introduction to the available resources and technologies for gene discovery but, most important, teaches readers how to use all the available tools and data to find new mutated genes. Another goal of this book is to predict the future of gene discovery. We intend to let readers not only understand the current concepts and technologies but also learn how to take advantage of these new resources and technologies in the future—namely, the ability to adapt to new discoveries in genetic sciences. In the post-genome era, a good geneticist should be able to use these rapidly accumulating genome resources and incredibly rapidly developed new biotechnologies effectively and efficiently. The large amount of benchwork now produces tens of thousands of times more data than was possible decades ago. Gene discovery to a certain degree is data collection and analysis from large resources. We do not expect that every reader will be able to predict the future of genetic research, but we do hope that, by reading this book, readers can sharpen their minds in preparation for expected or unexpected challenges in this booming era of genomic research. This book can be used as a handbook for gene cloning and discovery as well as a reference book for teachers and students in the fields of genetics and biology. Weikuan Gu and Yongjun Wang
fpref.indd viii
1/12/2011 9:44:46 AM
ACKNOWLEDGMENTS
We thank everyone who contributed to this book for their dedicated work in making this book available. This is a unique, international team with strong scientific background and broad experience. We appreciated the discussions and exchanging of ideas during the preparation of each chapter. We would like to thank the following people for kindly reviewing the chapters for this book: Beth Bennett, Cong-Yi Wang, Daniel Goldowitz, David C. Airey, Griffin Gibson, Junming Yue, Qing Xiong, and Yan Cui. Special thanks to Drs. Bruce Roe, Hongwen Deng, Xinmin Li, Xingen Lei, and Wesley Beamer for their suggestions and kind support during the preparation of this book. We appreciate the assistance of David L. Armbruster and Griffin Gibson for their contributions in editing the chapters and, finally, we would also like to thank Griffin Gibson, XiaoYue Liu, Lishi Wang, and Yue Huang for their assistance in formatting the chapters.
ix
flast01.indd ix
1/12/2011 9:44:46 AM
CONTRIBUTORS
David C. Airey, Department of Pharmacology, Vanderbilt University School of Medicine Nashville, TN, United States Rudi Alberts, Department of Infection Genetics, Helmholtz Center for Infection Research & University of Veterinary Medicine, Hannover, Germany Yun Bai, Department of Medical Genetics, Third Military Medical University, Chongqing, China Bo Chang, Jackson Laboratory, Bar Harbor, ME, United States Yan Cui, Department of Molecular Sciences, University of Tennessee Health Science Center, Memphis, TN, United States Bouchra Edderkaoui, School of Medicine, Loma Linda University, Loma Linda, CA, and Research Scientist, Musculoskeletal Disease Center, JLP Memorial VA Medical Center, Loma Linda, CA, United States Hanlin Gao, DNA core, City of Hope National Medical Center, Duarte, CA, United States Daniel Goldowitz, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada Jochen Graw, Helmholtz Center Munich, German Research Center for Environmental Health, Institute of Developmental Genetics, Neuherberg, Germany Weikuan Gu, Department of Orthopedic Surgery—Campbell Clinic, University of Tennessee Health Science Center, Memphis, TN, United States Yulin Jia, USDA-ARS Dale Bumpers National Rice Research Center, University of Arkansas, Stuttgart, AR, United States Yan Jiao, Department of Orthopedic Surgery—Campbell Clinic, University of Tennessee Health Science Center, Memphis, TN, United States xi
flast02.indd xi
1/12/2011 9:44:46 AM
xii
CONTRIBUTORS
Michal Korostynski, Department of Molecular Neuropharmacology, Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland Ching-Wan Lam, Department of Pathology, the University of Hong Kong, Queen Mary Hospital, Hong Kong, China Kin-Chong Lau, Department of Pathology, the University of Hong Kong, Queen Mary Hospital, Hong Kong, China Chun Li, Department of Biostatistics, Vanderbilt University School of Medicine Nashville, TN, United States Kai Li, Department of Pharmacology, Suzhou University, Suzhou, Jiangsu, China Zhao Long, Respiratory Department, The Second Hospital Affiliated with Dalian Medical University, Dalian, China Hector Martinez-Valdez, Department of Immunology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States Arijit Mukhopadhyay, Genomics & Molecular Medicine, Institute of Genomics & Integrative Biology (CSIR), Delhi, India Blanca Ortiz-Quintero, Department of Immunology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States Wang Qi, Respiratory Department, The Second Hospital Affiliated with Dalian Medical University, Dalian, China Kunal Ray, Molecular & Human Genetics Division, Indian Institute of Chemical Biology (CSIR), Kolkata, India Klaus Schughart, Department of Infection Genetics, Helmholtz Center for Infection Research & University of Veterinary Medicine, Hannover, Germany Mainak Sengupta, Molecular & Human Genetics Division, Indian Institute of Chemical Biology (CSIR), Kolkata, India Zhang Shu, The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China Wanping Sun, Department of Pharmacology, College of Pharmacy, Suzhou University, Suzhou, Jiangsu, China Theodore W. Thannhauser, Proteomics and Mass Spectrometry Core Facility, Robert W. Holley Center for Agriculture & Health, USDA-ARS, Cornell University, Ithaca, NY, United States Joris A. Veltman, Radboud University Nijmegen Medical Centre, Nijmegen Centre of Molecular Life Sciences, Department of Human Genetics, Nijmegen, The Netherlands
flast02.indd xii
1/12/2011 9:44:46 AM
CONTRIBUTORS
xiii
Lisenka E.L.M. Vissers, Radboud University Nijmegen Medical Centre, Nijmegen Centre of Molecular Life Sciences, Department of Human Genetics, Nijmegen, The Netherlands Cong-Yi Wang, The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta, GA, United States Yongjun Wang, Beijing Tiantan Hospital, Capital Medical University, Beijing, China Song Wu, Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, TN, United States Gary Guishan Xiao, Hospital Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China Hong-Guang Xie, Hospital Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China Xueqing Xu, Department of Medical Genetics, Third Military Medical University, Chongqing, China Ping Yang, The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China Yong Yang, Proteomics and Mass Spectrometry Core Facility, Robert W. Holley Center for Agriculture & Health, USDA-ARS, Cornell University, Ithaca, NY, United States Caroline J. Zeiss, Department of Comparative Medicine, Yale School of Medicine, New Haven, CT, United States Jia Zhang, DNA core, GNF Institute, San Diego, CA, United States Sheng Zhang, Proteomics and Mass Spectrometry Core Facility, Robert W. Holley Center for Agriculture & Health, USDA-ARS, Cornell University, Ithaca, NY, United States Wei Zhao, Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, TN, United States Hongwei Zheng, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
flast02.indd xiii
1/12/2011 9:44:46 AM
Figure 2.2. A microarray produced by a scanner. Each of the spots on the microarray represents a gene, and the color represents the amount of fluorescence that is measured, hence the amount of cDNA that was present in the original sample. Reprinted from Reinke (2006).
bins.indd 1
1/12/2011 9:43:43 AM
(a)
2
1
3
(c)
trans A B
1
(b)
A
cis
2
3
B
high
RILs
low
Figure 2.8. (a) The genomewide genotypes of eight recombinant inbred lines generated from a cross between two homozygous parents (A and B). Each row indicates the genome of a single RIL. The light or dark gray color in each of the RILs indicates whether that part of its genome was inherited from parent A or B. (b) Gene expression values are determined by microarrays. Four values are shown for each parent and one value for each of the RILs. (c) For three molecular markers, the gene expression values of the RILs are dissected into two groups, according to the allele they carry for that molecular marker (light or dark gray). A statistical test of each marker location calculates whether the means of both groups differ. The significances of the tests are plotted in a genomewide plot as a QTL plot. Here, a QTL peak is found for the second marker. Triangles in the QTL plot indicate the position of the gene, whose expression was used. If the gene coincides with the QTL peak, the QTL is referred to as a cis-QTL, otherwise, it is called a trans-QTL. Adapted from Alberts et al. (2005) by permission of Oxford University Press.
bins.indd 2
1/12/2011 9:43:44 AM
GTGTGTATGGTTGGGTGTTTTTGGGGTGGGTAGGGAGGTGT
GCGCGTACGGTCGGGCGTTTTTGGGGTGGGTAGGGAGGCGC
Figure 3.2. Bisulfite-specific PCR and direct sequencing. Genomic DNA underwent bisulfite conversion followed by PCR amplification. The resulting PCR products were then purified and directly sequenced. The results at the left are from the unmethylated DNA; the results at the right are for the methylated DNA.
bins.indd 3
1/12/2011 9:43:44 AM
(a)
Staurosporine
Microsyringe pump
TLM detection (532 nm)
Drain X-Y scanning stage
Cell culturing flask 30 µm
(b) 9–10 8–9
30 µm
7–8 6–7 5–6 4–5 3–4 2–3 1–2 0–1 + Staurosporine
Figure 4.4. A single-cell analysis system in a glass microchip using a thermal lens microscope (TLM). (a) Cell culture chip design and TLM scanning method. A microflask (1 mm × 10 mm × 0.1 mm) was fabricated in a glass microchip, and a cell suspension was introduced into it. After cultivation, the microchip with capillaries connected to syringe pumps was mounted on the TLM stage, and TLM signals were measured while scanning the stage to obtain a 2D-image. (b) Direct imaging of cytochrome-c in a cell and its distribution change during apoptosis (Tamaki et al., 2002).
bins.indd 4
1/12/2011 9:43:44 AM
(a)
A23187 concentrations
1 2 3 4 5 6 7 8
Low 0.0 µM
0.86 µM
1.71 µM
High 2.57 µM
(a) 3.42 µM
(b) 4.28 µM
(c) 5.13 µM
(d) 6.00 µM
(e)
(f)
(g)
(h)
a b c d e f g h
Cell culture chambers
Normalized fluorescence intensity per Cell
(b) 140.00 130.00 120.00 110.00 100.00 90.00 80.00 70.00 60.00 0.00
0.86
1.71
2.57
3.42
4.28
5.13
6.00
A23187 Concentrations (µM)
Figure 4.5. The expression of GRP78 on a protein level by immunofluorescence in SK-MES-1 cells. (a) Cells were treated with A23187 for 24 h and observed by fluorescence microscope (IX-71; Olympus Optical Co., Tokyo, Japan) (×400). The fluorescent indicated GRP78 in the cytoplasm. (b) The average expression of GRP78 per cell reflected by normalized fluorescent intensities increased with the concentrations of A23187. The normalized fluorescent intensities per cell were determined by the number of cells in a region divided by the fluorescent intensity in that region (Wang et al., 2009).
bins.indd 5
1/12/2011 9:43:44 AM
bins.indd 6
1/12/2011 9:43:45 AM
Figure 6.3. Function annotation with Blast2GO. In this example, 10 sequences are annotated. The upper panel shows the annotations transferred from homologous sequences. The lower panel shows the part of GO DAG containing the annotation terms assigned to the query sequences. Node color represents the annotation intensity.
(a) PCR
Conformation
(b)
Electrophonesis
Variant (2677T, Ser893) MDR1*1 (2677G, Ala893)
Figure 8.1. (a) Band patterns of single-stranded PCR products as visualized on a gel differ with the change in their conformations. (b) An example of how to identify two variants in the MDR1 gene using SSCP. (Kim et al., 2001.)
Model system
Clinical samples
Gene expression profiling
List of transcripts
Co-expression of genes
Association with phenotype
Mechanism of regulation
Gene expression signature
Gene function
Validation
Candidate drug targets
Candidate biomarkers
Discovery of new drug
Discovery of new diagnostic marker
Figure 9.1. Major concepts in gene transcription profiling.
bins.indd 7
1/12/2011 9:43:47 AM
(a)
14 10
12
Log intensity
5 0 –5 0
5
10
6
8
–10
Intensity ratio
10
16
(b)
15
1
Average intensity (c)
3
4
5
6
10 5 –5
0
0.0
0.5
Log-odds ratio
15
1.0
(d)
–0.5
Sample quantiles
2
–3
–2
–1
0
1
2
3
–4
–2
Theoretical quantiles (e)
0 2 4 Log2 fold change
6
(f) 0.6 0.4
PCA2
0.2 0
Class 1
–0.2 –0.4 Class 2
–0.6 –0.8 –1.0 –1.5
–1
–0.5
0
0.5
1
PCA1
Figure 9.4. Various methods of presentation of microarray quality control and data analysis. (See text for full caption.)
bins.indd 8
1/12/2011 9:43:47 AM
–4
–1
0
+1
+4
MMA
MMA
MMA
MMA
MMA
PMA
PMA
PMA
PMA
PMA
PMB
PMB
PMB
PMB
PMB
MMB
MMB
MMB
MMB
MMB
Target sequence (250-2000 bp) ... CAGACAGAGTCTTG[A/C]AATCTATTTCTCATA... Probe sequence (25 bp)
AA
PMA:
TGTCTTCAGAACTTTAGATAAAGAG
MMA:
TGTCTTCAGAACATTAGATAAAGAG
PMB:
TGTCTTCAGAACGTTAGATAAAGAG
MMB:
TGTCTTCAGAACCTTAGATAAAGAG
BB
AB
Figure 10.1. Probe array tiling and hybridization patterns (from Affymetrix).
bins.indd 9
1/12/2011 9:43:47 AM
Standard PCR protocol — 48 or 96 per batch Modified PCR protocol — no batch size limitation 1. Pool 700 µl PCR into deep well plate
1. Pool 700 µl PCR into 2-mL microcentrifuge tube
2. Add 1 ml magnetic beads
2. Add 1 ml magnetic beads
3. Pipetting up & down 5×; Incubate 10 min @ RT
3. Pipetting up & down 5×; Incubate 10 min @ RT
4. Transfer PCR + beads to filter plate
4. Place on magnetic stand for 10 min
5. Apply vacuum until all wells are dry (60–90 min)
5. Pipette out the supernatant
6. Add 1.8 mL 75% ethanol wash
6. Add 1.8 mL 75% ethanol wash
7. Apply vacuum until all wells are dry (10–20 min)
7. Vortex at 75% power for 2.5 min; incubate 7.5 min
8. Dry beads for further 10 min under vacuum
8. Place on magnetic stand for 10 min
9. Tap-off excess ethanol & attach catch plate
9. Pipette out the supematant; air-dry for 15 min
10. Add 55 µl elution buffer
10. Add 55 µL elution buffer
11. Incubate on vortexer for 10 min
11. Vortex at 75% power for 2.5 min; incubate 7.5 min
12. Apply vacuum until all wells are dry (15–30 min)
13. Centrifuge for 5 min at 1400 RCF @ RT
12. Place on magnetic stand for 10 min 13. Collect the eluate (~55 µL)
14. Remove catch plate with eluate (~50 µL)
Figure 10.3. Comparing PCR purification workflow between the Affymetrix standard and our modified protocols.
bins.indd 10
1/12/2011 9:43:47 AM
Figure 10.10. Identification of homozygous DYFS mutations in the homozygous region detected by SNP Array 6.0 (Lau et al., 2009).
bins.indd 11
1/12/2011 9:43:47 AM
(a)
Shearing of genomic DNA
End repairing of sheared DNA
Adapter mediated PCR enrichment of fragments
Addition of dATP at the 3’ends
Purification
Adapter ligation
(b) + Prepared Library
+ Hybridization Buffer
Biotinylated Probes
Optimum Temperature Regulation Hybridization Streptavidin Coated Magnetic Beads
+
Unbound Fraction Discarded
Wash Beads and Remove Probes
Bead Capture Amplify Sequencing
Figure 11.2. The hybridization-based sequencing method. (a) Genomic DNA is sheared and end repaired or modified. A poly-A tail is added to the fragments, adapters are ligated to the 3′-end of the fragments, and excess adapters or unligated primers are removed. The amplicons are purified, and adapter-specific PCR amplification is done to enrich the product pool to prepare a library. (b) The prepared library is hybridized with relevant biotinylated probes (specific sequences, whole exome, etc.) in solution in a hybridization array. The probes bind to the relevant sequences from the library. Then streptavidin-coated magnetic beads are released in the array, and a magnet is used to capture biotinylated probes bound to their complementary sequences. Those specific sequences can then be sequenced in appropriate platform. [Panel (b) of the illustration has been adapted from Protocol version 1.0.1, October 2009; SureSelect Human All Exon Kit from Agilent Technologies.]
bins.indd 12
1/12/2011 9:43:48 AM
(a)
(b) Primer library
(c)
Genomic DNA template
Microfluidic chip
1
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y
8 7
2
Droplet PCF
Genomic DNA
Break emulsion
3
gDNA removal
5
9 Fragmentation and nick translation
4
Sequence
6
Figure 11.3. Microdroplet PCR workflow. (a) Primer library generation: 1, Identify targeted sequences of interest in the genome. 2, Design and synthesize forward and reverse primer pairs for each targeted sequence (library element). 3, Generate primer pair droplets for each library element. A microfluidic chip is used to encapsulate the aqueous PCR primers in inert fluorinated carrier oil with a block-copolymer surfactant to generate the equivalent of a picoliter-scale test tube compatible with standard molecular biology. 4, Mix primer pair droplets of library elements together so that each library element has an equal representation. (b) Genomic DNA template mix preparation: 5, Biotinylate (red dots), fragment into 2- to 4-kb fragments, and purify genomic DNA. 6, Mix purified genomic DNA together with all of the components of the PCR reaction (DNA polymerase, dNTPs and buffer) except for the PCR primers. (c) Droplet merge and PCR: 7, Dispense primer library droplets to the microfluidic chip. 8, Deliver the genomic DNA template as an aqueous solution; template droplets are formed within the microfluidic chip. Then pair the primer pair droplets and template droplets in a 1:1 ratio. 9, Allow the paired droplets to flow through the channel of the microfluidic chip and pass through a merge area, where an electric field induces the two discrete droplets to coalesce into a single PCR droplet. Collect ∼1.5 million PCR droplets in a single 0.2-mL PCR tube. Process the PCR droplets (PCR library) in a standard thermal cycler for targeted amplification; break the emulsion of PCR droplets to release the PCR amplicons into solution for genomic DNA (gDNA) removal, purification, and sequencing. (Reprinted by permission from Macmillan Publishers Ltd: Nature Biotechnology, Tewhey et al., Microdroplet-based PCR enrichment for largescale targeted sequencing, 27, 1025–1031, 2009.)
bins.indd 13
1/12/2011 9:43:49 AM
A
B
A CGT
A T T C G A T A T CA A GC T T A TC G A T AC C G T C G A C C T
Figure 15.1. Manual Versus Automated DNA Sequencing. (A) Shows acrylamide gel electrophoresis results resolving typical chain termination reactions (Ho et al. unpublished data). Each lane corresponds to a designated reaction terminated with ddATP (A), ddCTP (C), ddGTP (G) and ddTTP (T) analogs (Ho et al. unpublished), which identifies respective nucleotides on target DNA template. (B) Depicts a color-coded chromatogram of typical automated DNA sequencing data (Albrechtson et al. unpublished).
Figure 15.2. Chromosome locus assignment of a newly discovered gene. Fluorescent in situ hybridization analysis, using a biotin-labeled genomic probe, which reveals the new gene at the 9q32 locus (Sims-Mourtada et al., 2005) upon binding of fluorescent Streptavidin (shown herein as pseudo yellow fluorescence) against DAPI (blue fluorescence) background. Arrows emphasize gene locus assignment on respective chromosome 9 alleles.
bins.indd 14
1/12/2011 9:43:49 AM
(a)
(b)
Figure 15.3. Gene Expression by Histological Methods. (See text for full caption.)
bins.indd 15
1/12/2011 9:43:50 AM
WT
rd-1
ONL
ONL
Figure 17.2. WT and rd-1 mouse retina at postnatal day 12. In rd-1 mice, a mutation in the cyclic phosphodiesterase beta gene results in rapid loss of the outer nuclear layer in the first 3 weeks of life.
bins.indd 16
1/12/2011 9:43:52 AM
CHAPTER 1
Gene Discovery: From Positional Cloning to Genomic Cloning WEIKUAN GU and DANIEL GOLDOWITZ
Contents 1.1 Concept of Classic Positional Cloning 1.2 Concept of Gene Discovery in the Post-Genome Era 1.3 Strategies for Gene Discovery in the Post-Genome Era 1.4 Future Direction 1.5 References
1 4 5 6 7
Despite the highly significant advances in studying the genetics and genomics of human populations, there are still large gaps in our understanding of the molecular genetic mechanisms involved in the pathogenesis of many human diseases. The mutated genes in many human diseases remain unknown. Identification of these mutations is crucial for correlating disease pathology and biology to the molecular basis of the disease. Discovery of new gene functions depends on the identification of the mutated genes responsible for disease in humans and other species. The techniques of positional cloning have oftentimes discovered new functions of known genes or new genes for known diseases. The goal of this book is to provide illustrations of the strategy in the post-genomic era for the identification and initial characterization of mutated genes in inherited human diseases and animal models.
1.1
CONCEPT OF CLASSIC POSITIONAL CLONING
Positional cloning, also called reverse genetics, is the identification and cloning of a specific gene, with its chromosomal location being the only available Gene Discovery for Disease Models, First Edition. Edited by Weikuan Gu, Yongjun Wang. © 2011 John Wiley & Sons, Inc. Published 2011 by John Wiley & Sons, Inc.
1
c01.indd 1
1/12/2011 9:43:53 AM
2
GENE DISCOVERY: FROM POSITIONAL CLONING TO GENOMIC CLONING
Collection of phenotype information
Collection of genotype information
Initial mapping of trait locus
Fine mapping of trait locus
Genomic contig construction
Analysis of genomic elements
Selection of candidate genes
Conformation of candidate genes
Figure 1.1. Procedure of identification of a mutated gene using strategy of classic positional cloning.
information about that gene (Collins, 1990). The identification of the X-linked gene for chronic granulomatous disease in 1986 was the first report employing such a strategy (Baehner et al., 1986; Royer-Pokora et al., 1986). For the past several decades, positional cloning has been widely used in humans, animals, and plants to isolate genes known only by their phenotypic effects. Underlying positional cloning is the assumption that a gene’s location can be pinpointed with sufficient precision to narrow down its location to a DNA segment that is small enough to be sequenced and/or subjected to transformation/complementation experiments. The classic procedure for positional cloning usually includes several steps as shown in Figure 1.1. It starts with the phenotype collection from a genetically mappable population. The population genetics necessary for creating the mappable population is beyond the scope of this chapter (Holsinger and Weir, 2009; Zou, 2009). Briefly, however, a mutant phenotype can be genetically mapped when (1) the phenotype shows Mendelian inheritance, (2) the phenotype is differentially distributed among individuals within the population, and (3) a population is large enough to reach a statistical significance when the phenotype is analyzed using mapping software. Parallel to the phenotype collection, genotype information of the same individuals in the same popula-
c01.indd 2
1/12/2011 9:43:53 AM
CONCEPT OF CLASSIC POSITIONAL CLONING
3
tion is collected. Usually, molecular markers that segregate in the population along each and every chromosome are analyzed. The collected phenotype and genotype data from the population are used in conducting linkage analysis by one of a variety of softwares to define the chromosomal regions that the locus is likely to occupy. If a trait is controlled by a single gene or locus, the linkage analysis should point to a single chromosomal region. For traits regulated by multiple genes, multiple loci, or quantitative trait loci, multiple chromosomal regions are identified. To actually identify the gene underlying the trait of interest, fine mapping has to be conducted to narrow down the chromosomal regions so that genomic searching is practical. The next step, then, is to construct a genomic contiguous region (contig), which is defined as a set of overlapping segments of DNA, to connect and cover all the genomic elements in the targeted area. After a precise contig is constructed, it will be sequenced and analyzed by a technique termed chromosomal walking. This is a lengthy procedure that involves the recognition of potential genes, noncoding genes, and/or coding and noncoding regions. Finally, potential candidate genes should be confirmed using a variety of genetic and biochemical methods. Because all of these procedures require a large amount of work, positional cloning typically requires a team effort and positional cloning projects have been known to take many years. First, the genetic region needs to be narrowed down as precisely as possible by means of initial linkage analysis and fine mapping. Second, linkage analysis requires both the availability of a large pedigree and PCR-based analysis of microsatellite markers of that pedigree to allow a whole-genome search for linkage. Fine mapping is a particularly difficult task consisting of breaking the linkage and identifying useful markers in the targeted region. Contig construction entails identification of a large insert genomic library, either BAC (bacterial artificial chromosomes) or YAC (yeast artificial chromosomes), with known markers. Analysis of genetic elements within a contig can be very difficult because of the lack of knowledge of both genes and gene organization. However, the recent completion of the human and mouse genome projects (e.g., Mouse Genome Sequencing Consortium. 2002), along with other new technology, such as mutation analysis and microarrays, allows unprecedented progress in positional cloning of mutant genes. There are four major changes in the technique of positional cloning (Hinkes et al., 2006): (1) Contig construction is no longer needed because of the availability of whole genomes that have been sequenced. (2) Sequencing of an entire region—usually 10 Mbp of the genome, is no longer necessary, as those sequences are now readily available through public (Ensembl) and private databases (Celera). (3) Sequence analysis requires much less time and effort since annotations of whole genomes have been done (e.g., we now know that the majority of the mouse genome is made up of repetitive sequences, such as transposons, that are easy to identify and, therefore, can be eliminated from further analysis). (4) Because of the availability of whole genome sequences and high-throughput
c01.indd 3
1/12/2011 9:43:53 AM
4
GENE DISCOVERY: FROM POSITIONAL CLONING TO GENOMIC CLONING
technologies, we can now work on a much larger genomic regions, which eliminates fine mapping. (5) Annotations of genomes and bioinformatic algorithms has paralleled the rapid acquisition of genomic data and has permitted an in silico assessment of candidate genes. This is the major theme of this book. As a result of new high-throughput technologies and whole-genome libraries, a genome-based integrative strategy is the most practical method for gene discovery in our current post-genome era (Gu et al., 2002; Jiao et al., 2005a, 2005b, 2007, 2008). Consequently, pure positional cloning in humans, animals, or plants is no longer necessary. The definition of positional cloning is cloning or identifying a gene with specific function purely according to its position. In humans, mice, and rats it is rare to localize mutations to a gene or the expression of that gene is unknown. For example, microarray technology has arrayed every gene into their chips. As a result, microarray analysis of gene expression profiles has become routine in many laboratories. Therefore, soon we may find out that expression data of every gene in every tissue is available to public. Thus, for any gene, even if nothing else is known about that gene, its expression level in a tissue can be assessed. As such, the classic positional cloning method is of little utility in the rapidly evolving arena of functional genomics. A new procedure that integrates both genomic and high-throughput technology has been created and will be, and should be, the next generation’s tool of choice.
1.2
CONCEPT OF GENE DISCOVERY IN THE POST-GENOME ERA
The strategy for gene discovery using positional cloning depends on the availability of genetic-based data and technology. The new approach for gene discovery is highly integrative and is based on the availability of genome resources and biotechnology (Rintisch et al., 2008). There are three distinct and significant differences between new gene discovery strategies and classical positional cloning. The first one is the elimination of fine mapping. Rather than narrowing down the genomic regions using several approaches, a large number of genomic regions can be searched to discover the genes of interest all at once. The second is the direct investigation of genetic elements within the targeted region, without construction of contig or sequencing, because of the availability of genomic sequences and annotation of genomic elements. The third one is the high-throughput screening of candidates within the targeted region. The high-speed analytical methods include mutation screening, resequencing, and both gene expression profiling and functional predictions (Jiao et al., 2008). The following chapters provide detailed information on each of those aspects. The first part of this book introduces the technologies and resources used in gene discovery in our post-genome era. The second part of this book provides experimental procedures and methodologies for gene discovery using both genome resources and high-
c01.indd 4
1/12/2011 9:43:53 AM
STRATEGIES FOR GENE DISCOVERY IN THE POST-GENOME ERA
5
throughput technologies. The third and final part of this book predicts the future direction of gene discovery based on the elucidation of genomes and developing technologies. We are living in an era of both technology explosion and unparalleled expansion of biological resources. of the advances in gene discovery, however, are rooted in the technology of genome sequencing. Without the completion of whole genome sequences for humans and other species, gene discovery would still be stuck in the classic positional cloning approach. Therefore, gene discovery in every chapter is based on the fact that genomic sequences are available for the subjects of interest. Parallel with the necessity of completed genomes is the demand for, and rapid development of, high-throughput technologies necessary for mutation screening, genome analysis, and bioinformatics. Without these tools, there would be no effective method for capitalizing on the completion of whole genomes and for allowing our current rapid methods for gene discovery. Due to the significance of these various technologies, Chapters 2–4 introduce these technologies. Chapters 2–6 illustrate a variety approaches, including SNP analysis, DNA methylation, protein turnover rate measurement, microarray analysis, and bioinformatic tools. Finally, the integrative analysis of data from a variety procedures provides clues for potential candidate genes for the follow-up experiments, such as RT-PCR, DNA sequencing of the potential mutation(s), and/or northern or western blot analysis to determine the significance of the mutated gene. An important reminder to readers is that although this book mainly focuses on coding sequences known as genes, mutations in many other genetic elements could be identified using the same or similar technologies or procedures. Those none-gene elements of the genome include not only the introns, 5′ and 3′ ends of the genes, but also many others (Chen et al., 2008), such as transcription factor binding sites, microRNAs, cis-acting elements, palindromic motifs, and/or conserved k-tuples (phylogenetic footprints) (Hui and Bindereif, 2010). Readers should keep in mind that gene regulation is a complicated process and regulators are not necessarily near the genes that they influence. They can be located at long distances, called distant regulatory elements (REs) (Gotea and Ovcharenko, 2008), such as enhancers, repressors, and silencers. In addition, repetitive sequences sometimes play unexpected roles in gene regulations (Hui and Bindereif, 2005).
1.3 STRATEGIES FOR GENE DISCOVERY IN THE POST-GENOME ERA Current experimental procedure strategies for mutation screening have been summarized (Jiao et al., 2008) and are shown in Figure 1.2. Individual chapters in this book focus on one or more steps or different approaches of this strategy. We briefly touch on screening for mutations in DNA in this introduction using
c01.indd 5
1/12/2011 9:43:53 AM
6
GENE DISCOVERY: FROM POSITIONAL CLONING TO GENOMIC CLONING
Identify mutation models and chromosomes of their disease loci Bioninformatic search
Screen of coding regions Whole genome sequencing Determination of mutated gene Knockdown
Gene network
Knockin
Function elucidation of mutated genes
Figure 1.2. Strategy of gene discovery through mutation models.
the mouse as the model. Detailed procedure and methodologies are presented in Chapters 7–13. The first step is to determine the total number of genes/transcripts within the targeted region. Chapter 7 describes the genetic markers and methods for determine the genomic location of target genetic loci. Any of the many recently developed software programs (see, for example, www.genediscovery.org/ pgmapper/index.jsp; Xiong et al., 2008a) can be used to identify every candidate gene from a defined genomic region. The next step is to evaluate candidate genes to reduce the number of genes in the list to a more workable and feasible amount (Chapters 8–13). At this step, obvious candidate genes are first evaluated. We believe that a large number of differences exist between the gene of interest (GOI) in mutation and in wild type (control). Our current knowledge of gene function and bioinformatics should allow us to eliminate most of the unlikely candidate genes. Series of comparisons and function analyses should be made to rule out the candidacy of variation in introns sequences, if those sequences do not affect the phenotype (Chapters 11–13) At the end, a short list of candiate genes are expected or, in the best case senario, only one gene will remain. Finally, mutation evaluation or testing is carried out (Chapters 14–20). This evaluation considers differences between the GOI and control, sequence differences in these genes, potential gene function changes due to these differences, and whether other strains or populations have similar differences. Information on differences is combined with gene expression profiling and possible gene function to determine a list of candidate genes. Finally, selected candidate genes are tested and confirmed using a variety of experimental approaches, such as gene knockout and/or knockin.
1.4
FUTURE DIRECTION
Gene discovery or mutation identification has gone through two stages, as we have discussed: the classical and the post-genome era. The next stage of gene discovery will depend on development of high-throughput technology and
c01.indd 6
1/12/2011 9:43:53 AM
REFERENCES
7
Disease phenotype /trait of interest Mapping information (which chromosome)
Fine mapping (where on chromosome) Contig construction (DNA assembly) Search based on genome sequences (Small region) (Large region)
Figure 1.3. Different stages of positional cloning (from left to right): classic, postgenome era, and future (dashed blue line).
bioinformatic tools. As shown in Figure 1.3, in the first stage, positional cloning a GOI (the classical approach) has to go through every step, including initial mapping, fine mapping, contig construction, and candidate searching based on genome sequences. Currently at the second stage, in most cases, fine mapping and contig construction are not necessary because of the available information of genomic sequences and genetic elements within the targeted region. The next stage of genomic cloning will allow researchers to conduct a search of candidate genes without mapping information (shown as dashed lines in Figure 1.3). At that stage, once a phenotype is found from an animal model or an individual, a search of candidate genes can be done based on the annotation of every gene or regulatory element in the genome. To reach the next stage, two critical improvements in our genomic research are needed. The first one is the complete evaluation of potential function of every gene and regulatory element in the whole genome. This seemingly large amount of work is most likely to be done within a decade or even sooner, as technologies for the analysis of gene function, SNP analysis, and proteomics are rapidly developing. The second is the availability of software for rapid automatic high-throughput searching. Currently, some programs such as PGmapper (Xiong et al., 2008a) has provided the capability to search genome regions of several megabases. The capability of searching whole chromosomes and whole genomes within a reasonable time (under an hour) will follow development of computational tools in coordination with genome and literature databases.
1.5
REFERENCES
Baehner RL, Kunkel LM, Monaco AP, Haines JL, Conneally PM, Palmer C, Heerema N, Orkin SH. (1986). DNA linkage analysis of X chromosome-linked chronic granulomatous disease. Proc Natl Acad Sci U S A 83(10):3398–401. Chen HP, Lin A, Bloom JS, Khan AH, Park CC, Smith DJ. (2008). Screening reveals conserved and nonconserved transcriptional regulatory elements including an E3/
c01.indd 7
1/12/2011 9:43:54 AM
8
GENE DISCOVERY: FROM POSITIONAL CLONING TO GENOMIC CLONING
E4 allele-dependent APOE coding region enhancer. Genomics 92(5):292–300. Epub Sept. 3. Collins FS. (1990). Identifying human disease genes by positional cloning. Harvey Lect 86:149–64. Gotea V, Ovcharenko I. (2008). DiRE: identifying distant regulatory elements of coexpressed genes. Nucleic Acids Res 36:W133–39. Epub May 17. Gu W, Li X, Lau KH, Edderkaoui B, Donahae LR, Rosen CJ, Beamer WG, Shultz KL, Srivastava A, Mohan S, Baylink DJ. (2002). Gene expression between a congenic strain that contains a quantitative trait locus of high bone density from CAST/EiJ and its wild-type strain C57BL/6J. Funct Integr Genomics 1(6):375–86. Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D, Nürnberg G, Garg P, Verma R, Chaib H, Hoskins BE, Ashraf S, Becker C, Hennies HC, Goyal M, Wharram BL, Schachter AD, Mudumana S, Drummond I, Kerjaschki D, Waldherr R, Dietrich A, Ozaltin F, Bakkaloglu A, Cleper R, Basel-Vanagaite L, Pohl M, Griebel M, Tsygin AN, Soylu A, Müller D, Sorli CS, Bunney TD, Katan M, Liu J, Attanasio M, O’toole JF, Hasselbacher K, Mucha B, Otto EA, Airik R, Kispert A, Kelley GG, Smrcka AV, Gudermann T, Holzman LB, Nürnberg P, Hildebrandt F. (2006). Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 38(12):1397–405. Epub Nov. 5. Holsinger KE, Weir BS. (2009). Genetics in geographically structured populations: defining, estimating and interpreting F(ST). Nat Rev Genet 10(9):639–50. Hui J, Bindereif A. (2005). Alternative pre-mRNA splicing in the human system: unexpected role of repetitive sequences as regulatory elements. Biol Chem 386(12): 1265–71. Jiao Y, Li X, Beamer WG, Yan J, Tong Y, Goldowitz D, Roe B, Gu W. (2005a). Identification of a deletion causing spontaneous fracture by screening a candidate region of mouse chromosome 14. Mammal Genome 16(1):20–31. Jiao Y, Yan J, Zhao Y, Donahue LR, Beamer WG, Li X, Roe BA, Ledoux MS, Gu W. (2005b). Carbonic anhydrase-related protein VIII deficiency is associated with a distinctive lifelong gait disorder in waddles mice. Genetics Epub Aug. 22. Jiao Y, Yan J, Jiao F, Yang H, Donahue LR, Li X, Roe BA, Stuart J, Gu W. (2007). A single nucleotide mutation in Nppc is associated with a long bone abnormality in lbab mice. BMC Genet 8:16. Jiao Y, Jin X, Yan J, Zhang C, Jiao F, Li X, Roe BA, Mount DB, Gu W. (2008). A deletion mutation in Slc12a6 is associated with neuromuscular disease in gaxp mice. Genomics 91(5):407–14. Koppel I, Aid-Pavlidis T, Jaanson K, Sepp M, Palm K, Timmusk T. (2010). BAC transgenic mice reveal distal cis-regulatory elements governing BDNF gene expression. Genesis 48(4):214–19. Mouse Genome Sequencing Consortium. (2002). Initial sequencing and comparative analysis of the mouse genome. Nature 420:520–62. Rintisch C, Ameri J, Olofsson P, Luthman H, Holmdahl R. (2008). Positional cloning of the Igl genes controlling rheumatoid factor production and allergic bronchitis in rats. Proc Natl Acad Sci U S A 105(37):14005–10. Epub Sept. 8. Royer-Pokora B, Kunkel LM, Monaco AP, Goff SC, Newburger PE, Baehner RL, Cole FS, Curnutte JT, Orkin SH. (1986). Cloning the gene for an inherited human
c01.indd 8
1/12/2011 9:43:54 AM
REFERENCES
9
disorder—chronic granulomatous disease—on the basis of its chromosomal location. Nature 322(6074):32–38. Xiong Q, Qiu Y, Gu W. (2008a). PGMapper: a web-based tool linking phenotype to genes. Bioinformatics 24(7):1011–13. Epub Jan. 18. Xiong Q, Jiao Y, Hasty KA, Stuart JM, Postlethwaite A, Kang AH, Gu W. (2008b). Genetic and molecular basis of QTL of rheumatoid arthritis in rat: genes and polymorphisms. J Immunol 181(2):859–64. Xiong Q, Jiao Y, Hasty KA, Canale ST, Stuart JM, Beamer WG, Deng HW, Baylink D, Gu W. (2009). Quantitative trait loci, genes, and polymorphisms that regulate bone mineral density in mouse. Genomics 93(5):401–14. Zou F. (2009). QTL mapping in intercross and backcross populations. Methods Mol Biol 573:157–73.
c01.indd 9
1/12/2011 9:43:54 AM
CHAPTER 2
High-Throughput Gene Expression Analysis and the Identification of Expression QTLs RUDI ALBERTS and KLAUS SCHUGHART
Contents 2.1 Concepts in High-Throughput Gene Expression Analysis 2.2 Technologies of High-Throughput Gene Expression Analysis 2.2.1 Gene Expression Microarrays 2.2.2 One-Channel Versus Two-Channel Microarrays 2.2.3 Oligonucleotide Versus Spotted Microarrays 2.2.4 Whole-Transcript Arrays 2.2.5 Genome Tiling Arrays 2.2.6 MicroRNA Arrays 2.3 Protocols 2.3.1 Image Analysis 2.3.2 Normalization 2.3.3 Quality Control 2.4 Applications and Limitations 2.4.1 Identification of Expression QTL and Gene Regulatory Networks 2.4.2 Identification of Differentially Expressed Genes 2.4.3 Identification of Cell-Type-Specific Genes 2.4.4 Determination of the Downstream Effects of a Mutation 2.4.5 Determination of the Downstream Effects of a Signaling Molecule 2.4.6 Predicting Vaccine Efficacy 2.4.7 Determination of Host Responses after Infection 2.4.8 Limitations 2.5 Questions and Answers
12 13 13 13 14 15 16 16 17 17 17 20 23 23 26 26 26 27 27 27 27 28
Gene Discovery for Disease Models, First Edition. Edited by Weikuan Gu, Yongjun Wang. © 2011 John Wiley & Sons, Inc. Published 2011 by John Wiley & Sons, Inc.
11
c02.indd 11
1/12/2011 9:43:59 AM
12 2.6 2.7
HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS
Acknowledgments References
28 28
2.1 CONCEPTS IN HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS Many diseases have a genetic basis. Together with influences from the environment, these genetic factors determine whether a certain disease will develop and how severe it will be. In some cases, a disease is determined by only one gene. The sickle-cell disease, for example, is caused by a mutation in the hemoglobin gene. This causes red blood cells to adopt an abnormal sickle shape. It results in a risk of various complications and a shortened life expectancy. Another example of a single gene disease is cystic fibrosis. This disease affects the exocrine glands of the lungs, liver, pancreas, and intestines and results in progressive disability and a severely shortened life expectancy. It is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTCR) gene. However, in most human diseases, multiple genes play a role in the development of the pathological symptoms. Examples for these, so-called complex genetic diseases are cancer, obesity, diabetes, hypertension, asthma, and heart disease. Here, each gene contributes to a certain degree to the establishment of the phenotype. And we can assume that the contributing genes and their products operate in regulatory networks. They may enhance or inhibit each other. If multiple genes contribute to the development of a disease and individual contributions of each gene are small, it is a major challenge to identify the causal disease genes and their interactions. The advent of new highthroughput analyses makes it now possible to study such complex genetic interactions and thus unravel the molecular basis of complex genetic diseases in humans. For example, high-throughput gene expression analysis allows one to measure the expression of tens of thousands of genes at the same time. Researchers can now compare complete gene expression profiles for diseased and healthy samples and obtain a direct insight into global gene expression changes. Thus these new technologies allow them to unravel the interplay between genes and to reconstruct gene regulatory networks for biological processes. The analysis of gene expression is based on the following basic biological principles: The genetic information of a cell is stored in genes, which are part of the DNA in the nucleus. DNA is transcribed into RNA and then processed to messenger RNA (mRNA), which transfers the information to the cytoplasm. Here the mRNA is translated into protein. Many proteins are enzymes that catalyze biochemical reactions. Other proteins have mechanical or structural functions. But proteins are also important in biological signaling pro-
c02.indd 12
1/12/2011 9:43:59 AM
TECHNOLOGIES OF HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS
13
cesses, such as growth factor responses, immune responses, cell adhesion, and the cell cycle. Since proteins are major players in living organisms, they are also involved in the development of diseases. Therefore, to gain an understanding of processes that lead to disease, it is of great value to have a global picture of the amount of mRNA of all genes that are expressed in diseased and in healthy subjects. High-throughput gene expression microarrays measure these global changes and differences of mRNA and, therefore, give a very good indication of the processes that are abnormal in disease tissues. 2.2 TECHNOLOGIES OF HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS 2.2.1
Gene Expression Microarrays
Gene expression microarray technology enables the measurement of mRNA abundances in a high-throughput manner. Instead of directly using mRNA, more stable cDNA molecules are used, which are an inverse copy of the RNA. This copy is created by a viral enzyme, reverse transcriptase, in a process called reverse transcription. Microarrays are small glass plates that are subdivided into thousands of spots. Short sequences of the nucleotides A, C, T, and G, commonly referred to as probes, are bound as spots to the glass surface (Fig. 2.1). All probes in one spot have a sequence that is reverse complementary to part of the sequence of the cDNA of a specific gene. The idea is that the cDNA generated from the mRNA that is expressed from this gene will hybridize (bind) to the probes on the specific spot. To make it possible to measure the amount of cDNA hybridized to the microarray, the cDNA is labeled with a fluorescent dye. After hybridization and removal of the cDNA that did not bind, the microarray is inserted into a scanner that reads the amount of fluorescence for each of the spots. These measurements represent the level of gene expression for all genes on the microarray and are generally represented in the manner shown in Figure 2.2. Using specialized software, the intensities of each spots in the image are quantified, providing a quantitative value of the mRNA expression level for each of the genes on the microarray. 2.2.2
One-Channel Versus Two-Channel Microarrays
There exist different kinds of microarrays. A general distinction that can be made is one-channel versus two-channel microarrays. On a one-channel microarray, one fluorescently labeled sample is hybridized and the resulting expression values are read as absolute expression values for that sample. To compare the expression values between multiple samples, it is necessary to use multiple microarrays. The most widely known provider of one-channel microarrays is Affymetrix (www.affymetrix.com). On two channel microarrays, one can directly compare the gene expression values of two different samples. Each of the samples is fluorescently labeled
c02.indd 13
1/12/2011 9:43:59 AM
14
HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS RNA fragments with fluorescent tags from sample to be tested
RNA fragment hybridizes with DNA on GeneChip array
Figure 2.1. Hybridization of labeled cDNAs to a gene expression microarray. The small glass plate contains millions of probes. Fluorescently labeled (spheres) cDNA binds to the probes on the microarray. Image courtesy of Affymetrix.
using a different dye. In most cases a Cy5 (red) dye is used for one sample and Cy3 (green) for the other. This produces images like Figure 2.2 with black, yellow, red, and green spots. A red spot indicates that the sample with the red labeling has a higher expression values (vice versa for green) and a yellow spot indicates that both samples have a similar expression values. If the spot remains black, there is no expression in either of the samples. Well-known providers of two-channel microrarrays are Agilent (www.agilent.com) and Illumina (www.illumina.com). 2.2.3
Oligonucleotide Versus Spotted Microarrays
A second important distinction between microarray setups are oligonucleotide arrays versus spotted arrays. On oligonucleotide arrays, the probes are attached to the microarray by the manufacturer. For example Affymetrix uses chemical synthesis and photolithographic masks to build up the probes on the microarray. Here, all probes on the microarray are simultaneously synthesized nucleotide by nucleotide. This results in high-density prefabricated microarrays.
c02.indd 14
1/12/2011 9:43:59 AM
TECHNOLOGIES OF HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS
15
Figure 2.2. (See color insert.) A microarray produced by a scanner. Each of the spots on the microarray represents a gene, and the color represents the amount of fluorescence that is measured, hence the amount of cDNA that was present in the original sample. Reprinted from Reinke (2006).
On the other hand, probes on spotted microarrays are synthesized before they are added (spotted) onto the glass. Such microarrays are sold without probes, and laboratories have to design and fabricate their own probes and fix them onto the microarray. This is often a cheaper solution since the gene density can be much lower. Also, the researcher can customize the microarray to each experiment. 2.2.4
Whole-Transcript Arrays
The classical microarrays mentioned earlier interrogate the mRNA at only one specific location. Agilent, for example, uses one 60-mer probe per gene to measure its expression. Affymetrix uses multiple 25-mer probes per gene to measure mRNA abundances, all of them located at the end of the gene, either in the 3′ untranslated region (3′ UTR) or in the last exon or exons (Fig. 2.3). Recent studies, however, indicate that alternative splicing plays a major role in the generation of proteins and thereby functional diversity in metazoan organisms (Blencowe 2006). Alternative splicing means that different transcript isoforms are produced from the same gene, by variations in pre-mRNA
c02.indd 15
1/12/2011 9:43:59 AM
16
HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS
Genome mRNA transcripts
Exon array probes 3´ array probes
Figure 2.3. Probe coverage along the transcript. Gray regions represent exons, and black regions are introns that are removed during splicing. The short dashes underneath the exon regions indicate probes of the exon array and the classical 3′ array setup.
splicing. It is estimated that 40–60% of human genes have multiple splice forms (Modrek and Lee, 2002). These findings led to the development of a new type of microarray, the whole-transcript array, which is able to measure mRNA levels over the whole length of the gene. As depicted in Figure 2.3, Affymetrix exon arrays cover every exon of a gene with, on average, four probes. By using these microarrays, one can study global gene expression profiles like before but also detect different isoforms of a gene, such as transcripts with alternative 5′ start sites or an undefined 3′ end, nonpolyadenylated messages, or truncated or alternatively spliced transcripts. 2.2.5
Genome Tiling Arrays
The design of gene expression arrays and whole-transcript arrays is based on sequence information and annotation of known transcripts. Genome tiling arrays contain probes that are tiled over the whole genome at regular intervals, including both annotated regions of the genome and regions considered to be noncoding. Tiling arrays can thus be used to discover novel transcripts. The Affymetrix Human Tiling 1.0 R array set is a set of 14 microarrays that contain 45 million oligonucleotide probes covering the whole human genome. Probes have a length of 25 nucleotides and are tiled at an average resolution of 35 bp, leaving an average gap of 10 bp between probes. 2.2.6
MicroRNA Arrays
MicroRNAs (miRNAs) are single-stranded RNAs of very short size, 21–23 nucleotides in length. They do not code for proteins but are complementary to certain mRNA sequences. Binding to their target mRNA causes its degradation. In this way, miRNAs can regulate gene expression. It has been shown that miRNAs have an effect on various biological processes—for example, the development of cancer (He et al., 2005) and heart disease (Thum et al., 2007). Several commercial products are available for large
c02.indd 16
1/12/2011 9:44:00 AM
PROTOCOLS
17
scale identification of miRNA. Example vendors are Affymetrix, Agilent, Invitrogen, Applied Biosystems, and Exiqon. 2.3 2.3.1
PROTOCOLS Image Analysis
After the microarrays have been scanned, one obtains a figure with thousands of individual spots (Fig. 2.2) representing the mRNA levels for each gene. Now image analysis is needed to quantify the intensity for each spot. Most of the microarray vendors provide software that performs image analysis and outputs quantitative intensity values per gene. Several steps are performed in such an image analysis. First, the image will be filtered. This is a cleaning procedure by which small contamination artifacts such as dust particles are removed. Next, the location of the center of each spot is identified. This is called gridding. Next, is a process called segmentation; for each of the pixels in the spot area, it is decided whether it belongs to the signal or to the background (signal detected by the scanner in the area where no hybridization has taken place). Finally, in the quantification step, the pixel values of each spot are summarized into one gene expression value and a background value. 2.3.2
Normalization
During a microarray experiment, there can be multiple factors that introduce unwanted variation into the data. For example, if the experiment includes analysis of many samples that cannot be labeled and hybridized in one day, the quality of the labeling may be different on different days. This will lead to global expression differences between different microarrays that are not due to biological differences. The aim of normalization is to remove such unwanted variations from the data so that different samples can be properly compared and real biological differences detected. This process is called normalization and several techniques exist. In the following sections, we describe the ones that are most commonly used. As a rule of thumb in microarray normalization, Wit and McClure (2004) suggest first normalizing all local features and then gradually progressing to normalizations that deal with several or all microarrays. This procedure involves the following steps. 2.3.2.1 Spatial Correction Since probes are randomly distributed over the microarray, one expects a similar distribution of signals on each location on the array. After performing microarray experiments, there might however be microarrays where this is not the case. For example, there might be an array where all signals tend to be structurally lower in one corner of the array. Yang et al. (2002) observed that the variation in signal can also be different at different locations on the array.
c02.indd 17
1/12/2011 9:44:00 AM
18
HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS
The spatial effect can be removed by robust smoothing of the expression data across the array in each channel separately. Here, a smooth surface is fit to the data and subsequently subtracted from the data. To also correct for differences in variation on different locations of the array, one can divide by a location-dependent scale parameter. This parameter is obtained by smoothing the absolute differences between the expression values and the first smoothed surface (Wit and McClure, 2004). In cases of very strong abnormal local effects, it may even be best to exclude this array and to repeat the experiment. 2.3.2.2 Background Correction Microarray scanners always detect a background signal, even in places where no true signal is present. To obtain more accurate quantifications of gene expression values, several methods have been proposed to adjust for this background. Some methods work with local background values per spot. These background values are measured directly near the spot. Eisen. (1999) simply subtracts the background value from the observed value to obtain a signal value. Kooperberg et al. (2002) apply a Bayesian approach, assuming that the mean of the observed pixel values is the sum of the mean true signal and the mean background signal. Because of the close vicinity of the background measurements and the signal measurements, there is a possibility that the background values are contaminated with true signal. Therefore, several global background correction methods have been proposed that do not use the background values per spot but global approaches. Wit and McClure (2004) suggest calculating the mean value of all empty spots on the array, subtracting that mean from all measurements and putting the negative values obtained to zero. Irizarry et al. (2003) propose a probabilistic model that determines the conditional expectation of the true signal given the observed signal, assuming that the observed signal is the sum of the true signal and a background signal and that the spot intensities are drawn from one exponential distribution and the background intensities from a normal distribution. Both methods give similar results. 2.3.2.3 Dye-Effect Correction The most commonly used dyes in twochannel microarray experiments are Cy5 (red) and Cy3 (green). Slight differences in the characteristics of these dyes, such as in the size of the molecules, lead to unwanted effects in the observed intensity signals. For Cy5 and Cy3 it was observed that the dyes often have an intensity-dependent effect. That is, for large expression values, one of the dyes tends to give higher expression values, while for small expression values they may give lower expression values (Fig. 2.4a). Yang and Speed (2003) suggest transforming the Cy3 vs. Cy5 scatter plot into an MA plot, which is basically a 45° rotation of the Cy3 vs. Cy5 scatter plot (Fig. 2.4b). The values of M and A are calculated as follows: M = log (Cy 5) − log (Cy3),
c02.indd 18
(2.1)
1/12/2011 9:44:00 AM
PROTOCOLS
(b)
2 −6 −4 −2
0
M
12 10 6
8
log2(Cy5)
14
4
6
16
(a)
6
8
10
12
14
16
4
6
8
log2(Cy3)
10 12 14 16 A
log2(Cy5)
4
6
8
4 2 0 −6 −4 −2
10 12 14 16
(d) 6
(c)
M
19
4
6
8
10 12 14 16
4
6
A
8
10 12 14 16
log2(Cy3)
Figure 2.4. (a) Scatterplot of Cy3 versus Cy5 signal. (b) MA plot. Gray curve fitted by loess. (c) Normalized MA plot. (d) Normalized Cy3 versus Cy5 plot.
A=
1 ∗ ( log (Cy 5) + log (Cy 3)). 2
(2.2)
Then, using a function such as loess, a smooth curve is fitted through all data points and a normalized MA plot is created by subtracting the distance to the line (Fig. 2.4c). The MA plot is transferred back into a normalized Cy5 vs. Cy3 scatter plot by applying the inverse of equations 2.1 and 2.2 on the calculated data (Fig. 2.4d): log (Cy 5) = A + M/ 2,
(2.3)
log (Cy 3) = A − M/ 2.
(2.4)
2.3.2.4 Normalization between Arrays The global range of gene expression values can differ between arrays from one experiment to the next. These
c02.indd 19
1/12/2011 9:44:00 AM
20
HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS
global changes are often the result of slight variations during the process of sample preparation, labeling, microarray hybridization, and washes. The aim of normalization between arrays is to remove global expression differences so that multiple samples can be properly compared and real biological differences detected. The most straightforward way to normalize between microarrays is to equalize the median or mean value for each of the arrays and to adjust the scale to some fixed value. A disadvantage of this method is that it performs a linear scaling, which is not optimal if the distributions of the expression values differ. Therefore, another method called quantile normalization was proposed by several authors (e.g., Bolstad et al., 2003). This method equalizes the distributions of the expression values of all microarrays. The procedure is as follows: 1. Given n arrays of length g, form matrix A of dimension g × n where each array is a column and each gene is a row. 2. Sort each column of A to give Asort. 3. Take the means across rows of Asort and assign this mean to each element in the row to get Asortmean. 4. Get A normalized by rearranging each column of Asortmean to have the same ordering as the original A. Figure 2.5 shows the distribution of all gene expression values before and after the quantile normalization procedure has been applied. After normalization, the distributions of values are all equal. 2.3.3 Quality Control The performance of microarray experiments involves many steps, and there are many stages where things can go wrong. Here we describe the most common procedures for quality control and explain how they can be used to inspect the quality of the data. 2.3.3.1 Inspection of Signal Plots As a first quality control measure one can make a signal plot of all measured signals for all microarrays before and after normalization. If probes are randomly distributed over the microarrays, there should not be any patterns visible in these plots. Visual inspection of these images may reveal cases in which, for example, a hair or pieces of dust disturb the signals. Also, one can detect if spatial effects are properly corrected by the normalization methods. 2.3.3.2 Dissimilarity Measures To detect deviating microarrays, Wit and McClure (2004) suggest calculating similarity measures between all pairs of microarrays. Suppose one wants to investigate two types of dissimilarity measures: absolute similarities indicating whether genes have similar levels over
c02.indd 20
1/12/2011 9:44:00 AM
21
PROTOCOLS
(b) 14
14
12
12 log 2 Signal
log 2 Signal
(a)
10 8
10 8
6
6
4
4
1
2
3
4
1
Microarrays
2
3
4
Microarrays
Figure 2.5. Quantile normalization. (a) Box plots of the log2 signals for four microarrays before normalization, showing differences in the distributions. (b) The distributions of the log2 signals for the same microarrays after quantile normalization.
different arrays and correlations indicating coordinated changes of genes between arrays. As absolute similarity measures they use power distances ngenes
d p ( x, y) =
p
∑ x −y i
i
p
(2.5)
i =1
and use both the Manhattan distance d1 and the Euclidean distance d2. Investigation of the dissimilarity matrices directly identifies microarrays in which processing problems may have occurred. 2.3.3.3 Dimensionality Reduction Another way to check for possible problems in the data is to perform a dimensionality reduction. A popular method is principal component analysis (PCA), which is a method that transfers a number of variables (gene expression values in this case) into a number of uncorrelated variables called principal components. The first component accounts for as much of the variability in the data as possible, and each following component accounts for as much of the remaining variability as possible. A quicker method for dimensionality reduction is Sammon mapping (Sammon, 1969). Instead of using the whole gene expression data matrix, it uses the distance matrix between arrays. It aims to find a representation of the arrays in a lower-dimensional space in such a way that the distances between the arrays are closest to the distances in the original matrix. Inspection of a two-dimensional (2D) Sammon mapping can indicate whether samples have been swapped or specific arrays have a deviating behavior. For example, the
c02.indd 21
1/12/2011 9:44:00 AM
HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS
60
22
B.3.2
40
B.3.3 A.3.3
20
B.3.1
B.1.3
A.2.3
A.3.2 B.2.2
0
B.1.2
B.2.3
B.2.1
A.2.2
−40
−20
B.1.1
A.3.1
A.1.3 A.1.2
−60
A.2.1 A.1.1 −60
−40
−20
0
20
40
60
Figure 2.6. Sammon mapping of microarray data of two strains of mice (A and B) infected with a virus, measured 3 days after the infection. Each measurement has been performed in three replicates: A.1.3 means mouse A, day 1 postinfection, replicate 3.
Sammon mapping in Figure 2.6 indicates that samples A.2.3 and B.2.3 have probably been swapped. 2.3.3.4 Pairwise Scatter Plots Another good way to detect deviating microarrays is to inspect scatter plots of all expression values for all possible pairs of microarrays. Normally, the amount of differentially expressed genes between two experimental conditions is small, relative to the total amount of genes on the microarray used. A figure in which the expression values of all genes in the two conditions are plotted against each other should reveal a cloud of points on the diagonal with relatively few points off the diagonal. Comparing the scatter plots of all possible pairs of microarrays might reveal a single microarray that shows deviating scatter plots with all other microarrays—for example, scatter plots in which the cloud on the diagonal is broader than in the other pairwise plots. This would indicate that the microarray shows many more and larger changes in gene expression compared to other samples than do other comparisons. If these changes are not expected from a biological point of view, there might have been technical problem causing these changes, and it will be better to repeat the microarray experiment for this sample.
c02.indd 22
1/12/2011 9:44:00 AM
APPLICATIONS AND LIMITATIONS
23
2.3.3.5 Sex-Specific Gene Expression If the experiment involves both male and female samples, mislabelings of the microarrays can be detected by comparing the expression values for sex-specific genes. Xist is one example of a female-specific gene. It should be expressed only in female samples. In this way, samples that have been mixed up can be easily identified. 2.4 APPLICATIONS AND LIMITATIONS 2.4.1 Identification of Expression QTL and Gene Regulatory Networks Combining gene expression profiles with genetic information represents a new, powerful approach for identifying genes in disease models. This approach is generally referred to as the identification of expression quantitative trait loci (eQTL) (Rockman and Kruglyak, 2006) or genetical genomics (Jansen and Nap, 2001). A quantitative trait locus is a specific region on the genome where one or more genes are located that most likely regulate a phenotypic trait. By making use of specific populations of organisms that are genetically related and by measuring the trait values for many individuals of the population and combining them with the genetic information of the individual organisms, one can identify the locations on the genome regulating the trait. Recombinant inbred lines (RIL) are often used for QTL analysis. In mice, these lines are obtained by breeding two genetically different inbred parental lines and by performing brother–sister mating from a large number of F1 hybrid pairs for about 20 generations. As can be seen from Figure 2.7, the parental strains produce F1 offspring that are heterozygous. The F1 offspring are mated to produce F2 animals. After many generations of brother–sister matings that start from a given F2 pair, recombinant inbred lines have evolved whose genomes represent a fixed mixture of the parental genomes and in which all individuals are again homozygous at every location. The fixed parental genome mixture is, however, different from one line (starting with a given F2 pair) to another line (starting with a different F2 pair). The genetic makeup of these recombinant inbred lines is then determined for each RIL using molecular markers. RILs now allow one to perform phenotype analysis, subsequently relating them to the genotypes. For the identification of eQTL, global gene expression profiles are determined by gene expression microarrays for each RIL. Subsequently, the gene expression profile for each gene is taken as a quantitative trait and is compared in a genome scan with the distribution of molecular markers (Fig. 2.8). For each molecular marker, the expression trait values are divided into two groups, according to the alleles that the individuals carry for that marker (Fig. 2.8c). Then a statistical test is performed that determines whether the means of both groups differ significantly. In this case, eQTL may be determined, as shown for the second marker in Figure 2.8. This result indicates that, with a high
c02.indd 23
1/12/2011 9:44:00 AM
24
HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS
x
x
Parents
x
F1
x
x
F2
F20
Figure 2.7. Generation of recombinant inbred lines.
probability, there are one or several factors (genes) at that genomic location that regulate the expression of the target gene, since all individuals carrying the one allele have a low expression and all individuals carrying the other allele have a high expression value. Once a QTL is identified, one can compare the location of the QTL with the location of the gene. If they coincide, the QTL is referred to as a cis-QTL or local QTL, otherwise it is called a transQTL, or distant QTL. There exist several methods for the identification of quantitative trait loci. The most straightforward method is called single-marker analysis. Here, a genomewide scan is performed and at each molecular marker a regression test determines whether a QTL is present. In a second method, called interval mapping, the QTL likelihood is determined at locations in between markers. At fixed genomic intervals and by making use of the information for the surrounding markers, this method is able to calculate QTL scores at the markers themselves and at places in between. Based on the idea that multiple QTL can regulate a quantitative trait, Jansen (1993) and Zeng (1993) proposed the method of composite interval mapping (multiple QTL mapping). Here, the existence of multiple QTLs regulating the expression of one trait is modeled. This allows identifying epistatic QTL—that is, multiple QTL regions that regulate the trait by interacting with each other. Also, it allows for the identification of multiple linked QTL. The GeneNetwork (www.genenetwork.org) has been established as a rich resource for systems genetics. It contains a large collection of genotypes, phenotypes, and gene expression profiles for multiple organisms and genetic
c02.indd 24
1/12/2011 9:44:00 AM
APPLICATIONS AND LIMITATIONS
(a)
2
1
3
(c)
trans A B
1
(b)
A
25
cis
2
3
B
high
RILs
low
Figure 2.8. (See color insert.) (a) The genomewide genotypes of eight recombinant inbred lines generated from a cross between two homozygous parents (A and B). Each row indicates the genome of a single RIL. The light or dark gray color in each of the RILs indicates whether that part of its genome was inherited from parent A or B. (b) Gene expression values are determined by microarrays. Four values are shown for each parent and one value for each of the RILs. (c) For three molecular markers, the gene expression values of the RILs are dissected into two groups, according to the allele they carry for that molecular marker (light or dark gray). A statistical test of each marker location calculates whether the means of both groups differ. The significances of the tests are plotted in a genomewide plot as a QTL plot. Here, a QTL peak is found for the second marker. Triangles in the QTL plot indicate the position of the gene, whose expression was used. If the gene coincides with the QTL peak, the QTL is referred to as a cis-QTL, otherwise, it is called a trans-QTL. Adapted from Alberts et al. (2005) by permission of Oxford University Press.
reference populations. It offers good tools for QTL and correlation analysis and the identification of QTL genes and gene networks. The identification of a trans-QTL means that the location probably regulates the expression of another gene, the target gene. Furthermore, several genes may map to the same trans-QTL, which indicates that all these genes appear to have a common regulator. By following links between genes, revealed by trans-QTLs, one can build up gene regulatory networks. These regulatory networks have the potential to explain the complex interplay of genes and their products affecting complex traits and diseases. Ferrara et al. (2008) demonstrated how eQTL can be used to reconstruct networks. They use an F2 intercross between a diabetes-resistant and a
c02.indd 25
1/12/2011 9:44:00 AM
26
HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS
diabetes-susceptible mouse strain and identified expression QTLs (eQTLs) as well as metabolite QTLs (mQTLs). mQTLs were determined by taking metabolite abundances as quantitative traits. For one metabolite, glutamate, they identified an mQTL interval that also contains eQTLs and transcripts with eQTLs elsewhere. Using this information, they reconstructed a regulatory network, demonstrating the validity of the network by showing that the genes respond to changes in glutamate. Crawford et al. (2008) described how eQTLs can be used to derive a transcriptional network that predicts breast cancer survival. In previous work, it was shown that extracellular matrix (ECM) gene dysregulation predicts both mouse mammary tumorigenesis and human breast cancer. They identified three reproducible eQTLs that regulate ECM gene expression. By correlation analyses and known association with metastasis, they identified seven candidate genes. Six out of the seven candidates appeared to suppress metastasis. 2.4.2
Identification of Differentially Expressed Genes
Microarrays are most often used for the identification of differentially expressed genes. In disease gene discovery, healthy samples and disease samples are compared and genes that are differentially expressed are identified. Thuong et al. (2008) for example, compared gene expression profiles of macrophages from individuals with different clinical manifestations of Mycobacterium tuberculosis infection. For three clinical phenotypes—latent, pulmonary, and meningeal tuberculosis—they identified lists of differentially expressed genes. Comparing the three phenotypes, they identified 261 genes having a greater than fivefold change in expression between any of the three conditions. Pennings et al. (2008) compared multiple microarray studies on acute lung inflammation models. The models included air pollutants; bacterial, viral, and parasitic infections; and allergic asthma models. They identified a cluster of 383 genes with an expression response that was common to all pulmonary diseases. 2.4.3
Identification of Cell-Type-Specific Genes
Another application of microarrays is to identify genes that are expressed in specific cell types. Sugimoto et al. (2006), for example, compared gene expression profiles in CD25+CD4+ regulatory T cells and CD25−CD4+ naive T cells. They found multiple genes that were expressed in a pattern that is specific for regulatory T cells. These genes are thought to be involved in differentiation and homeostatis of regulatory T cells. 2.4.4
Determination of the Downstream Effects of a Mutation
Von Bernuth et al. (2008) used microarrays to determine the downstream effects of a MyD88 mutation in human. Nine patients with MyD88 deficiency
c02.indd 26
1/12/2011 9:44:00 AM
APPLICATIONS AND LIMITATIONS
27
suffered from life-threatening, often recurrent pyogenic bacterial infections. The authors identified the functional pathways in healthy fibroblasts that were regulated after treatment with interlukin 1β (IL-1β), tumor necrosis factor α (TNF), or Poly(IC) and compared them to the expression levels obtained from cells derived from patients. They identified a complete, specific lack of response to IL-1β as a defining characteristic of MyD88 deficiency. 2.4.5 Determination of the Downstream Effects of a Signaling Molecule Type 1 interferon (IFN) contributes significantly to innate immune responses. Malakhova et al. (2006) reported that UBP43 is highly expressed in macrophages and inhibits type 1 IFN signaling. To understand the effect of UBP43 and type 1 IFN signaling, Zou et al. (2007) analyzed the genomewide gene expression profiles of IFN-β-stimulated genes in wild type and UBP43−/− bone marrow–derived macrophages (BMMs). They identified 749 genes that were uniquely upregulated in UBP43−/− BMMs, including a large number of previously unidentified IFN-stimulated genes. 2.4.6 Predicting Vaccine Efficacy Another application of microarrays is the identification of gene signatures that have a predictive value for a biological response. For example, Querec et al. (2009) used this approach to predict vaccine efficacy. They vaccinated humans with the yellow fever vaccine YF-17D and performed microarray experiments on 0, 1, 3, 7, and 21 days after vaccination in two independent trials. Using the DAMIP classification model (Lee 2007, Brooks and Lee 2008), they identified innate immune signatures that could predict subsequent adaptive immune responses. One signature predicted YF-17D CD8+ T cell responses with up to 90% accuracy and another signature predicted the neutralizing antibody response with up to 100% accuracy. 2.4.7 Determination of Host Responses after Infection Microarrays have been successfully used in the characterization of host responses after infection. For example, Kash et al. (2006) infected mice with a contemporary human influenza A/Texas/36/91 H1N1 virus (Tx91) and a reconstructed 1918 (H1N1) recombinant virus (r1918) that caused about 50 million deaths worldwide. They found that mice infected with the r1918 virus revealed a much stronger inflammatory response. As another example, Ding et al. (2008) found differences in mouse strains after infection with influenza A. 2.4.8 Limitations A limitation of using microarrays is that they measure mRNA abundances and not protein levels. Posttranscriptional modifications or mRNA degradation
c02.indd 27
1/12/2011 9:44:00 AM
28
HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS
might cause actual protein levels to be different from gene expression levels measured with microarrays. In these situations, the transcriptional profiles obtained by microarrays do not fully correspond to the proteome within the cell.
2.5
QUESTIONS AND ANSWERS
Q1. Why are multiple microarrays in an experiment normalized? Q2. What is an expression QTL (eQTL)? And how can it be used to discover gene-interaction networks? A1. Multiple microarrays are normalized to remove the nonbiological variation, such as technical variation, to maintain pure biological variation. A2. An eQTL is an expression quantitative trait locus—a genomic region that very likely contains one or multiple genes regulating the expression of another gene. Trans-eQTLs represent genomic regions that influence the expression of another gene located distantly. The trans-QTL region will very likely contain genes that directly influence the expression of the target gene(s). By relating multiple trans-QTLs with multiple target genes, one may obtain valuable hypotheses for gene–gene regulatory interactions.
2.6
ACKNOWLEDGMENTS
We would like to thank Dr. Robert Geffers for fruitful discussions. This work was supported by intramural grants from the HelmholtzAssociation (Program Infection and Immunity) and a research grant for the virtual institute GeNeSys (German Network for Systems Genetics, No VHVI-242) from the Helmholtz Association.
2.7
REFERENCES
Alberts R, Fu J, Swertz MA, Lubbers LA, Albers CJ, Jansen RC. (2005). Combining microarrays and genetic analysis. Briefings Bioinformatics 6(2):135–45. Blencowe BJ. (2006). Alternative splicing: new insights from global analyses. Cell 126:37–47. Bolstad BM, Irizarry RA, Astrand M, Speed TP. (2003). A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19(2):185–93. Brooks JP, Lee EK. (2008). Analysis of the consistency of a mixed integer programming based multi-category constrained discriminant model. Ann Oper Res 164:1–20.
c02.indd 28
1/12/2011 9:44:00 AM
REFERENCES
29
Crawford NP, Walker RC, Lukes L, Officewala JS, Williams RW, Hunter KW. (2008). The Diasporin pathway: a tumor progression-related transcriptional network that predicts breast cancer survival. Clin Exp Metastasis 25(4):357–69. Ding M, Lu L, Toth LA. (2008). Gene expression in lung and basal forebrain during influenza infection in mice. Genes Brain Behav 7(2):173–83. Eisen M. (1999). ScanAlyze User Manual. Available at http://rana.lbl.gov/manuals/ ScanAlyzeDoc.pdf. Ferrara CT, Wang P, Neto EC, Stevens RD, Bain JR, Wenner BR, Ilkayeva OR, Keller MP, Blasiole DA, Kendziorski C, Yandell BS, Newgard CB, Attie AD. (2008). Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling. PLoS Genet 4(3):e1000032. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. (2005). A microRNA polycistron as a potential human oncogene. Nature 435(7043):828–33. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4(2):249–62. Jansen RC. (1993). Interval mapping of multiple quantitative trait loci. Genetics 135: 205–11. Jansen RC, Nap JP. (2001). Genetical genomics: the added value from segregation. Trends Genet 17(7):388–91. Kash JC, Tumpey TM, Proll SC, Carter V, Perwitasari O, Thomas MJ, Basler CF, Palese P, Taubenberger JK, García-Sastre A, Swayne DE, Katze MG. (2006). Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 443(7111):578–81. Kooperberg C, Fazzio TG, Tsukiyama T. (2002). Improved background correction for spotted DNA microarrays. J Computat Biol 9:57–68. Lee EK. (2007). Large-scale optimization-based classification models in medicine and biology. Ann Biomed Eng 35:1095–109. Malakhova OA, Kim KI, Luo JK, Zou W, Kumar KG, Fuchs SY, Shuai K, Zhang DE. (2006). UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 25(11):2358–67. Modrek B, Lee C. (2002). A genomic view of alternative splicing. Nat Genet 30:13–19. Pennings JLA, Kimman TG, Janssen R. (2008). Identification of a common gene expression response in different lung inflammatory diseases in rodents and macaques. PLoS ONE 3(7):e2596. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H, Bennouna S, Oluoch H, Miller J, Vencio RZ, Mulligan M, Aderem A, Ahmed R, Pulendran B. (2009). Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10(1):116–25. Reinke V. (2006). Germline genomics. Available at www.wormbook.org. Rockman MV, Kruglyak L. (2006). Genetics of global gene expression. Nat Rev Genet 7:862–72. Sammon JW. (1969). A non-linear mapping for data structure analysis. IEEE Trans Comput 18:401–09.
c02.indd 29
1/12/2011 9:44:00 AM
30
HIGH-THROUGHPUT GENE EXPRESSION ANALYSIS
Sugimoto N, Oida T, Hirota K, Nakamura K, Nomura T, Uchiyama T, Sakaguchi S. (2006). Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int Immunol 18(8):1197–209. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J. (2007). MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116(3):258–67. Thuong NT, Dunstan SJ, Chau TT, Thorsson V, Simmons CP, Quyen NT, Thwaites GE, Thi Ngoc Lan N, Hibberd M, Teo YY, Seielstad M, Aderem A, Farrar JJ, Hawn TR. (2008). Identification of tuberculosis susceptibility genes with human macrophage gene expression profiles. PLoS Pathog 4(12):e1000229. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, Chrabieh M, Mustapha IB, Ghandil P, Camcioglu Y, Vasconcelos J, Sirvent N, Guedes M, Vitor AB, HerreroMata MJ, Aróstegui JI, Rodrigo C, Alsina L, Ruiz-Ortiz E, Juan M, Fortuny C, Yagüe J, Antón J, Pascal M, Chang HH, Janniere L, Rose Y, Garty BZ, Chapel H, Issekutz A, Maródi L, Rodriguez-Gallego C, Banchereau J, Abel L, Li X, Chaussabel D, Puel A, Casanova JL. (2008). Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321(5889):691–96. Wit E, McClure J. (2004). Statistics for Microarrays: Design, Analysis and Inference. New York, John Wiley and Sons. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP. (2002). Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30(4):e15. Yang YH, Speed T. (2003). Design and analysis of comparative microarray experiments. In Statistical Analysis of Gene Expression Microarray Data (ed. Speed T). Chapman & Hall/CRC, Boca Raton, FL, pp. 35–92. Zeng ZB. (1993). Theoretical basis for separation of multiple linked gene effects in mapping quantitative trait loci. Proc Natl Acad Sci U S A 90:10972–76. Zou W, Kim JH, Handidu A, Li X, Kim KI, Yan M, Li J, Zhang DE. (2007). Microarray analysis reveals that type I interferon strongly increases the expression of immuneresponse related genes in UBP43 (USP18) deficient macrophages. Biochem Biophys Res Commun 356(1):193–99.
c02.indd 30
1/12/2011 9:44:00 AM
CHAPTER 3
DNA Methylation in the Pathogenesis of Autoimmunity XUEQING XU*, PING YANG*, ZHANG SHU*, YUN BAI*, and CONG-YI WANG*
Contents 3.1 Introduction 3.2 General Information for DNA Methylation in Mammals 3.3 DNA Methyltransferases and Methyl-CpG-Binding Domain (MBD) Proteins 3.3.1 DNA Methyltransferases 3.3.2 MBD Proteins 3.4 DNA Methylation in T and B Cell Development 3.4.1 DNA Methylation of IFN-γ Locus in Th1 Cell Development 3.4.2 DNA Methylation of Th2 Cytokine Locus in Th2 Cell Development 3.4.3 DNA Methylation in Regulatory T Cell and Th17 Development 3.4.4 DNA Methylation in B Cell Maturation and Functionality 3.5 The Implication of DNA Methylation in Autoimmune Diseases 3.5.1 DNA Methylation in Systemic Lupus Erythematosus 3.5.2 DNA Methylation in Rheumatoid Arthritis 3.5.3 DNA Methylation in Type 1 Diabetes 3.6 Common Technological Approaches for Assay of DNA Methylation 3.6.1 Methylation-Specific PCR 3.6.2 Bisulfite PCR 3.6.3 Arbitrary Primed PCR 3.6.4 Methylated DNA Immunoprecipitation Chip 3.7 Summary 3.8 Acknowledgments 3.9 References
32 33 34 34 35 36 36 37 38 40 40 41 42 43 44 45 46 46 47 48 48 49
* These authors contributed equally to this work. Correspondence should be addressed to Dr. Cong-Yi Wang,
[email protected]. Gene Discovery for Disease Models, First Edition. Edited by Weikuan Gu, Yongjun Wang. © 2011 John Wiley & Sons, Inc. Published 2011 by John Wiley & Sons, Inc.
31
c03.indd 31
1/12/2011 9:44:01 AM
32
3.1
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
INTRODUCTION
Despite the characterization of our genome at DNA basepair level, we are still far from understanding the molecular events underlying the phenotypic variations such as disease susceptibility. It is now realized that epigenetic factors are also a significant contributor for a particular phenotype, indicating a dual inheritance for mammalian cells. Moreover, the epigenome-encoded information is superimposed on DNA sequences, consisting of three interconnected molecular mechanisms: DNA methylation (methylome) (Jeltsch et al., 2006; Vanden Berghe et al., 2006; Wilson et al., 2006), histone modification (chromatin remodeling) (Kouskouti and Talianidis, 2005; Trouche et al., 2003) and RNA interference (SiRNAs and microRNAs) (Andersen and Panning, 2003; Cheng et al., 2005; Mattick, 2001), among which, DNA methylation is the most profound epigenetic mechanism because DNA methylation changes are also linked with the presence of an aberrant pattern of histone modification and microRNA expressions (Callinan and Feinberg, 2006; Esteller, 2006; Jones and Martienssen, 2005; Rauscher, 2005; Wilson et al., 2006). DNA methylation is a type of postsynthesis modification after every cycle of DNA replication. It involves the addition of a methyl group to DNA to the number 5 carbon of the cytosine. It is the oldest epigenetic mechanism known to correlate with gene repression and is also the most thoroughly studied epigenetic modification so far. DNA methylation influences, most notably, gene expression, in that hypermethylation of promoter regions is usually associated with transcriptional repression, while hypomethylation of control regions is generally associated with active gene transcription. However, as indicated, the presence of methylcytosine in the promoter of specific genes also has profound consequences on local chromatin structure in addition to the regulation of gene expression. Therefore, the end results of DNA methylation go far beyond the control of gene expression with much broader implications in genetic regulation such as genomic imprinting, X chromosome inactivation, and chromatin structure modifications (Tollefsbol, 2004). DNA methylation has been found in every vertebrate examined. In adult somatic tissues, DNA methylation typically occurs in a CpG dinucleotide context, while non-CpG methylation is prevalent in embryonic stem cells. In plants, cytosines are methylated both symmetrically (CpG or CpNpG) and asymmetrically (CpNpNp, N can be any nucleotide but guanine). In mammals, CpG dinucleotides are usually located at the promoters of genes, and the methylation of DNA in such promoter regions plays an important role in the gene activation and expression. Similar as nuclear genome, DNA methylome consists all inheritable information encoded by DNA methyaltion, which is established during development in a tissue-specific fashion (Yung et al., 2001). Methylation of CpG dinucleotides (also called CpG islands, regions of DNA enriched with CpG sites) is a unique epigenomic mechanism for suppressing the expression of genes not essentially or potentially detrimental to cellular function. Abnormal
c03.indd 32
1/12/2011 9:44:01 AM
GENERAL INFORMATION FOR DNA METHYLATION IN MAMMALS
33
demethylation of these CpG islands would lead to active transcription of the suppressed genes associated with disease development, such as cancer. In this chapter we provide an overview for the role of DNA methylation in the development of autoimmunity. We particularly discuss its possible implication in the pathogenesis of systemic lupus erythematosus (SLE), rheumatoid arthritis (AR), and type 1 diabetes (T1D).
3.2 GENERAL INFORMATION FOR DNA METHYLATION IN MAMMALS DNA methylation is one of the most important epigenetic alterations in mammals. This modification can be inherited through cell division. DNA methylation is typically removed during zygote formation and reestablished through successive cell divisions during development. DNA methylation is a crucial part of normal organism development and cellular differentiation in mammalians such as regulation of imprinted genes and X chromosome inactivation. It also acts as a protective mechanism adopted by the pathogen DNA—for example, many bacteria take the advantage of DNA methylation against the endonuclease activity that destroys any foreign DNA. DNA methylation stably alters the expression pattern of a particular gene in cells such that the cells can “remember where they have been.” In this way, cells programmed to be pancreatic islet cells during embryonic development would remain within the pancreatic islets throughout the life of the organism, and there is no need for additional signals to direct them to be remained in the islets. In general, 70–80% of all CpGs in the human genome are methylated, and the majority of unmethylated CpG islands are located within or near gene promoters or first exons of housekeeping genes (Heller et al., 2010). In contrast, the promoters of noncoding RNAs and regulatory regions of transposable elements are methylated, thereby inhibiting the parasitic transposable and repetitive elements from replicating (Dolinoy et al., 2006). Studies in animal models indicated that DNA methylome-encoded information is both mitotically and meiotically heritable (Morgan et al., 1999; Rakyan et al., 2003). Alterations for DNA methylome can be induced by a plethora of environmental insults (discussed later). Studies in a large collection of human monozygotic (MZ) twins indicated that these changes in DNA methylome are accumulated during one’s lifetime, which establish a quantitative threshold for the induction of gene expression. This quantitative effect contributes to the phenotypic discordance, including the susceptibilities to disease and a wide range of anthropomorphic features among MZ twins (Fraga et al., 2005). DNA methylation may impact the transcription of genes in two ways. The methylation of DNA may itself physically impede the binding of transcription factors to the gene. More important, methylated DNA may be bound by proteins known as methyl-CpG-binding domain (MBD) proteins. MBD proteins
c03.indd 33
1/12/2011 9:44:01 AM
34
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
then recruit additional proteins to the locus, such as histone deacetylases and other chromatin remodeling proteins that can modify histones, thereby forming compact, inactive chromatin termed silent chromatin (Fatemi and Wade, 2006; Fraga et al., 2003).
3.3 DNA METHYLTRANSFERASES AND METHYL-CPG-BINDING DOMAIN (MBD) PROTEINS 3.3.1 DNA Methyltransferases DNA methylation is carried out by DNA methyltransferases (DNMTs), and at least five DNA methyltransferases (DNMT1, DNMT3a, DNMT3b, DNMT3L, and DNMT2) have been identified in the eukaryotic kingdom. DNMT1 preferentially methylates hemimethylated substrates, such as DNA in the S phase, and is primarily involved in the maintenance of methylation patterns with each cell replication (Bestor and Ingram, 1983; Leonhardt et al., 1992). In contrast, DNMT3a and DNMT3b, which have significantly higher de novo methylation activity than DNMT1, contribute to de novo methylation during embryogenesis (Fatemi et al., 2002). Another two DNMTs—DNMT2 and DNMT3L—are found without significant methylating activity. DNMT3L binds to DNMT3a and DNMT3b and regulates their functionality. The main function for DNMT2 is found to methylate the aspartyl-tRNA (Goll et al., 2006). Given the role of DNMTs in maintenance methylation and de novo methylation, they can be divided into two general classes. Maintenance methylation is necessary to preserve DNA methylation after every cellular DNA replication cycle. In the absence of this activity, the replication machinery itself would generate daughter strands that are unmethylated and over time would result in passive demethylation. DNMT1 is proposed to be a maintenance methyltransferase responsible for copying DNA methylation patterns to the daughter strands during DNA replication (Goyal et al., 2006). Mouse models with both copies of DNMT1 deleted are embryonic lethal at approximately day 9, due to the requirement of DNMT1 activity for development in mammalian cells (Chappell et al., 2006). It is thought that DNMT3a and DNMT3b are the de novo methyltransferases that set up DNA methylation patterns early in development. DNMT3L is a homologous protein to the other DNMT3s but has no catalytic activity. On the other hand, DNMT3L assists the de novo methyltransferases by increasing their binding capacity to DNA and stimulating their enzymatic activity (Brenner and Fuks, 2006). Recently, DNMT2 (TRDMT1) has been identified as a DNA methyltransferase homolog, containing all 10 sequence motifs common to all DNA methyltransferases. However, DNMT2 (TRDMT1) does not methylate DNA, instead it methylates cytosine-38 in the anticodon loop of aspartic acid transfer RNA (Goll et al., 2006).
c03.indd 34
1/12/2011 9:44:01 AM
DNA METHYLTRANSFERASES AND METHYL-CPG-BINDING DOMAIN (MBD) PROTEINS
3.3.2
35
MBD Proteins
A evolutionarily conserved family of DNA-binding proteins characterized by a common sequence motif called methyl-CpG-binding domain (MBD) is generally believed to convert the information represented by methylation patterns into the appropriate functional state (Fatemi and Wade, 2006; Hendrich et al., 1999). MBD forms a wedge-shaped structure composed of a β-sheet superimposed over an α-helix and loop. Amino acid side chains in two of the β-strands along with residues immediately N-terminal to the α-helix interact with the cytosine methyl groups within the major groove, which provides the structural basis for the selective recognition of methylated CpG dinucleotides (Ballestar et al., 2001; Ohki et al., 2001). Thus far, five MBD proteins (MeCP2 and MBD1–MBD4) have been identified in mammals (Fatemi and Wade, 2006). In fact, these proteins share pretty low homology for the primary structures between each other outside the MBD motif, except for MBD2 and MBD3, which indeed share substantial sequence similarity. Furthermore, unlike its amphibian counterpart, mammalian MBD3 does not have the capability to selectively recognize methylated DNA because a tyrosine to phenylalanine substitution within the MBD motif (Fraga et al., 2003). The other four MBD proteins are believed to function, at least in part, in transcriptional repression (Hendrich and Tweedie, 2003; Wade, 2001). It is interesting that MBD4 possesses DNA N-glycosylase enzymatic activity and may exert functionality in DNA repair (Bird and Wolffe, 1999). In most cases, all MBD proteins are ubiquitously expressed (Hendrich and Bird, 1998; Meehan et al., 1992). They represent an important class of chromosomal protein by associating with protein partners to play active roles in transcriptional repression and/or heterochromatin formation. Therefore, it is believed that DNA methylation pattern is “read” by the MBD proteins. Although they may have overlapped functional redundancy, genetic analysis indeed suggested functional heterogeneity for each MBD proteins. Most MBD-deficient animals can survive to adulthood although with varying abnormalities. However, mice deficient for MBD3 fail to survive embryogenesis (Hendrich et al., 2001). Lack of MeCP2 is associated with specific neurological defects in the mouse that mimic the symptoms observed in the human neurological disorder Rett syndrome, which is caused by mutation in the human MECP2 gene (Amir et al., 1999). Loss of MBD1 function is associated with neuronal defects, potentially related to the subtle upregulation of a specific class of endogenous retroelements (Zhao et al., 2003). Mice deficient for MBD4 were found with increased frequency for C → T transitions at CpG sites and showed accelerated tumor formation with CpG → TpG mutations in the Apc gene (Millar et al., 2002), indicating that MBD4 may be important to suppress CpG mutability and tumorigenesis. In contrast, MBD2 deficiency is associated with a decreased incidence of tumors of the colon promoted by mutation of the adenomatous polyposis coli gene (Sansom et al., 2003). More interesting, MBD2 could be also important in the regulation of immune
c03.indd 35
1/12/2011 9:44:01 AM
36
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
response as loss of MBD2 function leads to changes in the abundance of transcripts for certain cytokines essential for T cell development (Hutchins et al., 2002; Hutchins et al., 2005).
3.4
DNA METHYLATION IN T AND B CELL DEVELOPMENT
There is increasing evidence that DNA methylome organizes the ability of signal transduction pathways to generate a restricted set of progeny from a multipotent progenitor. In addition, epigenomic effects seem to allow dividing cells to memorize, or imprint, signaling events that occurred earlier in their development (Ballestar et al., 2006; Reiner, 2005; Richardson, 2003; Sekigawa et al., 2003, 2006; Teitell and Richardson, 2003). Therefore, DNA methylation is emerging as a common strategy in development and function of the mammalian immune system. Recent studies have not only demonstrated the importance of DNA methylation in T cell development and differentiation but also established its pivotal role in T cell polarization (Eivazova and Aune, 2004; Fields et al., 2004; Fitzpatrick and Wilson, 2003; Lee et al., 2002; Reiner, 2005). T cells and B cells are two of the most important components in the immune system, and the differentiation of T helper cells (i.e., Th1, Th2, or Th17) and the maturation of B cells play an important role in specific immune responses and antibody production. While the genomic DNA is the same, different T cell subsets have different functions, most likely through expressing different proteins. Th1 cells are characterized by producing IFNγ and Th2 cells secret IL-4 and IL-13 cytokines, while Th17 cells are preferential producers of IL-17A, IL-17F, IL-21, and IL-22. Another important T subset, T regulatory T cells (Treg), is manifested by expressing Foxp3 in the nucleus. There is mounting evidence that the production of cytokines and the expression of transcription factors necessary for T helper cell differentiation to different cell subsets are regulated at the DNA methylation level. 3.4.1
DNA Methylation of IFN-γ Locus in Th1 Cell Development
IFN-γ is a signature cytokine for Th1 cells. Unlike the well-defined Th2 cytokine loci, little is known about the regulatory elements that govern the expression of interferon. The methylation status of CpG sites in the regulatory elements around IFN-γ locus is quite complicated, different CpG sites show inconsistent methylation status during Th1 development. Multiple regulatory elements and conserved noncoding sequences (CNS) have been identified in a region that extends 60–70 kb upstream and downstream of the mouse Ifn-γ locus, which include enhancers at CNS-34, CNS-22, CNS-6, CNS+18–20 and CNS+29, as well as a putative insulator at CNS+46 (Hatton et al., 2006; Wilson et al., 2009). In naive murine T cells, the IFN-γ promoter +29 and +46 are unmethylated, while CNS-54, CNS-6, intron 3, CNS-18, CNS-20, and CNS-55 were methylated (Bowen et al., 2008). In Th1 cells, methyl groups were removed
c03.indd 36
1/12/2011 9:44:01 AM
DNA METHYLATION IN T AND B CELL DEVELOPMENT
37
from CpG dinucleotides at CNS-54, CNS-6, some CpGs in IFN-γ intron 3, CNS-18 and CNS-20, indicating a prerequisite role for demethylation of these elements in IFN-γ expression for polarizing Th1 development. The involvement of DNA methylation in IFN-γ expression during Th1 development is further supported by the observation in Th2 cells. The Th2 CpG methylation pattern resembles that in naive cells apart from the fact that more CpGs within the IFN-γ promoter were methylated. Studies have shown that during Th2 polarization, the DNA methyltransferase DNMT3a was enriched to the IFN-γ promoter; as a consequence, the promoter undergoes a progressive de novo methylation (Jones and Chen, 2006). It was found that CpGs located at the 53 position become methylated rapidly and such methylation inhibits ATF2/c-Jun and CREB transcription factors binding to the IFN-γ promoter, which then suppresses IFN-γ expression to polarize naive T cells to the Th2 condition. 3.4.2 DNA Methylation of Th2 Cytokine Locus in Th2 Cell Development The IL-4, IL-5, and IL-13 genes are linked closely in an evolutionarily conserved cytokine gene cluster. The region is called the Th2 cytokine locus and contains IL-4, IL-5, IL-13, and the constitutively expressed Rad50 genes, which transcribe well-known cytokines essential for Th2 development. Sustained TCR stimulation in the presence of IL-4 polarizes naive T cells to the Th2 condition, which silences the IFN-γ gene while activating the IL-4, IL-5, and IL-13 genes. Of note, the Th2 cytokine locus is conserved in the genomes of mammals in terms of gene composition and the linear relationship of genes within the locus (Wilson et al., 2009). The transcription of those Th2 cytokines is tightly regulated through their promoters and by several additional regulatory elements, implicating the epigenetic regulatory mechanisms such as DNA methylation. For example, the transcription of murine IL-4 is tightly controlled by the regulatory elements mapped to the DNAse I hypersensitive site I (HSI) and HSII in the second intron of IL-4, the DNAse I hypersensitive site VA (HSVA) and HSV located in the 3′ region of IL-4, and the DNAse I hypersensitive site s1 (HSs1) and HSs2 located between IL-13 and IL-4 (Wilson et al., 2009). During T helper cell differentiation the IL-4 locus undergoes a complex series of methylation and demethylation steps. The 5′ region of the IL-4 locus is hypermethylated in naive T cells and becomes specifically demethylated in Th2 cells, whereas the highly conserved HSVA and HSV regions at the 3′ end show the converse behavior, being hypomethylated in naive T cells and becoming methylated during Th1 differentiation. The 5′ demethylation is not required for primary transcription of the IL-4 gene but is strongly associated with efficient, high-level induction of IL-4 transcripts by differentiated Th2 cells (Lee et al., 2002). In humans, CpG methylation is predominantly present at the IL-4 and IL13 gene in naive and Th1 cells, while CpG demethylation occurs only in Th2-
c03.indd 37
1/12/2011 9:44:01 AM
38
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
cells around the Th2-specific DNAse I hypersensitive sites (Santangelo et al., 2002). This wave of CpG demethylation during Th2 development coincides with the consensus binding sites for the Th2-specific transcription factor GATA-3. Similarly, Makar and colleagues found that as naive T cells were differentiated into Th1 populations, the decreased capacity for IL-4 expression was accompanied by an increase in recruitment of DNMTs to the IL-4 and IL-13 promoters along with an increase in CpG methylation at these regions (Makar et al., 2003; Makar and Wilson, 2004). On the contrary, these promoters/ regions were significantly demethylated once those cells in the Th2 condition (Bowen et al., 2008; Makar et al., 2003). Together, these data establish that the CpG sites in the IL-4/IL-13 locus are mostly methylated in naive T cells and Th1 cells but are demethylated during Th2 differentiation. 3.4.3
DNA Methylation in Regulatory T Cell and Th17 Development
Regulatory T cells and Th17 cells are two recently described lymphocyte subsets with opposing actions. Tregs, also called as T suppressor cells, are a specialized subpopulation of T cells that act to suppress activation of the immune system and thereby maintain immune system homeostasis and tolerance to self-antigens (Bettini and Vignali, 2009; Wing and Sakaguchi, 2010). This subset of T cells is defined by the expression of the forkhead family transcription factor Foxp3. It is evident that Foxp3 is required for Treg development; therefore, it has been used as a marker for Tregs in most current studies. CD4+Foxp3+ Tregs are a very heterogeneous population in both mice and humans, and different subsets of Tregs possess different levels of CpG DNA methylation at the Foxp3 locus. Increased methylation of CpG nucleotides at the Foxp3 locus has been linked with less Foxp3 expression, decreased Treg stability, and reduced suppressive Treg function (Lal et al., 2009; Miyara et al., 2009). The methylation regulation of Foxp3 locus may be the most detailed studied. Demethylation induced by 5-aza-cytidine, an inhibitor of DNA methylation, in human NK cells leads to Foxp3 expression (Zorn et al., 2006). Approximately 70% of CpGs in the human Foxp3 promoter are methylated in CD4+CD25lo cells in contrast to about 5% in CD4+CD25hi T cells (Janson et al., 2008). Similarly, the methylation status of the CpG residues in the proximal promoter region has an essential role in murine Foxp3 expression. CpGs in the promoter region of mouse natural Tregs (nTregs) are all demethylated. In contrast, 10– 45% of these CpG sites are methylated in naive CD4+CD25– T cells (Kim and Leonard, 2007). It has been known for a while that TGF-β induces Foxp3 expression in peripheral naive CD4+CD25– T cells (Fu et al., 2004). It appears that TGF-β may increase Foxp3 expression by inducing demethylation of CpG islands at the promoter region in CD4+CD25– T cells (Luo et al., 2008). TGF-β was found being able to inhibit DNMT expression by suppressing the phosphorylation of ERK69, and as a result, inhibition of DNMT with either siRNA or chemicals leads to Foxp3 expression in CD4+ T cells (Lal et al., 2009).
c03.indd 38
1/12/2011 9:44:01 AM
DNA METHYLATION IN T AND B CELL DEVELOPMENT
39
In addition to promoter elements, there are regulatory cis-elements between noncoding exons that act as intronic enhancers. The intronic region (+4201 to +4500) of Foxp3 is highly conserved, and CpG islands within this region are completely methylated in naive CD4+CD25– T cells but fully demethylated in nTregs in mice (Floess et al., 2007; Kim and Leonard, 2007) and in humans (Baron et al., 2007). Consistent with these observations, TGF-β stimulation results in different levels of demethylation of CpG islands in this region both in mice and humans (Baron et al., 2007; Floess et al., 2007), leading to increased Foxp3 expression. The stable Foxp3 expression is vital in maintaining Treg function (Zhou et al., 2009a, 2009b). It has been noted that a fraction of CD4+Foxp3+ nTregs adoptively transferred into lymphophenic mice converted into Foxp3– T cells (Komatsu et al., 2009). Furthermore, under certain inflammatory conditions, Foxp3+ Tregs lose Foxp3 expression and suppressive function in an IL-6– dependent manner (Lal et al., 2009; Pasare and Medzhitov, 2003). Studies now provide evidence suggesting that DNA methylation may also play a role in the maintenance of Treg stability. For example, stable Foxp3 expression in nTregs is associated with demethylated CpG islands at the Foxp3 locus. In contrast, TGF-β-induced Tregs show methylated CpG associated with loss of their capability to maintain constitutive Foxp3 expression after restimulation in the absence of TGF-β (Lal et al., 2009). This emerging role is further supported by the observation that manipulation of DNA methylation can be used to induce Foxp3 expression and promote the conversion of naive T cells to Tregs (Moon et al., 2009). In contrast to Tregs, much less is known about the regulatory mechanisms and epigenetic processes that control Th17 development. Th17 cells are derived from naive CD4+ precursor cells and preferentially secrete a characteristic profile of cytokines, including IL-17A, IL-17F, IL-21, and IL-22 (Eisenstein and Williams, 2009). As a novel subset of effector cells, they have been implicated in the pathogenesis of allograft rejection and autoimmune diseases such as arthritis and experimental autoimmune encephalomyelitis (EAE) (Hofstetter et al., 2009; Yuan et al., 2008). It is interesting that both Th17 and Tregs can be developed from naive CD4+ T cell precursors in the presence of the same cytokine, the transforming growth factor β1 (TGF-β1), suggesting that they may be coordinately regulated by shared regulatory elements. Exposure of a naive CD4+ T cell to TGF-β1 and IL-6 results in the induction of RORγt, a orphan retinoic acid nuclear receptor, that directs Th17-specific differentiation (Ivanov et al., 2006). It is interesting to note that IL-6 suppresses the development and function of Tregs (Samanta et al., 2008). Studies have shown that IL-6 induces DNMT1 expression and enhances its activity (Hodge et al., 2001), which then leads to STAT3-dependent methylation of the upstream Foxp3 enhancer and, as a consequence, represses Foxp3 expression. Therefore, the action of IL-6 for polarizing naive T cells to the Th17 condition is likely, at least in part, by inducing remethylation of CpG DNA at the upstream enhancers of Foxp3 promoter.
c03.indd 39
1/12/2011 9:44:01 AM
40
3.4.4
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
DNA Methylation in B Cell Maturation and Functionality
Many transcription factors act in a hierarchical and combinational manner to induce specific gene expression necessary for each stage of differentiation of B-lineage cells. It is interesting that the DNA methylation profile during B-cell differentiation is characterized in a dynamic manner (Renaudineau et al., 2009). At the early B-cell differentiation stage, regulatory regions for the Pax5, Pu-1, and Igα/mb1 genes are demethylated (Amaravadi and Klemsz, 1999; Danbara et al., 2002; Maier et al., 2003). At the pre-pro-B-stage, demethylation occurs for the CD19 promoter (Walter et al., 2008), while the CD21 promoter in mature B cells is demethylated (Schwab and Illges, 2001). In unstimulated B cells, DNMT1 and DNMT3a are expressed at low levels, and histones are mainly acetylated. Once the BCR is engaged, DNMT1 is induced and overexpressed, which then methylates many CpG islands, leading to B cell maturation. The involvement of DNA methylation in B cell development is further manifested by the detection of DNMT3b missense mutations in patients with immunodefficiency, centromeric region instability, and facial anomalies (ICF) syndrome (Hansen et al., 1999; Shirohzu et al., 2002), which is a rare recessive disease characterized by B-cell differentiation abnormalities. Studies have shown that DNMT3b missense mutations account for 40% of patients reported all around the world (Ehrlich et al., 2006). More recent, studies have demonstrated that altered DNA methylation is associated with autoantibody production. For example, hydralazine and procainamide were found with the capability to interact with DNA (Dubroff and Reid, 1980; Lee et al., 2005), which then reverses the methylation of cytosines present in CpG islands. Hydralazine suppresses the induction of DNMT1 and DNMT3 transcription by inhibiting the extracellular signal-regulated kinase pathway, while procainamide inhibits DNMT1 enzymatic activity as 5-azacythidine (Deng et al., 2003; Lee et al., 2005). Both of them affect the methylation status of CpG islands within the regulatory sequences, leading to phenotypic changes of peripheral blood lymphocytes (PBL). As a result, treatment of animals with hydralazine-induced autoantibodies against self-antigens associated with the development of lupus erythematosus (Deng et al., 2003; Dubroff and Reid, 1980; Mazari et al., 2007). 3.5 THE IMPLICATION OF DNA METHYLATION IN AUTOIMMUNE DISEASES It has been well accepted that susceptibility to autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and type 1 diabetes (T1D) is influenced by both genetic and environmental (epigenetic) factors. DNA methylation has now been recognized as the major mechanism of epigenetics that initiates and maintains heritable patterns of gene expression and gene function in an inheritable manner without changing the sequence of the genome (Callinan and Feinberg, 2006; Dennis, 2003; Holliday, 2006;
c03.indd 40
1/12/2011 9:44:01 AM
THE IMPLICATION OF DNA METHYLATION IN AUTOIMMUNE DISEASES
41
Jones and Martienssen, 2005; Sutherland and Costa, 2003; Wilson et al., 2006). Therefore, it acts as a “footprint” for gene–environment interactions or accumulated environmental exposures (Ushijima et al., 2006). Alterations for DNA methylation can be induced by a plethora of environmental factors such as diet (Aggarwal and Shishodia, 2006; Junien et al., 2005; Liu et al., 2003), lifestyle (Fraga et al., 2005), stress (Dennis, 2003; Meaney and Szyf, 2005), chronic inflammation (Tao and Robertson, 2003; Vanden Berghe et al., 2006), bacterial and viral infections (Li et al., 2005a; Maekita et al., 2006; Waterland and Jirtle, 2004), irradiation (Koturbash et al., 2006a, 2006b), and toxicants (Bombail et al., 2004). More important, these changes are not only heritable but also stably accumulated during an individual’s lifetime (Ballestar et al., 2006; Egger et al., 2004; Fraga et al., 2005). 3.5.1
DNA Methylation in Systemic Lupus Erythematosus
SLE is a chronic inflammatory connective tissue disorder that can involve joints, kidneys, mucous membranes, and blood vessel walls (Wardle, 2009). The presence of anti-DNA autoantibody (Ab) and high levels of circulating free DNA is a hallmark for the onset of SLE. Therefore, sera originated from SLE patients show high levels of low molecular weight DNA (e.g., 100–250 bp) enriched with Alu sequences (55% versus 13% in the whole genome) (Li and Steinman, 1989; Sano et al., 1983). These Alu sequences were potentially derived from Z-DNA (Van Helden, 1985), and contain large amounts of demethylated CpG motifs associated with increased anti-DNA recognition in SLE patients and in mouse lupus models. In line with this observation, hydralazine was found being able to induce Z-DNA conformation in a polynucleotide and elicits anti(Z-DNA) antibodies in treated patients (Thomas et al., 1993). It is believed that these circulating free DNAs were derived from apoptotic cells as manifested by the observation that apoptotic hypomethylated DNAs are immunogenic (Wen et al., 2007). Studies from Richardson and colleagues have systematically demonstrated the role of DNA methylation in the occurrence of SLE (Kaplan et al., 2004; Quddus et al., 1993; Richardson, 1986; Richardson et al., 1990, 1992; Yung et al., 1996, 1995; Yung and Richardson, 1994). The group first noted global DNA hypomethylation in T cells derived from SLE patients (Richardson et al., 1990). They next reported that antigen-specific CD4 T cells develop self-reactivity to major histocompatibility complex determinants (HLA-D molecules) upon the treatment with 5-aza-deoxycytidine (5-aza C), a DNA methylation inhibitor (Richardson, 1986), associated with the expression of leukocyte function-associated antigen 1 (LFA-1), an essential molecule implicated in T cell activation. The abnormal activation of LFA-1 is likely caused by 5-aza C-mediated demethylation of regulatory elements, and overexpression of LFA-1 alone seems to be sufficient to cause autoreactivity in SLE patients (Richardson et al., 1992). As a result, T cells with exogenous LFA-1 expression can induce a disease similar to SLE (Yung et al., 1996). They further
c03.indd 41
1/12/2011 9:44:01 AM
42
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
reported that altered perforin expression in SLE T cells is probably induced as a result of DNA hypomethylation, which could in part account for the increase of T cell–mediated apoptosis in SLE patients (Kaplan et al., 2004). Studies in animals have shown that adoptive transfer of 5-aza C-treated cloned or polyclonal T cells induces diverse autoimmune manifestations such as antiDNA autoantibody production, immune complex-mediated glomerulonephritis, central nervous system lesions resembling those seen in human SLE, and pulmonary alveolitis (Quddus et al., 1993; Yung et al., 1995; Yung and Richardson, 1994). Together, the results suggest local hypomethylation of regulatory elements predisposes individuals to the increased risk for the development of SLE. Given the effect of DNA demethylation or hypomethylation on gene transcription, these data support the hypothesis that hypomethylation of SLE-associated genes results in their expression or overexpression and subsequent development of the disease. 3.5.2
DNA Methylation in Rheumatoid Arthritis
RA is a chronic inflammatory autoimmune disease that may affect many tissues and organs but principally attacks the joints, producing an inflammatory synovitis that often progresses to the destruction of articular cartilage and ankylosis of the joints (Korb et al., 2009). Similar to other complex disorders, genetic predisposition is involved in RA pathogenesis. However, studies have demonstrated that the influence of epigenetic processes (environmental triggers) on the development of rheumatic diseases is probably as strong as genetic factors in terms of disease predisposition. It has now become more and more evident that epigenetic factors increase the risk to RA development in those genetic predisposed individuals. Studies have shown that RA synovial fibroblasts (RASFs) have decreased levels of global DNA methylation (Karouzakis et al., 2009), which is associated with altered expression of cell-activating genes and could stimulate innate immune response through TLR9 signaling. In line with this observation, a retrotransposable element LINE-1 is reactivated and transcribed in RASF because of hypomethylation of CpG islands in its promoter (Neidhart et al., 2000). There is substantial evidence supporting that IL-6 is implicated in RA pathogenesis both in animal models and clinical patients (Alonzi et al., 1998; Nishimoto et al., 2004). It is interesting that IL-6 expression is tightly regulated by both transcriptional and posttranscriptional mechanisms. Studies in peripheral blood mononuclear cells (PBMCs) from RA patients and healthy controls found that a specific CpG site in the IL-6 promoter showed a lower level of methylation in cells from RA patients, which rendered PBMCs from RA patients with much higher sensitivity for induction of IL-6 expression upon LPS stimulation (Nile et al., 2008). In sharp contrast, CpG islands within the death receptor 3 (DR3) promoter is highly methylated in first- or second-passage RA synovial cells along with significant downregulation of DR3 expression (Takami et al., 2006). Since DR3 is a member
c03.indd 42
1/12/2011 9:44:01 AM
THE IMPLICATION OF DNA METHYLATION IN AUTOIMMUNE DISEASES
43
of the apoptosis-inducing Fas gene family, the down-regulation of DR-3 could be responsible for the resistance to apoptosis in these cells. Together, the data reviewed here suggest a strong interplay between DNA methylation and RA development. 3.5.3
DNA Methylation in Type 1 Diabetes
T1D is an autoimmune disorder resulted from the breakdown of peripheral tolerance (Wang et al., 2006; Wang and She, 2008). Similar to other autoimmune diseases, a characteristic feature for T1D is the selective targeting of a specific type of cells, the insulin-secreting β cells of the islets of Langerhans in the pancreas, by a certain population of autoreactive immune cells (Li et al., 2005b; Wang et al., 2006, 2008; Wang and She, 2008). It has been well accepted that exogenous (epigenetic) factors modulate T1D susceptibility in genetically predisposed individuals (Dahlquist, 1998; Knip et al., 2005; Metcalfe et al., 2001). As a result, a great deal of research in the past few years has been focused on dissecting environmental triggers for autoimmunity. There is an ever-increasing body of evidence demonstrating that T1D development and progression are associated with diverse environmental triggers such as viral infection. The most popular hypothesis circulating within and beyond the scientific community is that viral infections enhance or elicit autoimmune disorders such as T1D (Filippi and von Herrath, 2008; van der Werf et al., 2007). Indeed, the environmental triggers often used for the explanation of differences of disease frequency across many populations and the rapid rise in disease frequency in the last few decades (Atkinson, 2005). As mentioned, studies in the last several years have not only demonstrated the importance of DNA methylation in T cell development and differentiation but also established its pivotal role in T cell polarization (Eivazova and Aune, 2004; Fields et al., 2004; Fitzpatrick and Wilson, 2003; Lee et al., 2002; Reiner, 2005). To generate an appropriate response to an infectious condition, the type of cytokine as well as the cell type, dose range, and kinetics of its expression are of critical importance. The NFκB transcription factors are, therefore, crucial in rapid responses to stress and pathogens (innate immunity) as well as in the development and differentiation of immune cells (acquired immunity). It is interesting that recent studies confirmed DNA methylome settings are the ultimate integration sites of both environmental and differentiative inputs, determining proper expression of each NFκB-dependent gene (Egger et al., 2004; Fischle et al., 2003; Fuks, 2005; Henikoff et al., 2004; Natoli et al., 2005; Teferedegne et al., 2006; Vanden Berghe et al., 2006). Therefore, the expression of many cytokines implicated in T1D development such as IL-2, IFNγ, and IL-4 are actually also regulated by DNA methylation (Bix and Locksley, 1998; Bruniquel and Schwartz, 2003; Fitzpatrick et al., 1999; Grogan et al., 2001; Lee et al., 2002). A tissue-specific DNA hypomethylation was noted in male rats with type 1 diabetes (Williams et al., 2008). A recent study revealed that CpG islands both in the mouse INS2 and human INS promoters
c03.indd 43
1/12/2011 9:44:01 AM
44
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
are uniquely demethylated in insulin-producing pancreatic β cells (Williams et al., 2008). Methylation of these CpG sites could suppress insulin promoterdriven reporter gene activity by almost 90%, and particularly, the promoter activity can be reduced by 50% by specific methylation of CpG islands in the cAMP responsive element (CRE) within the promoter alone. In NOD mice, a human T1D prone model, we found that altered DNA methylation not only dysregulates T cell function but also results in abnormal DC activation (unpublished data). DNA methylation also affects all aspects of apoptosis right from its initiation to execution (Fulda et al., 2001; Gopisetty et al., 2006). The DNA methylome in NOD pancreatic islet undergoes a rapid switch to hypomethylation upon the development of insulitis, suggesting that autoimmune insult activated genes responsible for β cell apoptosis. In line with this notion, cytokine-induced apoptosis in NIT-1 cells, a NOD-derived β cell line, was significantly exaggerated upon the addition of a DNA methylation inhibitor, 5′-azaC (unpublished data). Taken together, these observations pinpoint an important role for DNA methylation in the regulation of gene expressions for control of autoimmunity and autoimmune-mediated β cell destruction during T1D development.
3.6 COMMON TECHNOLOGICAL APPROACHES FOR ASSAY OF DNA METHYLATION The analysis of DNA methylation patterns was once considered to be a formidable technical challenge. Methylation information is not retained during amplification steps that form the basis of most standard molecular biology techniques such as PCR, biological amplification by cloning in Escherichia coli, and signal amplification by probe hybridization. Therefore, methods for DNA methylation analysis generally rely on a methylation-dependent modification of the original genomic DNA before any amplification step (Eads et al., 2000), which can be roughly divided into two types, global and gene-specific methylation analysis. For global methylation analysis, the typical conventional approach is based on the property of some restriction enzymes to be unable to cut methylated DNA, and HpaII–MspI (CCGG) and SmaI–XmaI (CCCGGG) are the two classical enzyme pairs widely used for this purpose (Sadri and Hornsby, 1996). In contrast, microarray-based high-throughput technology is a typical example for modern technologies used for global DNA methylation analysis (Hayashi et al., 2007). For gene-specific methylation analysis, a large number of techniques have been developed. In the past, the most common way to study DNA methylation of particular sequences was almost entirely based on the use of enzymes that can distinguish between methylated and unmethylated recognition sites in genes of interest. The resulting products after digestion can be detected by either PCR or Southern blotting, which would generate different signal patterns according to the methylated sites or unmethylated sites (Ariel,
c03.indd 44
1/12/2011 9:44:01 AM
COMMON TECHNOLOGICAL APPROACHES FOR ASSAY OF DNA METHYLATION
45
2001). Recently, the bisulfate conversion based techniques have become quite popular and are referred to as the second generation of methylation assays (Frommer et al., 1992). In this section, we briefly introduce several commonly used techniques for analysis of both global and gene-specific DNA methylation patterns. 3.6.1
Methylation-Specific PCR
Methylation-Specific PCR (MSP) is a technique developed to rapidly assess the methylation status of practically any group of CpG sites within a CpG island, independent of the use of cloning or methylation-sensitive restriction enzymes (Herman et al., 1996). This technique includes an initial modification of DNA by sodium bisulfite that converts all unmethylated, but not methylated, cytosines to uracil, followed by PCR amplification using primers specific for methylated versus unmethylated DNA (Fig. 3.1). MSP requires only a very small amount of DNA and is sensitive to 0.1% methylated alleles for a given CpG island locus. Therefore, MSP has the capacity to examine almost all CpG sites, not just those within sequences recognized by the methylation-sensitive restriction enzymes, which can markedly increase the number of such sites to be assessed. Another advantage for this approach is that it can be applied to DNAs extracted from paraffin-embedded samples (Herman et al., 1996).
Figure 3.1. Methylation-specific PCR. After bisulfite convertion, genomic DNA was amplified with primers specific for the methylated DNA or unmethylated DNA. The resulting products were analyzed on the agarose gel. Sample 1 shows the products resulting from unmethylated DNA only; samples 2 and 3 are PCR products yielded from both methylated and unmethylated DNA.
c03.indd 45
1/12/2011 9:44:02 AM
46
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
Furthermore, MSP can eliminate the frequent false-positive results due to partial digestion of methylation-sensitive enzymes, and the amplified products can be easily validated by differential restriction patterns. Although MSP is a quick way to detect DNA methylation patterns, it has some drawbacks. It relies on PCR of complex CG-rich DNA and the differential signal patterns of the resulting PCR products. Therefore, it is quite difficult for quantitative assessment because of the PCR bias between different samples and different primers. The key issue for this approach is to design primers that can achieve good PCR efficiency. Primer sequences are usually chosen in regions containing frequent cytosines to distinguish unmodified from modified DNA. The location of CpG pairs within the PCR products should be near the 3′ end of the primers to provide maximal discrimination between methylated and unmethylated DNA. Because of primers for amplification have to cover CpG sites, this approach has limited capacity for the number of CpG residues to be analyzed in one assay, which renders this technique inapplicable for genomewide methylation analysis. 3.6.2
Bisulfite PCR
Similar to MSP, BSP also needs the initial bisulfite conversion. Unlike MSP, this approach is suitable for quantitative assessment and is applicable for whole genome-wide analysis. The most important difference between these two assays is the primer design. In contrast to MSP, primers for BSP do not cover any CpG site. Therefore, there is no difference between the primers binding to the methylated or unmethylated template and no discrimination process during the PCR step. This strategy leads to the simultaneous amplification of all sequence variants resulted from various patterns of DNA methylation in the region resided in between the two primers. The enrichment for each of those sequence variants in the PCR mixtures can be then easily assessed by a variety of standard methods such as DNA sequencing (Fig. 3.2). As PCR reactions are designed to be the same between methylated or unmethylated template, the results produced from this approach are more comparable. 3.6.3 Arbitrary Primed PCR Arbitrary primed PCR is a simply and reproducible way to generate fingerprints of complex genomes without knowing any prior sequence information (Welsh and McClelland, 1990). This approach can be combined with methylation-specific assays such as methylation-sensitive restriction digestion for analysis of whole genome methylation patterns. Several methods have been developed in this approach such as methylation-sensitive arbitrary primed PCR (Gonzalgo et al., 1997), methylated CpG-island amplification (MCA) (Toyota et al., 1999), and amplification of intermethylated sites (AIMS) (Frigola et al., 2002). These methods are particularly useful because arbitrary
c03.indd 46
1/12/2011 9:44:02 AM
COMMON TECHNOLOGICAL APPROACHES FOR ASSAY OF DNA METHYLATION
GTGTGTATGGTTGGGTGTTTTTGGGGTGGGTAGGGAGGTGT
47
GCGCGTACGGTCGGGCGTTTTTGGGGTGGGTAGGGAGGCGC
Figure 3.2. (See color insert.) Bisulfite-specific PCR and direct sequencing. Genomic DNA underwent bisulfite conversion followed by PCR amplification. The resulting PCR products were then purified and directly sequenced. The results at the left are from the unmethylated DNA; the results at the right are for the methylated DNA.
primed PCR is carried out using DNA templates that have been enriched for methyl sequences, which leads to preferential amplification of CpG islands and gene-rich regions. However, all of these techniques require further validation by bisulfite genomic sequencing, and a background of PCR “noise” resulted from repetitive sequences must be taken into account. 3.6.4
Methylated DNA Immunoprecipitation Chip
The completion of the Human Genome Project has brought significant advances in high-throughput technologies, and one typical example is the development of high-density oligonucleotide-based whole-genome microarray (tiling array), which has now been emerged as a new platform for genomic analysis far beyond simple gene expression profiling. Tiling arrays differ in the nature of the probes. Short fragments or probes (around 70-mer) are designed to cover the entire genome. These probes can be synthesized directly on the surface of the arrays by photolithography using light-sensitive synthetic chemistry and photolithographic masks (Fodor et al., 1991; Pease et al., 1994) or programmable optical mirrors (Nuwaysir et al., 2002). Tiling arrays can be made with >6,000,000 discrete features per chip, with each feature comprising millions of copies of a distinct probe sequence. Techniques for enriching genomewide methylated DNA sequences have also been developed, and one such technique is methylated DNA immunoprecipitation (MeDIP), which is carried out by chromatin immunoprecipitation of
c03.indd 47
1/12/2011 9:44:02 AM
48
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
methylated DNA using either monoclonal antibodies specific to 5-methylcytidine (5mC) or by methyl-binding domain (MBD) protein specific to methylated CpGs. One emerging technique is beginning to gain popularity is MeDIP chip that combining chromatin immunoprecipitation with microarray, which helps screen all unknown methylation sites in a genomewide scale. For MeDIP, DNA-protein complexes are first cross-linked in cells with formaldehyde followed by immunoprecipitation with specific antibodies against the protein of interest (e.g., MBD2). DNAs bound by MBD protein are sheared to 0.2- to 2-kb fragments by sonication. The immunoprecipitated DNA and appropriate controls are fluorescently labeled and subsequently applied to chips for microarray analysis. Using input DNA as background, the profiles for methylated DNA in the genome can be then characterized by comparing the immunoprecipitated DNA with background control. Unlike the conventional PCR amplification of specific target sequences from immunoprecipitated materials, MeDIP chip is a genomewide “reverse-genetic” approach (Wu et al., 2006). Another advantage of the MeDIP chip is that it targets genes directly bound by protein factors, while the classic expression arrays cannot distinguish between directly regulated genes and those changed secondarily.
3.7
SUMMARY
Along with the characterization of our genome at DNA basepair level, it has now been recognized that DNA methylome changes and the interactions between cis-acting elements and protein factors may play a central role in gene regulation, which could have significant implications in genome function both in health and disease state. Therefore, altered DNA methylation is thought to be an important risk factor contributing to the development of autoimmunity in genetic predisposed subjects. The novel high-throughput array-based method enables the analysis of DNA methylome in a genomewide scale. The results obtained with this method demonstrate its effectiveness for reliably profiling many CpG sites in parallel, by which informative methylation markers could be identified for disease prediction and prognosis. Therefore, the MeDIP chip approach is thus far the preferable strategy for advancing the genomewide analysis of the DNA methylome.
3.8
ACKNOWLEDGMENTS
This work was supported by grants from the Juvenile Diabetes Foundation International (JDRFI), the EFSD/CDC/Lilly Program for Collaborative Diabetes Research between China and Europe to CYW. The authors declare that they have no competing financial interest.
c03.indd 48
1/12/2011 9:44:02 AM
REFERENCES
3.9
49
REFERENCES
Aggarwal BB, Shishodia S. (2006). Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397–421. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V, Ciliberto G. (1998). Interleukin 6 is required for the development of collageninduced arthritis. J Exp Med 187:461–68. Amaravadi L, Klemsz MJ. (1999). DNA methylation and chromatin structure regulate PU.1 expression. DNA Cell Biol 18:875–84. Amir RE, Van DV, Wan M, Tran CQ, Francke U, Zoghbi HY. (1999). Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23:185–88. Andersen AA, Panning B. (2003). Epigenetic gene regulation by noncoding RNAs. Curr Opin Cell Biol 15:281–89. Ariel M. (2001). A PCR-based method for studying DNA methylation. Methods Mol Biol 181:205–16. Atkinson MA. (2005). ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can’t we prevent or reverse this disease? Diabetes 54:1253–63. Ballestar E, Esteller M, Richardson BC. (2006). The epigenetic face of systemic lupus erythematosus. J Immunol 176:7143–47. Ballestar E, Pile LA, Wassarman DA, Wolffe AP, Wade PA. (2001). A Drosophila MBD family member is a transcriptional corepressor associated with specific genes. Eur J Biochem 268:5397–406. Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, Dong J, Thiel A, Boeld TJ, Hoffmann P, Edinger M, Turbachova I, Hamann A, Olek S, Huehn J. (2007). DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated Foxp3(+) conventional T cells. Eur J Immunol 37:2378–89. Bestor TH, Ingram VM. (1983). Two DNA methyltransferases from murine erythroleukemia cells: purification, sequence specificity, and mode of interaction with DNA. Proc Natl Acad Sci U S A 80:5559–63. Bettini M, Vignali DA. (2009). Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 21:612–18. Bird AP, Wolffe AP. (1999). Methylation-induced repression—belts, braces, and chromatin. Cell 99:451–54. Bix M, Locksley RM. (1998). Independent and epigenetic regulation of the interleukin-4 alleles in CD4+ T cells. Science 281:1352–54. Bombail V, Moggs JG, Orphanides G. (2004). Perturbation of epigenetic status by toxicants. Toxicol Lett 149:51–58. Bowen H, Kelly A, Lee T, Lavender P. (2008). Control of cytokine gene transcription in Th1 and Th2 cells. Clin Exp Allergy 38:1422–31. Brenner C, Fuks F. (2006). DNA methyltransferases: facts, clues, mysteries. Curr Top Microbiol Immunol 301:45–66. Bruniquel D, Schwartz RH. (2003). Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol 4:235–40.
c03.indd 49
1/12/2011 9:44:02 AM
50
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
Callinan PA, Feinberg AP. (2006). The emerging science of epigenomics. Hum Mol Genet 15(Spec. no 1):R95–101. Chappell C, Beard C, Altman J, Jaenisch R, Jacob J. (2006). DNA methylation by DNA methyltransferase 1 is critical for effector CD8 T cell expansion. J Immunol 176: 4562–72. Cheng LC, Tavazoie M, Doetsch F. (2005). Stem cells: from epigenetics to microRNAs. Neuron 46:363–67. Dahlquist G. (1998). The aetiology of type 1 diabetes: an epidemiological perspective. Acta Paediatr Suppl 425:5–10. Danbara M, Kameyama K, Higashihara M, Takagaki Y. (2002). DNA methylation dominates transcriptional silencing of PAX5 in terminally differentiated B cell lines. Mol Immunol 38:1161–66. Deng C, Lu Q, Zhang Z, Rao T, Attwood J, Yung R, Richardson B. (2003). Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 48:746–56. Dennis C. (2003). Epigenetics and disease: altered states. Nature 421:686–88. Dolinoy DC, Weidman JR, Jirtle RL. (2006). Epigenetic gene regulation: linking early developmental environment to adult disease. Reprod Toxicol 23:297–307. Dubroff LM, Reid RJ Jr. (1980). Hydralazine-pyrimidine interactions may explain hydralazine-induced lupus erythematosus. Science 208:404–06. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. (2000). MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28:E32. Egger G, Liang G, Aparicio A, Jones PA. (2004). Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457–63. Ehrlich M, Jackson K, Weemaes C. (2006). Immunodeficiency, centromeric region instability, facial anomalies syndrome (ICF). Orphanet J Rare Dis 1:2. Eisenstein EM, Williams CB. (2009). The T(reg)/Th17 cell balance: a new paradigm for autoimmunity. Pediatr Res 65:26R–31R. Eivazova ER, Aune TM. (2004). Dynamic alterations in the conformation of the IFNγ gene region during T helper cell differentiation. Proc Natl Acad Sci U S A 101: 251–56. Esteller M. (2006). The necessity of a human epigenome project. Carcinogenesis 27: 1121–25. Fatemi M, Hermann A, Gowher H, Jeltsch A. (2002). DNMT3a and Dnmt1 functionally cooperate during de novo methylation of DNA. Eur J Biochem 269:4981–84. Fatemi M, Wade PA. (2006). MBD family proteins: reading the epigenetic code. J Cell Sci 119:3033–37. Fields PE, Lee GR, Kim ST, Bartsevich VV, Flavell RA. (2004). Th2-specific chromatin remodeling and enhancer activity in the Th2 cytokine locus control region. Immunity 21:865–76. Filippi CM, von Herrath MG. (2008). Viral trigger for type 1 diabetes: pros and cons. Diabetes 57:2863–71. Fischle W, Wang Y, Allis CD. (2003). Histone and chromatin cross-talk. Curr Opin Cell Biol 15:172–83.
c03.indd 50
1/12/2011 9:44:02 AM
REFERENCES
51
Fitzpatrick DR, Shirley KM, Kelso A. (1999). Cutting edge: stable epigenetic inheritance of regional IFN-gamma promoter demethylation in CD44highCD8+ T lymphocytes. J Immunol 162:5053–57. Fitzpatrick DR, Wilson CB. (2003). Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. Clin Immunol 109:37–45. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, Klein-Hessling S, Serfling E, Hamann A, Huehn J. (2007). Epigenetic control of the Foxp3 locus in regulatory T cells. PLoS Biol 5:e38. Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D. (1991). Light-directed, spatially addressable parallel chemical synthesis. Science 251:767–73. Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, Esteller M. (2003). The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res 31:1765–74. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suner D, Cigudosa JC, Urioste M, Benitez J, Boix-Chornet M, Sanchez-Aguilera A, Ling C, Carlsson E, Poulsen P, Vaag A, Stephan Z, Spector TD, Wu YZ, Plass C, Esteller M. (2005). Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 102:10604–09. Frigola J, Ribas M, Risques RA, Peinado MA. (2002). Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). Nucleic Acids Res 30:e28. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. (1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 89:1827–31. Fu S, Zhang N, Yopp AC, Chen D, Mao M, Chen D, Zhang H, Ding Y, Bromberg JS. (2004). TGF-beta induces Foxp3 + T-regulatory cells from CD4 + C. Am J Transplant 4:1614–27. Fuks F. (2005). DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 15:490–95. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. (2001). Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20:5865–77. Goll MG, Kirpekar F, Maggert KA, Yoder JA, Hsieh CL, Zhang X, Golic KG, Jacobsen SE, Bestor TH. (2006). Methylation of tRNAAsp by the DNA methyltransferase homolog DNMT2. Science 311:395–98. Gonzalgo ML, Liang G, Spruck CH III, Zingg JM, Rideout WM III, Jones PA. (1997). Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res 57:594–99. Gopisetty G, Ramachandran K, Singal R. (2006). DNA methylation and apoptosis. Mol Immunol 43:1729–40. Goyal R, Reinhardt R, Jeltsch A. (2006). Accuracy of DNA methylation pattern preservation by the DNMT1 methyltransferase. Nucleic Acids Res 34:1182–88. Grogan JL, Mohrs M, Harmon B, Lacy DA, Sedat JW, Locksley RM. (2001). Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immunity 14:205–15.
c03.indd 51
1/12/2011 9:44:02 AM
52
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, Weemaes CM, Gartler SM. (1999). The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci U S A 96:14412–17. Hatton RD, Harrington LE, Luther RJ, Wakefield T, Janowski KM, Oliver JR, Lallone RL, Murphy KM, Weaver CT. (2006). A distal conserved sequence element controls Ifng gene expression by T cells and NK cells. Immunity 25:717–29. Hayashi H, Nagae G, Tsutsumi S, Kaneshiro K, Kozaki T, Kaneda A, Sugisaki H, Aburatani H. (2007). High-resolution mapping of DNA methylation in human genome using oligonucleotide tiling array. Hum Genet 120:701–11. Heller G, Zielinski CC, Zochbauer-Muller S. (2010). Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev 29(1):95–107. Hendrich B, Abbott C, McQueen H, Chambers D, Cross S, Bird A. (1999). Genomic structure and chromosomal mapping of the murine and human MBD1, MBD2, MBD3, and MBD4 genes. Mamm Genome 10:906–12. Hendrich B, Bird A. (1998). Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 18:6538–47. Hendrich B, Guy J, Ramsahoye B, Wilson VA, Bird A. (2001). Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev 15:710–23. Hendrich B, Tweedie S. (2003). The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet 19:269–77. Henikoff S, Furuyama T, Ahmad K. (2004). Histone variants, nucleosome assembly and epigenetic inheritance. Trends Genet 20:320–26. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821–26. Hodge DR, Xiao W, Clausen PA, Heidecker G, Szyf M, Farrar WL. (2001). Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J Biol Chem 276:39508–11. Hofstetter H, Gold R, Hartung HP. (2009). Th17 cells in MS and experimental autoimmune encephalomyelitis. Int MS J 16:12–18. Holliday R. (2006). Dual inheritance. Curr Top Microbiol Immunol 301:243–56. Hutchins AS, Artis D, Hendrich BD, Bird AP, Scott P, Reiner SL. (2005). Cutting edge: a critical role for gene silencing in preventing excessive type 1 immunity. J Immunol 175:5606–10. Hutchins AS, Mullen AC, Lee HW, Sykes KJ, High FA, Hendrich BD, Bird AP, Reiner SL. (2002). Gene silencing quantitatively controls the function of a developmental trans-activator. Mol Cell 10:81–91. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. (2006). The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126:1121–33. Janson PC, Winerdal ME, Marits P, Thorn M, Ohlsson R, Winqvist O. (2008). Foxp3 promoter demethylation reveals the committed Treg population in humans. PLoS One 3:e1612. Jeltsch A, Walter J, Reinhardt R, Platzer M. (2006). German human methylome project started. Cancer Res 66:73–78.
c03.indd 52
1/12/2011 9:44:02 AM
REFERENCES
53
Jones B, Chen J. (2006). Inhibition of IFN-gamma transcription by site-specific methylation during T helper cell development. EMBO J 25:2443–52. Jones PA, Martienssen R. (2005). A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop. Cancer Res 65:11241–46. Junien C, Gallou-Kabani C, Vige A, Gross MS. (2005). [Nutritionnal epigenomics: consequences of unbalanced diets on epigenetics processes of programming during lifespan and between generations]. Ann Endocrinol (Paris) 66:2S19–28. Kaplan MJ, Lu Q, Wu A, Attwood J, Richardson B. (2004). Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J Immunol 172:3652–61. Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M. (2009). DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 60:3613–22. Kim HP, Leonard WJ. (2007). CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med 204:1543–51. Knip M, Veijola R, Virtanen SM, Hyoty H, Vaarala O, Akerblom HK. (2005). Environmental triggers and determinants of type 1 diabetes. Diabetes 54(Suppl 2):S125–36. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. (2009). Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A 106:1903–08. Korb A, Pavenstadt H, Pap T. (2009). Cell death in rheumatoid arthritis. Apoptosis 14:447–54. Koturbash I, Baker M, Loree J, Kutanzi K, Hudson D, Pogribny I, Sedelnikova O, Bonner W, Kovalchuk O. (2006a). Epigenetic dysregulation underlies radiationinduced transgenerational genome instability in vivo. Int J Radiat Oncol Biol Phys 66:327–30. Koturbash I, Rugo RE, Hendricks CA, Loree J, Thibault B, Kutanzi K, Pogribny I, Yanch JC, Engelward BP, Kovalchuk O. (2006b). Irradiation induces DNA damage and modulates epigenetic effectors in distant bystander tissue in vivo. Oncogene 25:4267–75. Kouskouti A, Talianidis I. (2005). Histone modifications defining active genes persist after transcriptional and mitotic inactivation. EMBO J 24:347–57. Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy DE, Bromberg JS. (2009). Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 182:259–73. Lee BH, Yegnasubramanian S, Lin X, Nelson WG. (2005). Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 280:40749–56. Lee DU, Agarwal S, Rao A. (2002). Th2 lineage commitment and efficient IL-4 production involves extended demethylation of the IL-4 gene. Immunity 16: 649–60. Leonhardt H, Page AW, Weier HU, Bestor TH. (1992). A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell 71:865–73. Li HP, Leu YW, Chang YS. (2005a). Epigenetic changes in virus-associated human cancers. Cell Res 15:262–71.
c03.indd 53
1/12/2011 9:44:02 AM
54
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
Li JZ, Steinman CR. (1989). Plasma DNA in systemic lupus erythematosus. Characterization of cloned base sequences. Arthritis Rheum 32:726–33. Li M, Guo D, Isales CM, Eizirik DL, Atkinson M, She JX, Wang CY. (2005b). Sumo wrestling with type 1 diabetes. J Mol Med 83:504–13. Liu L, Wylie RC, Andrews LG, Tollefsbol TO. (2003). Aging, cancer and nutrition: the DNA methylation connection. Mech Ageing Dev 124:989–98. Luo X, Zhang Q, Liu V, Xia Z, Pothoven KL, Lee C. (2008). Cutting edge: TGF-betainduced expression of Foxp3 in T cells is mediated through inactivation of ERK. J Immunol 180:2757–61. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M, Ushijima T. (2006). High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12:989–95. Maier H, Colbert J, Fitzsimmons D, Clark DR, Hagman J. (2003). Activation of the early B-cell-specific MB-1 (IG-alpha) gene by Pax-5 is dependent on an unmethylated ETS binding site. Mol Cell Biol 23:1946–60. Makar KW, Perez-Melgosa M, Shnyreva M, Weaver WM, Fitzpatrick DR, Wilson CB. (2003). Active recruitment of DNA methyltransferases regulates interleukin 4 in thymocytes and T cells. Nat Immunol 4:1183–90. Makar KW, Wilson CB. (2004). DNA methylation is a nonredundant repressor of the Th2 effector program. J Immunol 173:4402–06. Mattick JS. (2001). Non-coding RNAs: the architects of eukaryotic complexity. EMBO Rep 2:986–91. Mazari L, Ouarzane M, Zouali M. (2007). Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus. Proc Natl Acad Sci U S A 104:6317–22. Meaney MJ, Szyf M. (2005). Environmental programming of stress responses through DNA methylation: life at the interface between a dynamic environment and a fixed genome. Dialogues Clin Neurosci 7:103–23. Meehan RR, Lewis JD, Bird AP. (1992). Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res 20:5085–92. Metcalfe KA, Hitman GA, Rowe RE, Hawa M, Huang X, Stewart T, Leslie RD. (2001). Concordance for type 1 diabetes in identical twins is affected by insulin genotype. Diabetes Care 24:838–42. Millar CB, Guy J, Sansom OJ, Selfridge J, MacDougall E, Hendrich B, Keightley PD, Bishop SM, Clarke AR, Bird A. (2002). Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science 297:403–05. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, Mathian A, Nakahata T, Yamaguchi T, Nomura T, Ono M, Amoura Z, Gorochov G, Sakaguchi S. (2009). Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30:899–911. Moon C, Kim SH, Park KS, Choi BK, Lee HS, Park JB, Choi GS, Kwan JH, Joh JW, Kim SJ. (2009). Use of epigenetic modification to induce Foxp3 expression in naive T cells. Transplant Proc 41:1848–54.
c03.indd 54
1/12/2011 9:44:02 AM
REFERENCES
55
Morgan HD, Sutherland HG, Martin DI, Whitelaw E. (1999). Epigenetic inheritance at the agouti locus in the mouse. Nat Genet 23:314–18. Natoli G, Saccani S, Bosisio D, Marazzi I. (2005). Interactions of NF-kappaB with chromatin: the art of being at the right place at the right time. Nat Immunol 6: 439–45. Neidhart M, Rethage J, Kuchen S, Kunzler P, Crowl RM, Billingham ME, Gay RE, Gay S. (2000). Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum 43:2634–47. Nile CJ, Read RC, Akil M, Duff GW, Wilson AG. (2008). Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum 58:2686–93. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. (2004). Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761–69. Nuwaysir EF, Huang W, Albert TJ, Singh J, Nuwaysir K, Pitas A, Richmond T, Gorski T, Berg JP, Ballin J, McCormick M, Norton J, Pollock T, Sumwalt T, Butcher L, Porter D, Molla M, Hall C, Blattner F, Sussman MR, Wallace RL, Cerrina F, Green RD. (2002). Gene expression analysis using oligonucleotide arrays produced by maskless photolithography. Genome Res 12:1749–55. Ohki I, Shimotake N, Fujita N, Jee J, Ikegami T, Nakao M, Shirakawa M. (2001). Solution structure of the methyl-CpG binding domain of human MBD1 in complex with methylated DNA. Cell 105:487–97. Pasare C, Medzhitov R. (2003). Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033–36. Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP. (1994). Lightgenerated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci U S A 91:5022–26. Quddus J, Johnson KJ, Gavalchin J, Amento EP, Chrisp CE, Yung RL, Richardson BC. (1993). Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupuslike disease in syngeneic mice. J Clin Invest 92:38–53. Rakyan VK, Chong S, Champ ME, Cuthbert PC, Morgan HD, Luu KV, Whitelaw E. (2003). Transgenerational inheritance of epigenetic states at the murine Axin(Fu) allele occurs after maternal and paternal transmission. Proc Natl Acad Sci U S A 100:2538–43. Rauscher FJ III. (2005). It is time for a Human Epigenome Project. Cancer Res 65: 11229. Reiner SL. (2005). Epigenetic control in the immune response. Hum Mol Genet 14(Special issue 1):R41–46. Renaudineau Y, Garaud S, Le, DC, onso-Ramirez R, Daridon C, Youinou P. (2009). Autoreactive B cells and epigenetics. Clin Rev Allergy Immunol 39:85–94. Richardson B. (1986). Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. Hum Immunol 17:456–70.
c03.indd 55
1/12/2011 9:44:02 AM
56
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
Richardson B. (2003). DNA methylation and autoimmune disease. Clin Immunol 109:72–79. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. (1990). Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 33:1665–73. Richardson BC, Strahler JR, Pivirotto TS, Quddus J, Bayliss GE, Gross LA, O’Rourke KS, Powers D, Hanash SM, Johnson MA. (1992). Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum 35:647–62. Sadri R, Hornsby PJ. (1996). Rapid analysis of DNA methylation using new restriction enzyme sites created by bisulfite modification. Nucleic Acids Res 24:5058–59. Samanta A, Li B, Song X, Bembas K, Zhang G, Katsumata M, Saouaf SJ, Wang Q, Hancock WW, Shen Y, Greene MI. (2008). TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci U S A 105:14023–27. Sano H, Imokawa M, Steinberg AD, Morimoto C. (1983). Accumulation of guaninecytosine-enriched low M.W. DNA fragments in lymphocytes of patients with systemic lupus erythematosus. J Immunol 130:187–90. Sansom OJ, Berger J, Bishop SM, Hendrich B, Bird A, Clarke AR. (2003). Deficiency of MBD2 suppresses intestinal tumorigenesis. Nat Genet 34:145–47. Santangelo S, Cousins DJ, Winkelmann NE, Staynov DZ. (2002). DNA methylation changes at human Th2 cytokine genes coincide with DNase I hypersensitive site formation during CD4(+) T Cell differentiation. J Immunol 169:1893–903. Schwab J, Illges H. (2001). Silencing of CD21 expression in synovial lymphocytes is independent of methylation of the CD21 promoter CpG island. Rheumatol Int 20:133–37. Sekigawa I, Kawasaki M, Ogasawara H, Kaneda K, Kaneko H, Takasaki Y, Ogawa H. (2006). DNA methylation: its contribution to systemic lupus erythematosus. Clin Exp Med 6:99–106. Sekigawa I, Okada M, Ogasawara H, Kaneko H, Hishikawa T, Hashimoto H. (2003). DNA methylation in systemic lupus erythematosus. Lupus 12:79–85. Shirohzu H, Kubota T, Kumazawa A, Sado T, Chijiwa T, Inagaki K, Suetake I, Tajima S, Wakui K, Miki Y, Hayashi M, Fukushima Y, Sasaki H. (2002). Three novel DNMT3B mutations in Japanese patients with ICF syndrome. Am J Med Genet 112:31–37. Sutherland JE, Costa M. (2003). Epigenetics and the environment. Ann N Y Acad Sci 983:151–60. Takami N, Osawa K, Miura Y, Komai K, Taniguchi M, Shiraishi M, Sato K, Iguchi T, Shiozawa K, Hashiramoto A, Shiozawa S. (2006). Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells. Arthritis Rheum 54:779–87. Tao Q, Robertson KD. (2003). Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Clin Immunol 109: 53–63. Teferedegne B, Green MR, Guo Z, Boss JM. (2006). Mechanism of action of a distal NF-kappaB-dependent enhancer. Mol Cell Biol 26:5759–70.
c03.indd 56
1/12/2011 9:44:02 AM
REFERENCES
57
Teitell M, Richardson B. (2003). DNA methylation in the immune system. Clin Immunol 109:2–5. Thomas TJ, Seibold JR, Adams LE, Hess EV. (1993). Hydralazine induces Z-DNA conformation in a polynucleotide and elicits anti(Z-DNA) antibodies in treated patients. Biochem J 294(Pt 2):419–25. Tollefsbol TO. (2004). Methods of epigenetic analysis. Methods Mol Biol 287:1–8. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, Baylin SB, Issa JP. (1999). Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 59:2307–12. Trouche D, Khochbin S, Dimitrov S. (2003). Chromatin and epigenetics: dynamic organization meets regulated function. Mol Cell 12:281–86. Ushijima T, Nakajima T, Maekita T. (2006). DNA methylation as a marker for the past and future. J Gastroenterol 41:401–07. van der Werf N, Kroese FG, Rozing J, Hillebrands JL. (2007). Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 23:169–83. Van Helden PD. (1985). Potential Z-DNA-forming elements in serum DNA from human systemic lupus erythematosus. J Immunol 134:177–79. Vanden Berghe W, Ndlovu MN, Hoya-Arias R, Dijsselbloem N, Gerlo S, Haegeman G. (2006). Keeping up NF-kappaB appearances: epigenetic control of immunity or inflammation-triggered epigenetics. Biochem Pharmacol 72:1114–31. Wade PA. (2001). Methyl CpG-binding proteins and transcriptional repression. Bioessays 23:1131–37. Walter K, Bonifer C, Tagoh H. (2008). Stem cell-specific epigenetic priming and B cellspecific transcriptional activation at the mouse CD19 locus. Blood 112:1673–82. Wang CY, Han J, She JX. (2008). Genetic factors for human type 1 diabetes. In Current Topics in Human Genetics (Studies in Complex Diseases). Vol. 24. Ed. World Scientific Publishing Co. Pte. Ltd., Hackensack, NJ 07601, pp. 693–727. Wang CY, Podolsky R, She JX. (2006). Genetic and functional evidence supporting SUMO4 as a type 1 diabetes susceptibility gene. Ann N Y Acad Sci 1079:257–67. Wang CY, She JX. (2008). SUMO4 and its role in type 1 diabetes pathogenesis. Diabetes Metab Res Rev 24:93–102. Wardle EN. (2009). Systemic lupus erythematosus conundrums. Saudi J Kidney Dis Transpl 20:731–36. Waterland RA, Jirtle RL. (2004). Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition 20:63–68. Welsh J, McClelland M. (1990). Fingerprinting genomes using PCR with arbitrary primers. Nucleic Acids Res 18:7213–18. Wen ZK, Xu W, Xu L, Cao QH, Wang Y, Chu YW, Xiong SD. (2007). DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-non-susceptible mice. Rheumatology (Oxford) 46: 1796–803. Williams KT, Garrow TA, Schalinske KL. (2008). Type I diabetes leads to tissue-specific DNA hypomethylation in male rats. J Nutr 138:2064–69. Wilson CB, Rowell E, Sekimata M. (2009). Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 9:91–105.
c03.indd 57
1/12/2011 9:44:02 AM
58
DNA METHYLATION IN THE PATHOGENESIS OF AUTOIMMUNITY
Wilson IM, Davies JJ, Weber M, Brown CJ, Alvarez CE, MacAulay C, Schubeler D, Lam WL. (2006). Epigenomics: mapping the methylome. Cell Cycle 5:155–58. Wing K, Sakaguchi S. (2010). Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11:7–13. Wu J, Smith LT, Plass C, Huang TH. (2006). ChIP-chip comes of age for genome-wide functional analysis. Cancer Res 66:6899–902. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, D’Addio F, Mfarrej B, Donnarumma M, Habicht A, Clarkson MR, Iacomini J, Glimcher LH, Sayegh MH, Ansari MJ. (2008). A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 205:3133–44. Yung R, Powers D, Johnson K, Amento E, Carr D, Laing T, Yang J, Chang S, Hemati N, Richardson B. (1996). Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 97:2866–71. Yung R, Ray D, Eisenbraun JK, Deng C, Attwood J, Eisenbraun MD, Johnson K, Miller RA, Hanash S, Richardson B. (2001). Unexpected effects of a heterozygous dnmt1 null mutation on age-dependent DNA hypomethylation and autoimmunity. J Gerontol A Biol Sci Med Sci 56:B268–76. Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC. (1995). Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 154:3025–35. Yung RL, Richardson BC. (1994). Role of T cell DNA methylation in lupus syndromes. Lupus 3:487–91. Zhao X, Ueba T, Christie BR, Barkho B, McConnell MJ, Nakashima K, Lein ES, Eadie BD, Willhoite AR, Muotri AR, Summers RG, Chun J, Lee KF, Gage FH. (2003). Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. Proc Natl Acad Sci U S A 100:6777–82. Zhou L, Chong MM, Littman DR. (2009a). Plasticity of CD4+ T cell lineage differentiation. Immunity 30:646–55. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. (2009b). Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 21:281–85. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, Frank DA, Ritz J. (2006). IL-2 regulates Foxp3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108:1571–79.
c03.indd 58
1/12/2011 9:44:02 AM
CHAPTER 4
Cell-Based Analysis with Microfluidic Chip WANG QI and ZHAO LONG
Contents 4.1 Introduction 4.2 Fabrication of the Microfluidic Chip and Cell Culture 4.2.1 Fabrication of the Microfluidic Chip 4.2.2 Cell Culture and Analysis 4.3 Application of the Cell-Based Microfluidic Chip 4.3.1 Genomic Analysis on Chip 4.3.2 Protein Analysis on Chip 4.3.3 Analysis of Chemotherapy Resistance in Tumor Cells 4.4 Conclusions and Future Prospects 4.5 Acknowledgments 4.6 References
4.1
59 60 60 62 67 68 70 72 75 76 76
INTRODUCTION
Micro total analysis systems (TAS), also called labs on a chip, integrate analytical processes for sequential operations like sampling, sample pretreatment, analytical separation, chemical reaction, analytical detection, and data analysis in a single microfluidic device. Microfluidic-based research has made significant advances over the last few years and has become very much a hot topic. Because of its advantages—including low reagent and power consumption, short reaction time, portability for in situ use, low cost, versatility in design, and potential for parallel operation and integration with other miniaturized devices—microfluidic chip-based systems for biological cell studies have Gene Discovery for Disease Models, First Edition. Edited by Weikuan Gu, Yongjun Wang. © 2011 John Wiley & Sons, Inc. Published 2011 by John Wiley & Sons, Inc.
59
c04.indd 59
1/12/2011 9:44:03 AM
60
CELL-BASED ANALYSIS WITH MICROFLUIDIC CHIP
attracted significant attention. The microfluidic technique has started to play an increasingly important role in discoveries in cell biology, neurobiology, pharmacology, and tissue engineering. As cell-based assay is deemed to be essential for the functional characterization and detection of drugs, pathogens, toxicants, and odorants, some articles concerning microfluidics for cell analysis have been published during the past few years. Andersson and Berg et al. (2003) presented some research on microfluidics for cellomics, which covered the microfluidic devices for cell sampling, cell trapping and sorting, cell treatment, and cell analysis. Erickson and Li (2004) focused on integrated microfluidic devices for cell handling and cytometry, dielectrophoretic cellular manipulation and sorting, and general cellular analysis. There were a large number of reports on the microfluidicbased biological applications such as cell culture, PCR, DNA separation, DNA sequencing, and clinical diagnostics (Auroux et al., 2002; Vilkner et al., 2004). Recently, microfluidics for cell culture, flow cytometers, and other microscale flow-based cell analysis systems were presented (Tai and Shuler, 2003; Huh et al., 2005), where cell detection and enumeration systems and microfluidic fluorescence-activated cell sorting systems were described (Huh et al., 2005). This chapter is to provide an in-depth look at the applications of cell-based analysis with microfluidic devices. In this chapter, we summarize some reports on the use of cell-based microfluidic chip to carry out specific functions on microchips. The chapter consists mainly of three sections, covering fabrication of the microfluidic devices; cell culture and manipulation; and cell-based analysis including protein analysis, genomic analysis and tumor cell chemotherapy analysis. Selected examples for the manipulation method are described in detail to reveal their advantages and disadvantages. An outlook of this promising and rapidly expanding area is presented in the concluding remarks. Some typical microchips are shown in Figure 4.1.
4.2 FABRICATION OF THE MICROFLUIDIC CHIP AND CELL CULTURE Fabrication of miniaturized cell manipulator is the first step toward microfluidics for cell-based assays. The commonly used methods for cell manipulation on chip can be categorized based on the manipulating force employed. In this section, a few selected microfluidic devices fabrication and cell culture are described. 4.2.1 Fabrication of the Microfluidic Chip Microfluidic devices can be fabricated from a variety of materials using different techniques. The materials are silicon, glass, and polydimethylsiloxane (PDMS), each with differently characteristics; the main fabricateing techniques are lithography, UV laser ablation, and hot embossing.
c04.indd 60
1/12/2011 9:44:03 AM
FABRICATION OF THE MICROFLUIDIC CHIP AND CELL CULTURE
Glass four-channel array electrophoresis chip
Glass PCR chip
Quarts electrophoresis chip
PDMS-glass drug-screening chip
61
Gradient chip for cell culture and drug screen
Figure 4.1. Typical microchips.
4.2.1.1 Different Materials Silicon and glass are traditional materials and have been used to create microfluidic devices (Li et al., 1999; McClain et al., 2003). The particularly attractive advantages of glass and quartz include their well-defined surfaces and excellent optical properties, which are highly desired for signal readout of microarrays by fluorescence. Because of the defects of silicon and glass, such as strong and expensive, polymers are rapidly evolving as alternative substrate materials for many microfluidic applications due to their diverse properties, which can be selected to suit the particular application need and the ability to microfabricate structures in a high-production mode and at low cost. Recently, PDMS, a kind of polymer, has became one of the materials extensively used in microfluidic devices due to its biocompatibility, low toxicity, high oxidative and thermal stability, optically transparency, low permeability to water, and low electrical conductivity; furthermore, it can be easily fabricated into microstructures using soft lithography. 4.2.1.2 Fabrication Technique The fabrication of the prerequisite fluidic networks on polymer substrates can be achieved by lithography, UV laser ablation, hot embossing, injection molding, or direct micromilling techniques (Ford et al., 1999; Friedrich et al., 1997; Grass et al., 2001; Ihlemann and Rubahn, 2000; Martynova et al., 1997; Qi et al., 2002; Robert et al., 1997; Rossier et al., 1999; Soper et al., 2000). Lithography is the earlier technique that has been accomplished in glass/silicon substrates. However, the fabrication processes involved are fairly time-consuming, labor intensive, and expensive. Using UV laser ablation or micromilling, a polymer substrate can be exposed to laser radiation or a milling bit, resulting in the direct writing of the microstructures into the polymer part. In the case of laser ablation, the laser
c04.indd 61
1/12/2011 9:44:03 AM
62
CELL-BASED ANALYSIS WITH MICROFLUIDIC CHIP
photons, typically from a pulsed excimer laser, are focused directly on the polymer. Fluidic channels are produced either by moving the polymer substrate or by moving a focused laser beam across the surface. This method offers the ability to form complex features with various geometries, even in three dimensions because the patterning beam can be moved both horizontally and vertically on the substrates. In either case, fluidic prototypes can be rapidly produced using direct writing techniques to optimize the device performance before mass production using microreplication techniques. Hot embossing and/or injection molding involves the use of mold masters containing the desired microstructures to stamp patterns into the required substrate. The patterns poised on the mold masters can be made either by micromachining or by a lithography-based approach, such as LiGA (lithograhie electroformung abformung, lithography electroplating molding). The LiGA processing steps using x-ray lithography to build the microstructures on the mold master is shown in Figure 4.2. The important aspect of this technology is that the difficult fabrication steps, lithography and electroplating, are performed only once and then parts are microreplicated from the master mold using either injection molding or hot embossing. Soft lithography, also named PDMS fabrication technology, was developed by Whitesides and co-workers and has been widely adopted for the fabrication of different microfluidic networks (Anderson et al., 2000a; Duffy et al., 1998, 1999; McDonald and Whitesides, 2002; Sia and Whitesides, 2003). Fabrication of microfluidic structures using PDMS technology involves pouring a solution containing the PDMS prepolymer and a curing agent over a relief (mold) containing the prerequisite microstructures followed by curing to cross-link the polymer. This technology first requires creation of positive relieves using a variety of techniques (Becker and Gartner, 2000; Love et al., 2001), such as wet etching of silicon or glass followed by photolithography, micromachining metals, or reactive ion etching. A solution containing the pr-polymer and curing agent is then cast against the relief and the cross-linked polymer conforms to the shape of the relief. After casting, the polymer is simply removed from the relief, resulting in a replica that contains the network of microfluidic channels. Finally, the PDMS replicate can be plasma oxidized and sealed to other surfaces by conformal contact to enclose the fluidic network. Plasma oxidation also renders the PDMS channels hydrophilic so that they can easily be filled with aqueous solutions. Besides plasma oxidation, Quake and coworkers (2000) have described a method for sealing fluidic networks created in PDMS, which involves the use of two slabs; one slab consists of an excess of base while the other contains the curing agent. These two are then brought into conformal contact followed by curing. 4.2.2
Cell Culture and Analysis
Microfluidic devices are especially suitable for biological applications, particularly on cellular level, because the scale of the channels is commensurate with
c04.indd 62
1/12/2011 9:44:03 AM
FABRICATION OF THE MICROFLUIDIC CHIP AND CELL CULTURE
63
Lithography Synchrotron irradiation Absorber structure Mask membrane Resist Base plate
Resist structure
Electroplating
Metal Resist structure Electrically conductive base plate
Molding
Mould cavity Plastic structure
Figure 4.2. Processing steps required to prepare a mold master using x-ray LiGA and molding finished parts. The process starts with a lithography step using a mask that transfers the desired pattern into a photoresist. Following development of the resist, the underlying metal layer is exposed, which serves as a plating base for another metal that fills the voids left by the resist that was removed due to exposure to the patterning radiation. The deposited metal forms the desired microstructures. The unexposed resist is then removed, forming the finished master mold. This master mold is then available for microreplicating parts in polymers or other materials using hot embossing or injection molding. At the right is the master mold and parts that have been prepared from it (Situma et al., 2006; Ford et al., 1999).
c04.indd 63
1/12/2011 9:44:03 AM
64
CELL-BASED ANALYSIS WITH MICROFLUIDIC CHIP
that of the cells’ (Walker et al., 2004), and the scale of the device allows important factors (e.g., growth factors) to accumulate locally, forming a stable microenvironment for cell culture (Mahoney et al., 2005). Compared to traditional culture tools, microfluidic platforms provide much greater control over cell microenvironments and rapid optimization of media composition using relatively small numbers of cells. 4.2.2.1 Static Cell Culture In recent years, there have been many reports concerning cell culture with microdevices, various cells such as epithelium cells, interstitial cells, cancer cells, and even stem cells grow well in the devices. Most of the culture processes involve static medium—for instance, our research group developed a single-channel PDMS chip used for the culture of lung cancer cell line H446 to explore the function of glucose-regulated protein 78 (GRP78), an endoplasmic reticulum chaperone, in chemotherapy-resistance lung cancer (Ying-Yan et al., 2008). Also, Wlodkowic et al. (2009) describe an inexpensive method for production of reusable, optical-grade PDMS microculture chips that provide a static and self-contained microwell system analogous to conventional polystyrene multiwell plates. Shao and co-workers (2009) developed an integrated microfluidic cell culture platform in which endothelial cells (ECs) are under static conditions or exposed to a pulsatile and oscillatory shear stress. Until now, static cell culture was still a key method for studying biological function of cells. But static environments are far from representative of cells in vivo and rarely involve long-term cell culture. Therefore, it is essential to establish a microfluidic platform supplied with fresh medium of oxygen and nutrition at a continuous control flow rate for mimicking cellular microenvironments and achieving cell culture and biomedical assay in an environment closer to the in vivo situation. 4.2.2.2 Dynamic Cell Culture To achieve the goal of long-term cell culture in higher density and larger numbers in a microenvironment closer to in vivo conditions, continuous nutrition and oxygen supply and waste removal through the culture medium have to be ensured. Takayama and co-workers (2004) described the use of horizontally oriented mini-reservoir arrays as a gravitydriven pumping system to generate multiple fluid streams inside microfluidic cell culture channels at a constant flow rate for prolonged periods. Maharbiz et al. (2003) presented a microfabricated electrolytic oxygen generator for high-density miniature cell culture arrays. Long-term (>2 weeks) cultures of muscle cells spanning the whole process of differentiation from myoblasts to myotubes was reported by Folch and co-workers. Prokop et al. (2004) developed nanoliter bioreactors (NBRs) for long-term culture and maintaining up to several hundred cultured mammalian cells in volumes three orders of magnitude smaller than those in standard multiwell screening plates. Refreshable Braille display–based microfluidic bioreactors, which are more densely packed and not limited to linear and unidirectional perfusion, were developed for cell culture up to 3 weeks under perfusion (Gu et al., 2004). Yasuda and co-workers
c04.indd 64
1/12/2011 9:44:03 AM
FABRICATION OF THE MICROFLUIDIC CHIP AND CELL CULTURE
3 cm
1
65
2
5 cm
24 h
48 h
72 h
96 h
Figure 4.3. Long-term cell culture of SPCA cells in the microfluidic system. An LM photo for each time period (from 1 day to 4 days) indicated SPCA cells grew well and propagated gradually. Magnification is ×100. (Zhao et al., 2010).
developed a type of on-chip microcultivation chamber, which could directly measure the valve opening/closing by optical microscope, for long-term cultivation of swimming cells. Fujii and co-workers achieved large-scale cell culture (up to 107 cells/cm3) in a microfluidic device with a multilayer bioreactor containing an oxygen supply system. Lee and co-workers presented a microfluidic cell culture array that could assay 100 different cell-based experiments in parallel for long-term cellular monitoring. Repeated cell growth/passage cycles, reagent introduction, and real-time optical analysis could all be achieved in this microdevice. Recently, our research group developed a integration microfluidic system consisting of a MS26 syringe pump and single-channel PDMS chip used for a lung cancer cell line culture (SPCA1) for at least 5 days (Zhao et al., 2010) (Fig. 4.3). 4.2.2.3 3D Cell Culture To improve the efficiency of cell culture and closer to the stereoscopic manner in vivo, some approaches, such as fabricating threedimensional (3D) microstructures (Kojima et al., 2003; Moriguchi et al., 2002; Tan and Desai, 2004) and attempting other biocompatible materials (Leclerc et al., 2004), are presented. Yasuda and co-workers developed a method that
c04.indd 65
1/12/2011 9:44:03 AM
66
CELL-BASED ANALYSIS WITH MICROFLUIDIC CHIP
made use of noncontact 3D phototherma etching with a 1480-nm or 1064-nm infrared focused laser beam to form shapes of agar microstructures for cultivating cells. Desai and co-workers fabricated a 3D heterogeneous multilayer tissue-like structure inside microchannels for cell culture. Single and multiple stepwise microstructures were fabricated in photosensitive biodegradable polymers poly-(caprolactone (CL)-dl-lactide (LA)) tetraacrylate for static cell culture of Hep G2 cells and fetal human hepatocyte (FHH) cells (Leclerc et al., 2004). Other approaches for microfluidic cell culture were also studied. Cell cultivation was performed in a highly parallelized manner in fluid segments that were formed as droplets at a channel junction. Organic and cellcontaining aqueous phases were merged at channel junctions (Martin et al., 2003). A multichannel microelectrode array that could influence and record electrical cellular activity was integrated into the microfluidics for cell culture (Pearce et al., 2005). A gradient-generating microfluidic platform for optimizing proliferation and differentiation of neural stem cells in culture was described by Jeon and co-workers. 4.2.2.4 Single-Cell Analysis Systems Our understanding of many biological processes would greatly benefit if we had the ability to analyze the content of single cells. Today, there are only a few conventional systems that enable direct intrinsic studies of single cells, including capillary electrophoresis (CE) and flow cytometry. These systems, however, are based on conventional technologies and instrumentation, they give only limited information about the cell content and do not present a general method for single cell analysis. Recent, rapid developments in microfabrication and nanofabrication technologies, have already led to the successful so called laboratory on a chip (LOC) concept and these developments offer great opportunities for the analysis of single cells. Takayama et al. (2001) reported that by using multiple laminar streams, which constitute one of the most important characteristics of a microfluidic channel, it has been possible to partially stimulate selected domains inside cells. These investigators used fluorescent tags to detect subcellular positioning of small molecules. Microchips with complicated microstructures can also be used to screen for gap-junction formation between two adjacent cardiomyocytes. Tanaka and co-workers (2002) developed a novel single-cell analysis system consisting of a scanning thermal lens microscope (TLM) detection system and a cell culture microchip (Figure 4.4a). TLM is a sensitive instrument to detect nonfluorescent molecules using a microspace. The detection process is based on absorption of visible or UV light followed by a photothermal process (Kitamori et al., 2004). Generally, fluorescent probes are labeled to cells to detect subcellular positioning of small molecules. However, it is difficult to detect subcellular molecules directly without using fluorescent tags by this method. On the other hand, the system using TLM could detect nonfluorescent biological substances with extremely high sensitivity without any labeling materials, and it had a high spatial resolution of ∼1 μm. The microchip system was good for liquid control and simplified troublesome procedures. This system
c04.indd 66
1/12/2011 9:44:03 AM
APPLICATION OF THE CELL-BASED MICROFLUIDIC CHIP
(a)
67
Staurosporine
Microsyringe pump
TLM detection (532 nm)
Drain X-Y scanning stage
Cell culturing flask 30 µm
(b) 9–10 8–9
30 µm
7–8 6–7 5–6 4–5 3–4 2–3 1–2 0–1 + Staurosporine
Figure 4.4. (See color insert.) A single-cell analysis system in a glass microchip using a thermal lens microscope (TLM). (a) Cell culture chip design and TLM scanning method. A microflask (1 mm × 10 mm × 0.1 mm) was fabricated in a glass microchip, and a cell suspension was introduced into it. After cultivation, the microchip with capillaries connected to syringe pumps was mounted on the TLM stage, and TLM signals were measured while scanning the stage to obtain a 2D-image. (b) Direct imaging of cytochrome-c in a cell and its distribution change during apoptosis (Tamaki et al., 2002).
was applied to monitoring cytochrome-c distribution in a neuroblastomaglioma hybrid cell cultured in the microflask (Fig. 4.4b). This system seems to be applicable to monitoring compounds released in cells, when used in combination with analytical microchips. 4.3
APPLICATION OF THE CELL-BASED MICROFLUIDIC CHIP
Microfluidic chips are used for transporting and manipulating minute amount of fluids and/or biological entities through microchannel manifolds, allowing
c04.indd 67
1/12/2011 9:44:03 AM
68
CELL-BASED ANALYSIS WITH MICROFLUIDIC CHIP
integration of various chemical and biochemical processes into fast and automated monolithic microflow systems. It has become evident that there is a tremendous market potential for microdevices aiding in diagnostics, drug discovery, and evaluation of new pharmaceuticals, since these devices are expected to satisfy the urgent demand for high-throughput and large-scale applications. In this section, some applications cover genomics and proteomics analysis and chemotherapy resistance in cancer with the microfluidic devices are described. 4.3.1
Genomic Analysis on Chip
Separation of nucleic acids is one of the leading applications of microchipbased analysis today. Due to the negligible deteriorating effects of Joule heating during electric field–mediated separations in microchannels and the ability to inject very small, well-defined sample plugs, the resolving power of microfluidic bioanalytical devices are mainly diffusion limited, resulting in superior performance compared to slab gel and capillary electrophoresis. Rapid, high-quality separations on chip have been demonstrated for the analysis of oligonucleotides and RNA and DNA fragments. 4.3.1.1 Sample Preparation and Separation The shorter separation distances, compared to those used in conventional CE, represent new challenges to the optimization of separation conditions, such as electrokinetic manipulations, channel geometry, and sieving media. The geometrical effects of folded microchannel structures on band broadening have been extensively studied and developed for CE instruments, based on viscous solutions of entangled water-soluble polymers, and successfully applied to microchip electrophoresis. Linear polyacryamide and its derivatives—polydimethy-acryamide, polyethylene oxide, polyethylene glycol with fluorocarbon tails, hydroxyethylcellulose and various cellulose derivatives, and other polysaccharides—have been used for size separation of nucleic acid molecules in capillaries, and some of these matrices have also been adapted for microchip electrophoresis. Recently introduced novel thermoresponsive co-polymers, making up hydrophobic and hydrophilic blocks have also shown promising results in terms of efficiency and the possibility of theoretical modeling of acrylamide grafted with polyethylene oxide chains (Liang et al., 1999). These matrices have a pronounced temperature-dependent viscosity transition point, which suggests promising implementations. In particular, thermoresponsive polymers can offer some practical advantages for microchannel electrophoresis, enabling easier handling and loading of the viscous polymer solutions without the requirement of a high-pressure manifold. Buchholz et al. (2001) have constructed interesting ‘‘viscosity switch’’ materials, which respond to changes of temperature, pH, or ionic strength. These matrices are based on co-polymers of acrylamide derivatives with variable hydrophobicity and possess a reversible temperature-controlled viscosity
c04.indd 68
1/12/2011 9:44:03 AM
APPLICATION OF THE CELL-BASED MICROFLUIDIC CHIP
69
switch from high-viscosity solutions at room temperature to low-viscosity colloid dispersions at elevated temperatures. Also, high resolving power and good DNA persequencing performance were achieved with these sieving media. 4.3.1.2 DNA Analysis and Genotyping Major applications of electrophoresis microchips include sizing of double-stranded DNA fragments (Effenhauser et al., 1997; Woolley and Methies, 1994; McCormick et al., 1997; Duffy et al., 1999; Ronai et al., 2001), short single-stranded oligonucleotides (Effenhauser et al., 1994), and ribosomal RNA fragments (Ogura et al., 1998). High separation performance and speed have been achieved. DNA genotyping on microchips enables quick identification of genes and can substantially enhance the capabilities of genomic, diagnostic, pharmacogenetic, and forensic tests. The identification of genes related to heredity diseases, such as hemachromatosis (Woolley et al., 1997), has been successfully performed on chip. An ultra-fast allelic profiling assay for the analysis of short tandem repeats (STRs) has also been demonstrated (Schmalzing et al., 1999). Separation of a CTTv quadruplex system was accomplished in <2 min using a 26-mm separation distance, which is 10–100 times faster than capillary or slab gel electrophoresis, respectively (Schmalzing et al., 1997). Two-color multiplex analysis of eight STR loci has also been performed by the same group. 4.3.1.3 Polymerase Chain Reaction The polymerase chain reaction (PCR) is a key process in genetic analysis and has played an important role in modern biology and biochemistry research. However, the conventional 96well PCR devices usually have a thermal cycling rate of 1–2°C/s; therefore, a complete PCR amplification needs 1–2 h or even longer. Moreover, by this approach, both the sample preparation and the post-PCR product detection need to be performed off-line, resulting in a long analysis process and a high risk of cross-contamination. Therefore, there have been many driving forces to exploit the potential benefits of microsize PCR apparatus (also called PCR microfluidic chips), which include reduced consumption of samples and reagents, shorter analysis time, greater sensitivity, portability, and disposability. The obvious benefits of such miniaturization come from the improved thermal energy transfer compared to conventional macrovolumes, resulting in a greatly increased speed of thermal cycling, reduced amount of expensive reagents used, and the possibility to create versatile, multifunctional integrated systems. However, potential problems, associated with PCR downscaling, such as surface-related effects, become greatly enhanced with shrinking reaction volumes and the resulting increase in surface-to-volume ratio. Various biocompatible PCR-friendly surfaces have been investigated by passive silicon, fusedintro silica, glass or plastic walls via coatings by chemical modification, and/or physical adsorption. Another issue is related to handling of small volumes of liquids and the incorporation of miniaturized DNA amplification units into the chain of
c04.indd 69
1/12/2011 9:44:03 AM
70
CELL-BASED ANALYSIS WITH MICROFLUIDIC CHIP
sample processing and analysis, to develop truly automated and highthroughput technology. A number of studies have been done to optimize microscale DNA amplification. Two possible embodiments can be envisioned— closed microchamber and open format, both of which can be multiplexed to an array. Fast real-time PCR analysis was demonstrated in silicon microchambers by several groups (Belgrader et al., 1999; Northrup et al., 1998; Wilding et al., 1998). DNA amplification can be coupled with special microfluidic cartridges designed to carry out several sequential steps of DNA extraction from different sample types (tissues, cells, whole blood, soil, food, etc.) before the PCR. DNA amplification in open format has not yet been reported, but other chemical and enzymatic reactions conducted in nanovials and picovials have shown promising results (Litborn et al., 1999, 2000; Clark and Ewing, 1998; Bernhard et al., 2001). 4.3.2 Protein Analysis on Chip The conventional approach to analyzing protein molecules typically comprises their extraction from cells, separation and detection by one- or two-dimensional gel electrophoresis, bands cut out and in gel digestion, followed by MS analysis of the resulting peptide mixture. These traditional techniques are slow and labor intensive. Fast and high-throughput integrated multisample systems are in great demand. Microfluidic devices offer opportunities that are unavailable in traditional protein analysis technologies, with the potential to control and automate multiple sample processing steps. The majority of recent developments in microfluidics for protein applications have been related to the combination of single or multidimensional microchannel separations and MS detection. 4.3.2.1 Separation and System Integration A number of research groups have been focusing on the realization of traditional 2D gel electrophoresis in a microchip format. The problems of protein purification and desalting before the analysis were addressed in microfabricated structures using semipermeable membranes, sandwiched between microfluidic manifold layers and connecting the buffer and analyte counterflows (Jiang et al., 2001). Such microdialysis enabled effective cleanup of analytes of interest from low molecular mass compounds and enhanced the following MS characterization. Figeys and Pinto (2001) reported examples of isoelectric focusing (IEF) of proteins in microchips, demonstrating the potential of microscale techniques. Chip-based IEF has been accomplished in 30 s in a 7-cm channel with a peak capacity of 30–40 peaks (Hofmann et al., 1999). Electroosmotically driven mobilization of the focused zones was found the most suitable technique for the microchip approach due to its easy implementation and high speed. An integrated IEF-electrospray ionization-MS plastic microfluidic device, coupling an electrospray tip to an IEF microchip, has also been reported (Wen et al., 2000).
c04.indd 70
1/12/2011 9:44:03 AM
APPLICATION OF THE CELL-BASED MICROFLUIDIC CHIP
71
Chromatography and electrophoresis are the two major separation techniques for proteins. The latter is by far more popular in microchip applications due to its easier realization in miniaturized formats. Nevertheless, on-chip chromatographic separations have recently been attempted by trapping coated beads into a microcavity within a microchannel network or using in situ microfabricated (He et al., 1999) or polymerized (Ericson et al., 2000) beds. The development of more sophisticated microfluidic systems with both horizontal integration (by building parallel analysis lanes for high-throughput applications) and vertical integration (by implementing several functions on a single device) is perhaps the most exciting trend in the microchip world. Recently, a new microfluidic glass device was developed for an integrated protein sizing assay that performs separation, staining, virtual destaining and detection steps and can sequentially analyze 10 different samples in <30 min (Bousse et al., 2001). Universal noncovalent fluorescent on chip labeling was employed in combination with postseparation dilution to reduce the fluorescent background associated with SDS micelle-bound dye and increase the signal-to-noise ratio. The applicability of this technique to microscale protein separations has been investigated by several research groups (Colyer et al., 1997; Liu et al., 2000; Csapo et al., 2000). High speed; the sensitivity of microseparations; and the option of on-chip precolumn or postcolumn labeling, mixing, destaining, and so on proved to be clearly beneficial in combination with noncovalent protein staining dyes. High separation efficiency and good detection limits were demonstrated. 4.3.2.2 Immunoassay Immunoassays represent a very important tool in clinical diagnostics and biomedical research and industry. Various miniaturized immunoassays, mostly based on competitive antigen–antibody interactions, were successfully performed on electrophoresis microchips, demonstrating greater speed and feasibility of automated analysis in a portable format. Among recent developments, Gottschlich et al. (2000) reported an integrated microchip device that sequentially performed enzymatic reactions, electrophoretic separation of the products, and postseparation on-line labeling of the peptides and proteins, followed by fluorescent detection. Our group also detected the expression of glucose regulated protein 78 (GRP78) in an integrated PDMS chip with immunoassay, showing several advantages over conventional testing in terms of time and sensitivity (Wang et al., 2009). A new class of microfluidic immunoassays is based on solid supported lipid bilayers (Yang et al., 2001). The bilayers, created on PDMS surfaces of an array of parallel microchannels contained dinitrophenyl (DNP) conjugated lipids for binding with fluorescently labeled anti-DNP antibodies of different concentrations in each channel. The methodology can be used for performing rapid and accurate heterogeneous assays in a single experiment, and the amount of proteins required is significantly reduced compared to conventional methods.
c04.indd 71
1/12/2011 9:44:03 AM
72
CELL-BASED ANALYSIS WITH MICROFLUIDIC CHIP
4.3.2.3 Microchip and Mass Spectrometry Since MS is one of the most frequently used methods of choice in protein analysis and characterization, a number of successful efforts have been reported to couple microfluidic devices to mass spectrometers (Figeys and Pinto, 2001; Licklider et al., 2000). Such combinations enabled automated sample delivery and enhanced MS analysis efficiency—for instance, sample processing, enrichment, cleanup, and fractionation before the detection. These devices can transport the analyte fluid electrokinetically or by pressure and generate electrospray via an attached capillary or more complex emitter couplings. Enzymatic digestion was monitored by peptide mass fingerprinting in real time, with high detection sensitivity on a hybrid microchip nanolectrospray device (Lazar et al., 2001). Ekstrom et al. (2000) also described the automated MS analysis, using a porous microfabricated digestion chip, integrated with a sample pretreatment robot and microdispenser for transferring the reaction products to an MALDI target plate. 4.3.3
Analysis of Chemotherapy Resistance in Tumor Cells
Cancer is the third leading cause of death worldwide. The major clinical strategy for administration of cancer with the advanced stages is chemotherapy. However, the success of the treatment is limited by the intrinsic or acquired resistance of cancer cells to chemotherapy. Microchip-based systems or lab on a chip have many advantage, such as a short diffusion distance, a large specific interface area, and a rapid and efficient reaction, showing a promising future for the research on chemotherapy resistance. Recently, our group and other researchers have done much work on chemotherapy resistance with this platform. 4.3.3.1 Assay of Drug Resistance Related Protein The conventional methods for the in vitro detection of drug resistance related protein mainly include immunoprecipitation, Western blotting, and gel electrophoretisis on the cells cultured in flasks (Ramsay et al., 2005; Reddy et al., 2003). These processes involve a relatively long time, troublesome liquid-handling procedures, and large quantities of consumed reagents; some require labor-intensive purification of the protein and complex analysis steps. Our group fabricated three kinds of chips: a straight channel chip, a gradient chip, and a micro-pump chip. Figure 4.5 shows a gradient chip, it was composed of an upstream concentration gradient generator (CGG) and a downstream cell culture module. The chip was fabricated in PDMS by using standard soft lithography methods and rapid prototyping techniques. Gradient concentrations of an anticancer drug can be formed through the concentration gradient generator. Lung cancer cells were introduced into the cell culture chambers and grew well in that. This work aimed to study the correlation between the expression of GRP78 and the resistance to the anticancer drug VP-16 in the human lung squamous carcinoma cell line SK-MES-1 using the integrated microfluidic gradient chip
c04.indd 72
1/12/2011 9:44:03 AM
73
APPLICATION OF THE CELL-BASED MICROFLUIDIC CHIP
(a)
A23187 concentrations
1 2 3 4 5 6 7 8
Low 0.0 µM
0.86 µM
1.71 µM
High 2.57 µM
(a) 3.42 µM
(b) 4.28 µM
(c) 5.13 µM
(d) 6.00 µM
(e)
(f)
(g)
(h)
a b c d e f g h
Cell culture chambers
Normalized fluorescence intensity per Cell
(b) 140.00 130.00 120.00 110.00 100.00 90.00 80.00 70.00 60.00 0.00
0.86
1.71
2.57
3.42
4.28
5.13
6.00
A23187 Concentrations (µM)
Figure 4.5. (See color insert.) The expression of GRP78 on a protein level by immunofluorescence in SK-MES-1 cells. (a) Cells were treated with A23187 for 24 h and observed by fluorescence microscope (IX-71; Olympus Optical Co., Tokyo, Japan) (×400). The fluorescent indicated GRP78 in the cytoplasm. (b) The average expression of GRP78 per cell reflected by normalized fluorescent intensities increased with the concentrations of A23187. The normalized fluorescent intensities per cell were determined by the number of cells in a region divided by the fluorescent intensity in that region (Wang et al. 2009).
c04.indd 73
1/12/2011 9:44:03 AM
74
CELL-BASED ANALYSIS WITH MICROFLUIDIC CHIP
device. We used A23187, a GRP78 inducer, with a gradient concentration in the upstream network of the device to induce the expression of GRP78 in the cells cultured in the downstream before the addition of VP-16. The expression of GRP78 was detected by immunofluorescence, the apoptosis for the cells treated by VP-16 was assessed morphologically by 4′,6-diamidino-2phenylindole (DAPI) staining. The results indicated that the expression of GRP78 increased greatly for the cells under the induction of A23187 in a dose-depended manner, while the percentage of apoptotic cells decreased significantly after being treated by VP-16. The results confirmed the role GRP78 plays in the chemotherapy resistance to VP-16 in the SK-MES-1 cell line, suggesting that the integrated microfluidic systems may be an unique approach for characterizing the cellular responses. (Wang et al., 2009). 4.3.3.2 Anticancer Drug Cytotoxicity Assay Sugiura et al. (2008) reported a pressure-driven perfusion culture chip developed for parallel drug cytotoxicity assay. The device is composed of an 8 × 5 array of cell culture microchambers with independent perfusion microchannels. It is equipped with a simple interface for convenient access by a micropipette and connection to an external pressure source, which enables easy operation without special training. The unique microchamber structure was carefully designed with consideration of hydrodynamic parameters and was fabricated out of a polydimethylsiloxane by using multilayer photolithography and replica molding. The microchamber structure enables uniform cell loading and perfusion culture without cross-contamination between neighboring microchambers. A parallel cytotoxicity assay was successfully carried out in the 8 × 5 microchamber array to analyze the cytotoxic effects of seven anticancer drugs. The pressure-driven perfusion culture chip, with its simple interface and well-designed microfluidic network, will likely become platform for future high-throughput drug screening by microchip. 4.3.3.3 Analysis of Anticancer Drugs Efficiency Popovtzer and coworkers (2008) describe a new method for rapid, sensitive, and high-throughput detection of colon cancer cells’ response to differentiation therapy using a novel electrochemical lab-on-a-chip system. Differentiation-inducing agents such as butyric acid and its derivatives were introduced to minuature colon cancer samples within the nanovolume chip chambers. The efficacy of each of the differentiation-inducing agents was evaluated by electrochemical detection of the cellular enzymatic activity level, whereas reappearance of normal enzymatic activity denotes effective therapy. The results demonstrate the ability to evaluate simultaneously multiplex drug effects on miniature tumor samples (approximately 15 cells) rapidly (5 min) and sensitively, with quantitative correlation between the number of cancer cells and the induced current. The use of miniature analytical devices is of special interest in clinically relevant samples, in that it requires less tissue for diagnosis and enables
c04.indd 74
1/12/2011 9:44:03 AM
CONCLUSIONS AND FUTURE PROSPECTS
75
high-throughput analysis and comparison of various drug effects on one small tumor sample, while maintaining uniform biological and environmental conditions.
4.4
CONCLUSIONS AND FUTURE PROSPECTS
In this chapter we reviewed a sampling of recently reported cell-based bioanalysis with microfluidic chips. The objective was to provide a glimpse into the current state of the art in these fields. As we have stated, microfluidic devices are powerful tools for cell-based analysis exhibiting numerous advantages, such as reduced reagent consumption, improved performance, multifunctional possibilities with interconnected network of channels, inherent mechanical stability of monolithic systems, and the possibility of parallelization and inexpensive mass production. System integration plays one of the most significant roles in miniaturization and will lead to greater process intensification. As miniaturization greatly improves heat and mass transfer, it opens new horizons and leads to revolutionary changes in bioanalytical sciences and separation technology. Microfluidic systems enable rapid identification of nucleic acids, proteins, drugs, and other compound, using subnanogram amounts of sample and provide online interface with upstream/downstream processing and analysis, such as sample preparation, microdialysis, separation, and MS detection. In the meantime, current cell-based bioanalysis with microfluidic chips still require improvements, especially in microfabrication techniques. The successful applications of cell-based microfluidics analysis include cell lysis, cell culture, chemical and biochemical sensing, and other perform process. On-chip cell lysis can be realized using chemical, mechanical, and electrical methods. All these lysis methods should be integrated with microfluidics. To achieve efficient deliveries of lysis reagents or on-chip generation of lysis reagents, more microfluidic components should be fabricated, increasing the complexity of the microdevices. Mechanical-based lysis also faces the same challenge. Electrical-based lysis is the most widely used in microfluidic cell lysis due to its easy integration and simplified instrumentation and will obtain more applications. On-chip cell culture can be successfully achieved in microfluidic platform. Different materials (silicon, PDMS, and borosilicate) have proved to be suitable substrates for cell growth. Due to its inherent properties, PDMS has become the dominant material for fabricating cell culture chips. Micropumps and oxygen generators have been incorporated into microfluidics to achieve long-term cell culture and culturing cells up to higher density and larger numbers. To improve the efficiency of cell culture, 3D microstructures have also been fabricated in cell culture chips. Electroporation and electrofusion microchips can achieve the necessary electric field with a much lower required applied voltage, avoiding the potential risks of using high voltage and dissipating heat more quickly due to large surface/volume ratio. Though they
c04.indd 75
1/12/2011 9:44:03 AM
76
CELL-BASED ANALYSIS WITH MICROFLUIDIC CHIP
still suffer from the low survival rate, their advantages have not been fully exploited. Complicated optical setup and complex operation limit applications of optimization of microchips. Miniaturization of analytical devices promises numerous benefits, including reduced cell consumption, automated and reproducible reagent delivery, and improved performance. Microcytometry is the most successful application of microfluidic systems for cell-based assays. Various detection methods such as confocal detection, optical stretcher, impedance spectra, and coincident light scattering detection can be incorporated into microcytometers for different applications. Many of the necessary components and functionalities of a typical room-size laboratory, such as pumps, dampers, switch valves, and input and output wells can be integrated into a small chip for cell sorting. Chemical cytometry can also be successfully achieved in microfluidic platform. A variety of small molecules, large proteins, and DNA can be simultaneous analyzed in chemical cytometer chip within a single run. Especially arresting is the possibility of treating and analyzing single living cells using microfluidic devices. A variety of intracellular parameters and cell metabolites have been analyzed and detected using microfluidics, which also demonstrate the versatility of microfluidics. With the employment of nanotechnology, single cell-based microfluidic devices for various sophisticated experiments will be the future direction of this research area.
4.5
ACKNOWLEDGMENTS
This work was supported by the National Nature Science Foundation of China (30670532).
4.6
REFERENCES
Anderson JR, Chiu DT, Jackman RJ, Cherniavskaya O, McDonald JC, Wu H, Whitesides SH, Whitesides GM. (2000a). Fabrication of topologically complex three-dimensional microfluidic systems in PDMS by rapid prototyping. Anal Chem 72(14): 3158–64. Andersson H, van den Berg A. (2003). Microfluidic devices for cellomics: a review. Sensors Actuators Chemi 92(3):315–25. Auroux PA, Iossifidis D, Reyes DR, Manz A. (2002). Micro total analysis systems. 2. Analytical standard operations and applications. Anal Chem 74:2637–52. Becker H, Gartner C. (2000). Polymer microfabrication methods for microfluidic analytical applications. Electrophoresis 21(1):12–26. Belgrader P, Benett W, Hadley D, Richards J, Stratton P, Mariella R Jr, Milanovich F. (1999). PCR detection of bacteria in seven minutes. Science 284:449–50. Bernhard DD, Mall S, Pantano P. (2001). Fabrication and characterization of microwell array chemical sensors. Anal Chem 73:2484–90.
c04.indd 76
1/12/2011 9:44:03 AM
REFERENCES
77
Bousse L, Mouradian S, Minalla A, Yee H, Williams K, Dubrow K. (2001). Protein sizing on a microchip. Anal Chem 73:1207–12. Buchholz BA, Doherty EA, Albarghouthi MN, Bogdan FM, Zahn JM, Barron AE. (2001). Microchannel DNA sequencing matrices with a thermally controlled “viscosity switch.” Anal Chem 73(2):157–64. Clark RA, Ewing AG. (1998). Characterization of electrochemical responses in picoliter volumes. Anal Chem 70:1119–25. Colyer CL, Mangru SD, Harrison DJ. (1997). Microchip-based capillary electrophoresis of human serum proteins. J Chromatogr 781:271–76. Csapo Z, Gerstner A, Sasvari-Szekely M, Guttman A. (2000). Automated ultra-thinlayer SDS gel electrophoresis of proteins using noncovalent fluorescent labeling. Anal Chem 72:2519–25. Duffy DC, Schueller OJA, Brittain ST, Whiteside GM. (1999). Rapid prototyping of microfluidic switches in poly(dimethylsiloxane) and their actuation by electroosmotic flow. J Micromech Microeng 9(3):211–17. Effenhauser CS, Bruin GJM, Paulus A. (1997). Integrate chip-based capillary electrophoresis. Electrophoresis 18:2203. Effenhauser CS, Paulus A, Manz A, Widmer HM. (1994). High-speed separation of antisense oligonucleotides on a micromachined capillary electrophoresis device. Anal Chem 66:2949–53. Ekstrom S, Opperfjord P, Nilsson J, Bengsson M, Laurell T, Marko-Varga G. (2000). Integrated microanalytical technology enabling rapid and automated protein identification. Anal Chem 72:286–93. Ericson C, Holm J, Ericson T, Hjerten S. (2000). Electroosmosis and pressure-driven chromatography in chips using continuous beds. Anal Chem 72:81–87. Erickson D, Li DQ. (2004). Integrated microfluidic devices. Anal Chim Acta 507:11–26. Figeys D, Pinto D. (2001). Protomics on a chip: promising developments. Electrophoresis 22:208–16. Ford SM, Davies J, Kar B, Qi SD, McWhorter S, Soper SA, Malek CK. (1999). Micromachining in plastics using x-ray lithography for the fabrication of microelectrophoresis devices. J Biomech Eng 121(1):13–21. Friedrich CR, Coane PJ, Vasile, MJ. (1997). Micromilling development and applications for microfabrication. Microelectron Eng 35(1–4):367–72. Gottschlich N, Culbertson CT, McKnight TE, Jacobson SC, Ramsey JM. (2000). Integrated microchip-device for the digestion, separation, and postcolumn labeling of proteins and peptides. J Chromatogr 745:243–49. Grass B, Neyer A, Johnck M, Siepe D, Eisenbeiss F, Weber G, Hergenroder, R. (2001). A new PMMA-microchip device for isotachophoresis with integrated conductivity detector. Sens. Actuators B 72(3):249–58. Gu W, Zhu X, Futai N, Cho BS, Takayama S. (2004). From the cover: computerized microfluidic cell culture using elastomeric channels and braille displays. Proc natl Acad Sci U S A 101:15861–66. He B, Li J, Regnier F. (1999). Capillary electrochromatography of peptides in a microfabricated system. J Chromatogr A 853:257–62. Hofmann O, Chi D, Cruickshank KA, Muller UR. (1999). Adaptation of capillary isoelectric focusing to microchannels on a glass chip. Anal Chem 71:678–86.
c04.indd 77
1/12/2011 9:44:04 AM
78
CELL-BASED ANALYSIS WITH MICROFLUIDIC CHIP
Huh D, Gu W, Kamotani Y, Grotberg JB, Takayama S. (2005). Microfluidics for flow cytometric analysis of cells and particles. Physiol Meas 26:R73–98. Ihlemann J, Rubahn, K. (2000). Excimer laser micro-machining: fabrication and applications of dielectric masks. Appl Surf Sci 154–155: 587–92. Jiang Y, Wang P-C, Locascio LE, Lee CS. (2001). Integrated plastic microfluidic deviceswith ESI-MS for high throughput drug screening and residue analysis. Anal Chem 73:2048–53. Kitamori T, Tokeshi M, Hibara A, Sato K. (2004). Thermal lens microscopy and microchip chemistry. Anal Chem 76(3):52A–60A. Kojima K, Moriguchi H, Hattori A, Kaneko T, Yasuda K. (2003). Two-dimensional network formation of cardiac myocytes in agar microculture chip with 1480-nm infrared laser photo-thermal etching. Lab Chip 3:292–96. Lazar IM, Ramsey RS, Ramsey JM. (2001). On-chip proteolytic digestion and analysis using “wrong-way-round” electrospray time-of-flight mass spectrometry. Anal Chem 73:1733–39. Leclerc E, Furukawa KS, Miyata F, Sakai Y, Ushida T, Fujii T. (2004). Fabrication of microstructures in photosensitive biodegradable polymers for tissue engineering applications. Biomaterials 25:4683–90. Li J, Thibault P, Bings NH, Skinner CD, Wang C, Colyer C, Harrison J. (1999). Integration of microfabricated devices to capillary electrophoresis electrospray mass spectrometry using a low dead volume connection: application to rapid analyses of proteolytic digests. Anal Chem 71(15):3036–45. Liang D, Song L, Zhou S, Zaitsev VS, Chu B. (1999). Poly(N-isopropylacrylamide)-gpoly(ethyleneoxide) for high resolution and high speed separation of DNA by capillary electrophoresis. Electrophoresis 20:2856–63. Licklider L, Wang X, Desai A, Tai YC, Lee T. (2000). A micromachined chip-based electrospray source for mass spectrometry. Anal Chem 72:367–75. Litborn E, Emmer A, Roeraade J. (1999). Chip-based nanovials for tryptic digest and capillary electrophoresis. Anal Chim Acta 401:11–19. Litborn E, Emmer A, Roeraade J. (2000). Parallel reactions in open chip-based nanovials with continuous compensation for solvent evaporation. Electrophoresis 21:91–99. Liu Y, Foote RS, Jacobson SC, Ramsey RS, Ramsey JM. (2000). Electrophoretic separation of proteins on a microchip with noncovalent, postcolumn labeling. Anal Chem 72:4608–13. Love JC, Wolfe DB, Jacobs HO, Whitesides GM. (2001). Microscope projection photolithography for rapid prototyping of masters with micronscale features for use in soft lithography. Langmuir 17(19):6005–12. Maharbiz MM, Holtz WJ, Sharifzadeh S, Keasling JD, Howe RT. (2003). A microfabricated electrochemical oxygen generator for high-density cell culture arrays. Microelectromech Syst 12:590–99. Mahoney MJ, Chen RR, Tan J, Saltzman WM. (2005). The influence of microchannels on neurite growth and architecture Biomaterials 26:771–78. Martin K, Henkel T, Baier V, Grodrian A, Schön T, Roth M, Michael Köhler J, Metze J. (2003). Generation of larger numbers of separated microbial populations by cultivation in segmented-flow microdevices. Lab Chip 3:202–07.
c04.indd 78
1/12/2011 9:44:04 AM
REFERENCES
79
Martynova L, Locascio LE, Gaitan M, Kramer GW, Christensen RG, MacCrehan WA. (1997). Fabrication of plastic microfluid channels by imprinting methods. Anal Chem 69(23):4783–89. McClain MA, Culbertson CT, Jacobson SC, Allbritton NL, Sims CE, Ramsey JM. (2003). Microfluidic devices for the high-throughput chemical analysis of cells. Anal Chem 75(21):5646–55. McCormick RM, Nelson RJ, Alonso-Amigo MG, Benvegnu DJ, Hooper HH. (1997). Microchannel electrophoretic separations of DNA in injection-molded plastic substrates. Anal Chem 69:2626–30. McDonald JC, Whitesides GM. (2002). Poly(dimethylsiloxane) as a material for fabricating microfluidic devices. Acc Chem Res 35(7): 491–9. Moriguchi H, Wakamoto Y, Sugio Y, Takahashi K, Inoue I, Yasuda K. (2002). An agarmicrochamber cell-cultivation system: flexible change of microchamber shapes during cultivation by photo-thermal etching. Lab Chip 2:125–30. Northrup MA, Benett B, Hadley D, Landre P, Lehew S, Richards J, Stratton P. (1998). A miniature analytical instrument for nucleic acids based on micromachined silicon reaction chambers. Anal Chem 70:918–22. Ogura M, Agata Y, Watanabe K, McCormick RM, Hamaguchi Y, Aso Y, Mitsuhashi M. (1998). RNA chip: quality assessment of RNA by microchannel linear gel electrophoresis in injection-molded plastic chips. Clin Chem 44:2249–55. Oleschuk RD, Shultz-Lockyear LL, Ning Y, Harrison DJ. (2000). Trapping of Bead Based Reagents within Microfluidic Systems: On-chip Solid Phase Extraction and Electrochromatography. Anal Chem 72:585–90. Pearce TM, Wilson JA, Oakes SG, Chiu SY, Williams JC. (2005). Integrated microelectrode array and microfluidics for temperature clamp of sensory neurons in culture. Lab Chip 5:97–101. Popovtzer R, Neufeld T, Popovtzer A, Rivkin I, Margalit R, Engel D, Nudelman A, Rephaeli A, Rishpon J, Shacham-Diamand Y. (2008). Electrochemical lab on a chip for high-throughput analysis of anticancer drugs efficiency. Nanomedicine 4(2):121–26. Prokop A, Prokop Z, Schaffer D, Kozlov E, Wikswo J, Cliffel D, Baudenbacher F. (2004). Nanoliter bioreactor: long-term mammalian cell culture at nanofabricated scale. Biomed Microdevices 6:325–39. Qi S, Liu X, Ford S, Barrows J, Thomas G, Kelly K, McCandless A, Lian K, Goettert J, Soper SA. (2002). Microfluidic devices fabricated in poly(methyl methacrylate) using hot-embossing with integrated sampling capillary and fiber optics for fluorescence detection. Lab Chip 2(2): 88–95. Ramsay RG, Ciznadija D, Mantamadiotis T, Anderson R, Pearson R. (2005). Expression of stress response protein glucose regulated protein-78 mediated by c-Myb. Int J Biochem Cell Biol 37:1254–68. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. (2003). Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 278:20915–24. Roberts MA, Rossier JS, Bercier P, Girault H. (1997). UV laser machined polymer substrates for the development of microdiagnostic systems. Anal Chem 69(11): 2035–42.
c04.indd 79
1/12/2011 9:44:04 AM
80
CELL-BASED ANALYSIS WITH MICROFLUIDIC CHIP
Ronai Z, Barta C, Sasvari-Szekely M, Guttman A. (2001). DNA analysis on electrophoretic microchips: effect of operational variables. Electrophoresis 22:294–99. Rossier JS, Schwarz A, Reymond F, Ferrigno R, Bianchi F, Girault HH. (1999). Microchannel networks for electrophoretic separations. Electrophoresis 20 (4–5): 727–31. Schmalzing D, Koutny L, Adourian A, Belgrader P, Matsudaira P, Ehrlich D. (1997). DNA typing in thirty seconds with a microfabricated device. Proc Natl Acad Sci U S A 94:10273–78. Schmalzing D, Koutny L, Chisholm D, Adourian A, Matsudaira P, Ehrlich D. (1999). Two-color multiplexed analysis of eight short tandem repeat loci with an electrophoretic microdevice. Anal Biochem 270:148–52. Shao J, Wu L, Wu J, Zheng Y. (2009). Integrated microfluidic chip for endothelial cells culture and analysis exposed to a pulsatile and oscillatory shear stress. Lab Chip 9(21):3118–25. Sia SK, Whitesides GM. (2003). Microfluidic devices fabricated in poly (dimethylsiloxane) for biological studies. Electrophoresis 24(21):3563–76. Situma C, et al. (2006). Biomolecular Engineering 23:213–31. Soper SA, Ford SM, Qi S, McCarley RL, Kelly K, Murphy MC. (2000). Polymeric microelectromechanical systems. Anal Chem 72(19):643A–651A. Sugiura S, Edahiro J, Kikuchi K, Sumaru K, Kanamori T. (2008). Pressure-driven perfusion culture microchamber array for a parallel drug cytotoxicity assay. Biotechnol Bioeng 100:1156–65. Tai HP, Shuler ML. (2003). Integration of cell culture microfabrication technology. Biotechnol Prog 19:243–53. Takahashi K, Orita K, Matsumura K, Yasuda K. (2003). On-chip microcultivation chamber for swimming cells using visualized poly(dimethylsiloxane) valves. Jpn J Appl Phys 42:L1104–07. Takayama S, Ostuni E, LeDuc P, Naruse K, Ingber DE, Whitesides GM. (2001). Subcellular positioning of small molecules. Nature 411:1016. Tamaki E, Sato K, Tokeshi M, Sato K, Aihara M, Kitamori T. (2002). Single-cell analysis by a scanning thermal lens microscope with a microchip: direct monitoring of cytochrome c distribution during apoptosis process. Anal Chem 74:1560–64. Tan W, Desai TA. (2004). Layer-by-layer microfluidics for biomimetic three-dimensional structures. Biomaterials 25:1355–64. Unger MA, Chou H-P, Thorsen T, Scherer A, Quake SR. (2000). Monolithic microfabricated valves and pumps by multilayer soft lithography. Science 288(5463): 113–16. Vilkner T, Janasek D, Manz A. (2004). Micro total analysis systems. Recent developments. Anal Chem 76:3373–85. Walker GM, Zeringue HC, Beebe DJ. (2004). Microenvironment design considerations for cellular scale studies. Lab Chip 4:91–97. Wang S, Yue F, Zhang L. (2009). Application of microfluidic gradient chip in the analysis of lung cancer chemotherapy resistance. J Pharm Biomedi Anal 49(3):806–10. Wen J, Lin Y, Xiang F, Matson DW, Udseth HR, Smith RD. (2000). Microfabricated isoelectric focusing devices for direct electrospray ionization-mass spectrometry. Electrophoresis 21:191–97.
c04.indd 80
1/12/2011 9:44:04 AM
REFERENCES
81
Wilding P, Kricka LJ, Cheng J, Hvichia G, Shoffner M, Fortina P. (1998). Integrated cell isolation and polymerase chain reaction analysis using silicon microfilter chambers. Anal Biochem 257:95–100. Wlodkowic D, Faley S, Skommer J. (2009). Biological implications of polymeric microdevices for live cell assays. Anal Chem 81(23):9828–33. Woolley AT, Mathies RA. (1994). Ultra-high-speed DNA fragment separations using microfabricated capillary ar ray electrophoresis chips. Proc Natl Acad Sci U S A 91:11348–52. Woolley AT, Sensabaugh GF, Mathies RA. (1997). High-speed DNA geno-typing using microfabricated capillary array electrophoresis chips. Anal Chem 69:2181–86. Yang T, Jung J-Y, Mao H, Cremer PS. (2001). Fabrication of phospholipid bilayer-coated microchannels for on-chip immunoassays. Anal Chem 73:165–69. Ying-Yan W, Tao W, Xin L. (2008). The analysis of chemotherapy resistance in human lung cancer cell line with microchip-based system. Biomed Microdevices 10: 429–35. Zhao L, Wang Z, Fan S, Meng Q, Li B, Shao S, Wang Q. (2010). Chemotherapy resistance research of lung cancer based on micro-fluidic chip system with flow medium. Biomed Microdevices. Zhu X, Yi Chu L, Chueh BH, Shen M, Hazarika B, Phadke N, Takayama S. (2004). Arrays of horizontally-oriented mini-reservoirs generate steady microfluidic flows for continuous perfusion cell culture and gradient generation. Analyst 129(11): 1026–31.
c04.indd 81
1/12/2011 9:44:04 AM
CHAPTER 5
Missing Dimension: Protein Turnover Rate Measurement in Gene Discovery GARY GUISHAN XIAO
Contents 5.1 Protein Turnover as Significant Missing Dimension in Gene Function and Discovery 5.2 Determination of the Rate of Turnover of Specific Proteins 5.3 Future Direction 5.4 Questions and Answers 5.5 Acknowledgments 5.6 References
83 84 89 90 90 90
5.1 PROTEIN TURNOVER AS SIGNIFICANT MISSING DIMENSION IN GENE FUNCTION AND DISCOVERY Multiple levels of analysis are normally exploited in functional genomics, including genome, transcritome, proteome, and metabolome. The dynamic changes of those molecules (mRNAs, proteins, and metabolites) depend on the physiological, developmental or pathological state of living cells (Pratt et al., 2002). A change in the proteome may be the most important for the analysis of gene function and interaction. Because of a wild range of protein concentration in cells, it is also the most difficult to study in a truly comprehensive manner. Standard proteomics usually compares amounts of proteins in cells in two different states (e.g., disease vs. normal) or conditions (e.g., treatment vs. non treatment) (Xiao et al., 2008b); it does not address the dynamics of the proteome in the different biological states that are being compared, nor does it provide information about the mechanisms whereby the system changes from one state to the other. Protein turnover, which is also Gene Discovery for Disease Models, First Edition. Edited by Weikuan Gu, Yongjun Wang. © 2011 John Wiley & Sons, Inc. Published 2011 by John Wiley & Sons, Inc.
83
c05.indd 83
1/12/2011 9:44:04 AM
84
MISSING DIMENSION: PROTEIN TURNOVER RATE MEASUREMENT IN GENE DISCOVERY
known as protein accretion, is the balance between protein synthesis and protein degradation (or breakdown). To illustrate, an increase in the level of expression of a protein could be achieved by an enhanced rate of synthesis, or a diminished rate of degradation (Pratt et al., 2002; Xiao et al., 2008a; Zhao et al., 2009a). Protein turnover is believed to decrease with age in all senescence organisms, including humans. This results in an increase in the amount of damaged protein within the body. It is unknown if this is a cause or consequence of aging, but it seems likely that it is in fact both. The damaged protein results in a slower protein turnover, which then results in more damaged protein causing an exponential increase in damage to all protein within the body and to aging. Protein turnover is being considered as a missing dimension in proteomics for biomedical research (Pratt et al., 2002). The dynamics of protein turnover is another key feature to the understanding of regulation of protein expression and protein–protein interaction in cells (Xiao et al., 2008a; Zhao et al., 2009a). The level of expression of a protein depends on the rates of its synthesis and degradation. Thus the turnover of a protein is an important indicator of its functional significance in cells. Despite its evident importance, the role of protein turnover has not previously been considered in analyses of the proteome. Protein turnover can be quantified on a protein-by-protein basis.
5.2 DETERMINATION OF THE RATE OF TURNOVER OF SPECIFIC PROTEINS The dynamics of protein turnover is key to the understanding of regulation of protein expression in cells (Doherty et al., 2005; Pratt et al., 2002). Unlike other quantitative proteomics methods using stable isotope labeling of protein after its synthesis such as in ICAT (Gygi et al., 1999) and iTRAQ (Gan et al., 2007) measurement of protein synthesis requires labeling of protein in vitro or in vivo using pathways of protein synthesis and amino acid metabolism (Pratt et al., 2002; Xiao et al., 2008a; Zhao et al., 2009a). In general, measurement of protein synthesis depends on the use of precursor–product relationship. For example, when a radioactive amino acid is used to trace protein synthesis, one has to first determine the specific activity of the radioactive amino acid in the cell and the specific activity of the same amino acid in the protein of interest (Fern and Garlick, 1974). With the advent of mass spectrometry, many stable isotope methods have been developed for the estimation of protein turnover (Busch et al., 2006; Cargile et al., 2004; Papageorgopoulos et al., 1999, 2002; Pratt et al., 2002; Previs et al., 2004). In these methods precursor enrichment is either determined directly or indirectly. In the deuterated water methods of Busch et al. (2006) and Previs et al. (2004), plasma alanine enrichment is used as the precursor enrichment, and fractional synthesis is determined from the ratio of alanine enrichment in protein to its enrichment in plasma. Precursor enrichment can also be determined indirectly by isotopomer ratio method
c05.indd 84
1/12/2011 9:44:04 AM
DETERMINATION OF THE RATE OF TURNOVER OF SPECIFIC PROTEINS
85
such as those established for fatty acid synthesis using MIDA (Lee et al., 1992, 1994). Such an approach was employed in the recent method of Doherty et al. (2005), where relative isotope abundance was estimated from peptides containing two or three molecules of leucine. Depending on how precursor enrichment is estimated, the approach by which enrichment in the labeled protein is determined also differs in these published methods for measurement of protein turnover. Recently, we developed a general method for determination of protein synthesis using deuterated water and mass isotopomer distribution analysis (Xiao et al., 2008a). The approach is based on the concept that mass isotopomer distribution in the newly synthesized protein due to isotope incorporation is a concatenation of 13C isotopomers from 13C natural abundance with 2 H isotopomers. Precursor and product enrichment can be determined by comparing the labeled and unlabeled spectra. Fraction of protein synthesis (FSR) is provided by the ratio of the old and new isotopomer distributions. Our method differs from the methods of Busch et al. (2006) and Previs et al. (2004) in that enrichment of 2H in amino acids and in the peptide is determined from mass isotopomer distribution and average mass of the peptide. Once precursor enrichment is known, protein synthesis is determined from isotopomer distribution and average mass of the peptide similar to the approach of Vogt et al. (2003, 2005). This novel method for measuring protein turnover rate was further much improved. We extended the application of this new technique of mass isotopomer distribution analysis for in vitro research using 15N labeling to illustrate the handling of spectral data when precursor enrichment is high, resulting in sufficient mass shift in the new protein. Since the change in average mass (mass shift) of a new peptide is given by the product of the number of nitrogen atoms (NN) in the peptide and the average enrichment of 15N in the amino acids (p′), the 15N enrichment can be estimated from the mass shift by curve fitting (Fig. 5.1), and the expected isotopomer distribution of the new peptide can be generated by the concatenation function. FSR can be calculated by multiple linear regression analysis of the observed peptide spectrum on the expected new and the old (unlabeled) spectra. Since the method for determining precursor and product enrichment dictates the nature of the isotope and its infusion as well as the sensitivity and precision in estimating protein turnover of proteins with widely different half-lives, the approach described for use of low enrichment of deuterated water (Xiao et al., 2008a) and 15N amino acids should be generally applicable in most in vivo and in vitro studies of quantitative proteomics. The isotopomer distribution of a peptide is the concatenation of isotopomers from stable isotope species. For example, isotopomer distribution of a protein synthesized in the presence of 15N amino acids is the result of concatenation of the isotopomers contributed by natural abundance of 13C and the isotopomers contributed by the 15N in amino acids. When the natural abundance of the stable isotope species is low (e.g., 15N and deuterium), the mass
c05.indd 85
1/12/2011 9:44:04 AM
86
MISSING DIMENSION: PROTEIN TURNOVER RATE MEASUREMENT IN GENE DISCOVERY
0.4 13
C N Concatenation
Molar Fraction
15
0.3 Ncp 0.2
Nnp´ Ncp + Nnp´
0.1
0.0
0
2
4
6
8
10
12
14
16
18
Isotopomer
Figure 5.1. The isotope envelops of three theoretical mass isotopomer distributions showing effect of concatenation. The first curve (䉬) is that of the distribution of 13C isotopomers calculated from a binomial distribution assuming the carbon number to be 94 and the natural enrichment of 13C to be 0.0111. The second curve (䊏) represents the distribution of 15N isotopomers with a nitrogen number of 21 and an enrichment of 0.333. The third curve (䉱) is that of concatenation of these two distributions representing the newly synthesized protein after incorporation of 15N. The sum of molar fractions for each curve is 1. Reprinted with Permission from Zhao et al. (2008).
shift of the isotope envelope formed by the isotopomers can be shown to be a function of N, the number of positions that can be substituted, and p, the enrichment of the isotope in question. The observed spectrum of a peptide (both preexisting and newly synthesized) is then linear combination of isotopomers of natural (unlabeled) and the expected labeled peptides, and the ratio of labeled to the total isotopomers provides a molar fraction of the newly synthesized protein. Since the presence of 13C and 15N in an amino acid are independent of each other and are not mutually exclusive, the spectrum of the labeled peptide can be constructed using the concatenation operation on the 13C and 15N isotopomers. The 13C isotopomer distribution of a hypothetical natural peptide and 15 N isotopomer distribution of a labeled peptide show a typical binomial distribution (Fig. 5.1). The mean and variance of the 13C isotopomer distribution around the monoisotopic peak (m0) are NCp and NCp(1 − p), respectively, where NC is the number of carbon atoms in the peptide, and p is the natural abundance of 13 C. Similarly, the mean and variance of the 15N isotopomer distribution are NNp′ and NNp′(1 − p′), respectively, and p′ is the average 15N enrichment. The isotopomer distribution after concatenation is also shown in Figure 5.1.
c05.indd 86
1/12/2011 9:44:04 AM
DETERMINATION OF THE RATE OF TURNOVER OF SPECIFIC PROTEINS
87
The mean and variance of the new distribution is given by (NCp + NNp′) and [NCp(1 − p) + NNp′(1 − p′)], respectively. The mass shift of the new distribution is [(NCp + NNp′) − NCp] = NNp′. Therefore, the mass shift is a function of the 15N isotopomer distribution. Because NN can be determined from the known peptide sequence, the 15N enrichment (p′) can be determined by curve fitting (mass shift/NN). Once the natural isotopomers and the 15N isotopomers are known, the isotopomers of the 13C- and 15N-labeled peptide can be constructed using concatenation operation. The resultant distribution is the expected distribution of the new peptide and can be used to determine newly synthesized fraction. This novel method (Zhao et al., 2009a, 2009b) has been successfully applied to cancer research in hope for discovery of biomarker and drug target (Xiao et al., 2008a; Zhao et al., 2009b). Understanding the principles that govern cancer responses to small molecule metabolic inhibitors and to drugs targeting specific signaling pathways remains a major challenge in the development of chemotherapeutic agents. The alteration of intracellular signaling pathways by extrinsic growth factors or by mutation is currently the basic premise on which development of chemopreventive and chemotherapeutic targets is based. In a recent study of pancreatic cancer, we used this method to study protein dynamics in pancreatic cancer cells MIA PaCa-2 in response to treatment of oxythiamine (OT), a transketolase inhibitor in the pentose phosphate cycle of glycolysis pathway. In that study, we investigated the effect of inhibition of the transketolase pathway on signaling pathways in MIA PaCa cancer cells using the newly developed proteomic techniques described above (Fig. 5.2). MIA PaCa-2 cells were cultured in media containing an algal 15N amino acid mixture at 50% enrichment, with and without OT, to determine protein expression and synthesis. Analysis of cell lysates using 2-DE-MALDI-TOF/TOF MS identified 12 phosphor proteins that were significantly suppressed by OT treatment. Many of these proteins are involved in regulation of cycle activities and apoptosis. Among the proteins identified, expression of the phosphor heat shock protein 27 (Hsp27) was dramatically inhibited by OT treatment, while the level of its total protein remained unchanged. Hsp27 expression and phoshporylation are known to be associated with drug resistance and cancer cell survival. The changes in phosphorylation of key proteins of cancer proliferation and survival suggest that protein phosphorylation is the confluence of the effects of OT on metabolic and signaling pathways. This study revealed that a small molecule metabolic inhibitor such as OT, through its metabolic action can result in specific and nonspecific inhibition of translational and posttranslational changes in signaling molecules. Our understanding of the cellular metabolic network would suggest that the inhibition of a single metabolic pathway invariably results in metabolic inefficiency of other metabolic reactions in the network (Lee, 2006). Inhibition of the transketolase reaction may cause a global deficiency in high-energy phosphate bonds, resulting in nonspecific decrease in phosphorylation of proteins. Depending on the enzymatic properties of these kinases, the decrease in
c05.indd 87
1/12/2011 9:44:04 AM
88
MISSING DIMENSION: PROTEIN TURNOVER RATE MEASUREMENT IN GENE DISCOVERY
Intensity × 104 (a.u.)
(a)
4 Da
Intensity (a.u.)
(b)
m/z
Figure 5.2. Mass spectra of 960 m/z fragment from Hsp27 of lysates of cells grown in the presence of (a) natural amino acids and (b) 50% enriched 15N algal amino acid mixtures. The spectrum of control in panel a shows the binomial distribution of isotopomic peaks largely due to natural existence of 13C. Incorporation of 15N resulted in an obvious mass shift in isotopomic distribution. The synthesis rate of a protein was based on the isotopomer distribution of these two spectra.
phosphorylation may appear to be specific, as illustrated by the phosphorylation of Hsp27. We found that phosphor proteins that are sensitive to OT inhibition have high turnover rates (>60%), suggesting that the function of these proteins are regulated by both protein synthesis and protein degradation. The intracellular concentration of a protein depends on its synthesis and breakdown. Therefore, protein concentration can be controlled either by changes in its synthesis or degradation. It is generally held that the turnover rate of a protein must be high in order for it to change its concentration quickly inside a cell. Our finding
c05.indd 88
1/12/2011 9:44:04 AM
FUTURE DIRECTION
89
of relatively high turnover rates in these signaling proteins is in agreement with this view and suggests that the determination of protein turnover may be useful to identify the signaling target in chemotherapy. As reported in our previous study, in contrast with SILAC, labeling of proteins with low enrichment of 15N amino acids mixture (mSILAC) provides a characteristic isotope envelop of the peptide spectrum, which can be used for the determination of newly synthesized fraction (Zhao et al., 2009a, 2009b). The importance of the secreted protein can be ranked by its synthesis rate. In another study, we identified secreted proteins from cultured MIA PaCa-2 pancreatic cancer cells and their response to OT treatment using 15N amino acids and serum-free media (Xiao et al., 2010). Using two-dimensional gel electrophoresis (2-DE), we detected 14 differentially expressed proteins in media of control (untreated) and OT-treated cells. Among the proteins identified, tissue inhibitor of metalloproteases 1 (TIMP 1) and cytokeratin 10, two known pancreatic cancer biomarkers, were heavily labeled with 15N, and their expressions were inhibited by OT treatment. The results from ELISA assays with human pancreatic cancer sera showed that TIMP 1, although having a weaker signal than CA19–9, has the characteristics of a biomarker of pancreatic cancer. Thus labeling of proteins with 15N amino acids and serum-free medium is a potentially useful approach in serum biomarkers discovery using cell culture. In summary, the newly developed technology provides a general method for determination of protein synthesis rate using labeling of amino acids with deuterium or 15N at low enrichment (Xiao et al., 2008a; Zhao et al., 2009a). Modified SILAC can measure protein synthesis rate quantitatively based on analysis of mass isotopmer distribution (MIDA) of the newly synthesized protein (Xiao et al., 2008a; Zhao et al., 2009a). Once precursor enrichment is known, protein synthesis is determined from isotopomer distribution. This method obviates the need for the use of a 100% newly synthesized protein as a reference as in Vogt’s (2003, 2005) methods. The concatenation function provides an ideal 100% labeled spectrum, and multiple regression analysis uses all the information from the mass spectrum. Our mathematical algorithm represents a major improvement in the calculation of protein synthesis rate, permitting the use of isotope labeling of protein through the pathways of amino acid metabolism with low cost isotopes (Lee et al., 1992, 1994; Xiao et al., 2008a, 2008b; Zhao et al., 2009a, 2009b).
5.3
FUTURE DIRECTION
The recent development of mass spectrometry–based strategies for absolute protein quantification offers great opportunity for biomarker discovery. While the prospects of this technology are exciting and promising, the current methodology is far from perfect. First, most current methods require complicated sample preparation, such as immuno-subtraction, multidimensional LC separation, immunoaffinity and solid phase extraction, to enhance the analytical
c05.indd 89
1/12/2011 9:44:04 AM
90
MISSING DIMENSION: PROTEIN TURNOVER RATE MEASUREMENT IN GENE DISCOVERY
dynamic range and detection sensitivity. To establish a high-throughput pipeline, we should ideally have a one-step preparation. Second, useful and validated biomarkers are still rare based on these developed methods because low abundance biomarkers are always immersed in large quantities of routine proteins, especially in plasma samples. There is much room for improvement of sensitivity. 5.4
QUESTIONS AND ANSWERS
Q1. Which dimension is missed in current proteomics research? Q2. What are the advantages of mSILAC over classical SILAC? Q3. What art the limitations of this technique? A1. Current research (information obtained from a steady-state of cells) focuses on either gene expression in two states of the disease (disease vs. healthy) or conditions (treatments vs. control). As demonstrated by recent studies, protein turnover (protein dynamics) can truly reflect cellular physiology and function, which are the dimensions missed in current proteomics studies in biomedical research. A2. There are three advantages that mSILAC offers compared to conventional SILAC. (1) More dynamics protein information can be obtained. (2) It is fast and economic; this technique requires an experimental time of 2 days and low concentrations of stable isotope (e.g., as low as 5–10% stable isotope enrichment), whereas SILAC requires an experimental time of 1 week and a 100% enrichment of stable isotope used for the experiment. (3) Unique algorithms deal with overlapped isotope envelops (as shown in Figure 5.2). A3. This technique must be improved for the analysis of low abundance proteins. 5.5
ACKNOWLEDGMENTS
This work is fully supported by grants awarded to Dr. Gary Guishan Xiao (GGX) from the Bone Biology Program of the Cancer and Smoking Related Disease Research Program and the Nebraska Tobacco Settlement Biomedical Research Program (LB692, LB595, and LB506). 5.6
REFERENCES
Busch R, Kim YK, Neese RA, Schade-Serin V, Collins M, Awada M, Gardner JL, Beysen C, Marino ME, Misell LM, Hellerstein MK. (2006). Measurement of protein
c05.indd 90
1/12/2011 9:44:04 AM
REFERENCES
91
turnover rates by heavy water labeling of nonessential amino acids. Biochim Biophys Acta 1760(5):730–44. Cargile BJ, Bundy JL, Grunden AM, Stephenson JL Jr. (2004). Synthesis/degradation ratio mass spectrometry for measuring relative dynamic protein turnover. Anal Chem 76(1):86–97. Doherty MK, Whitehead C, McCormack H, Gaskell SJ, Beynon RJ. (2005). Proteome dynamics in complex organisms: using stable isotopes to monitor individual protein turnover rates. Proteomics 5(2): 522–33. Fern EB, Garlick PJ. (1974). The specific radioactivity of the tissue free amino acid pool as a basis for measuring the rate of protein synthesis in the rat in vivo. Biochem J 142(2):413–19. Gan CS, Chong PK, Pham TK, Wright PC. (2007). Technical, experimental, and biological variations in isobaric tags for relative and absolute quantitation (iTRAQ). J Proteome Res 6(2):821–27. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. (1999). Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17(10):994–99. Lee WN, Bassilian S, Ajie HO, Schoeller DA, Edmond J, Bergner EA, Byerley LO. (1994). In vivo measurement of fatty acids and cholesterol synthesis using D2O and mass isotopomer analysis. Am J Physiol 266(5 pt 1):E699–708. Lee WN, Bergner EA, Guo ZK. (1992). Mass isotopomer pattern and precursor-product relationship. Biol Mass Spectrom 21(2):114–22. Lee WN. (2006). Characterizing phenotype with tracer based metabolomics. Metabolomics 2(1):31–39, 5–20. Papageorgopoulos C, Caldwell K, Shackleton C, Schweingrubber H, Hellerstein MK. (1999). Measuring protein synthesis by mass isotopomer distribution analysis (MIDA). Anal Biochem 267(1):1–16. Papageorgopoulos C, Caldwell K, Schweingrubber H, Neese RA, Shackleton CH, Hellerstein M. (2002). Measuring synthesis rates of muscle creatine kinase and myosin with stable isotopes and mass spectrometry. Anal Biochem 309(1):1–10. Pratt JM, Petty J, Riba-Garcia I, Robertson DH, Gaskell SJ, Oliver SG, Beynon RJ. (2002). Dynamics of protein turnover, a missing dimension in proteomics. Mol Cell Proteomics 1(8):579–91. Previs SF, Fatica R, Chandramouli V, Alexander JC, Brunengraber H, Landau BR. (2004). Quantifying rates of protein synthesis in humans by use of 2H2O: application to patients with end-stage renal disease. Am J Physiol Endocrinol Metab 286(4): E665–72. Vogt JA, Hunzinger C, Schroer K, Hölzer K, Bauer A, Schrattenholz A, Cahill MA, Schillo S, Schwall G, Stegmann W, Albuszies G. (2005). Determination of fractional synthesis rates of mouse hepatic proteins via metabolic 13C-labeling, MALDI-TOF MS and analysis of relative isotopologue abundances using average masses. Anal Chem 77(7):2034–42. Vogt JA, Schroer K, Hölzer K, Hunzinger C, Klemm M, Biefang-Arndt K, Schillo S, Cahill MA, Schrattenholz A, Matthies H, Stegmann W. (2003). Protein abundance quantification in embryonic stem cells using incomplete metabolic labelling with 15N amino acids, matrix-assisted laser desorption/ionisation time-of-flight mass
c05.indd 91
1/12/2011 9:44:04 AM
92
MISSING DIMENSION: PROTEIN TURNOVER RATE MEASUREMENT IN GENE DISCOVERY
spectrometry, and analysis of relative isotopologue abundances of peptides. Rapid Commun Mass Spectrom 17(12):1273–82. Xiao GG, Garg M, Lim S, Wong D, Go VL, Lee WN. (2008a). Determination of protein synthesis in vivo using labeling from deuterated water and analysis of MALDI-TOF spectrum. J Appl Physiol 104(3):828–36. Xiao GG, Recker RR, Deng HW. (2008b). Recent advances in proteomics and cancer biomarker discovery. Clin Med Oncol 2:63–72. Xiao J, Lee WN, Zhao Y, Cao R, Go VL, Recker RR, Wang Q, Xiao GG. (2010). Profiling pancreatic cancer-secreted proteome using 15N amino acids and serumfree media. Pancreas 39(1):e17–23. Zhao Y, Lee WN, Lim S, Go VL, Xiao J, Cao R, Zhang H, Recker RR, Xiao GG. (2009a). Quantitative proteomics: measuring protein synthesis using 15N amino acid labeling in pancreatic cancer cells. Anal Chem 81(2):764–71. Zhao Y, Lee WN, Xiao GG. (2009b). Quantitative proteomics and biomarker discovery in human cancer. Expert Rev Proteomics 6(2):115–18.
c05.indd 92
1/12/2011 9:44:05 AM
CHAPTER 6
Bioinformatics Tools for Gene Function Prediction YAN CUI
Contents 6.1 Gene Ontology: Description of Gene Function with Controlled and Structured Vocabulary 6.2 Sequence-Based Function Prediction 6.2.1 Annotation Transfer by Sequence Homology 6.2.2 Phylogenomic Methods for Function Prediction 6.2.3 Function Prediction Using Sequence Motif 6.3 Structure-Based Function Prediction 6.3.1 Protein Structure Comparison for Function Prediction 6.3.2 Predicting Functional Sites on Protein Surface 6.4 Function Prediction Using Integrated Data 6.4.1 Types of Data for Facilitating Function Prediction 6.4.2 Integrative Methods for Function Prediction 6.5 Questions and Answers 6.6 References
93 95 95 99 99 100 100 102 102 102 104 106 106
6.1 GENE ONTOLOGY: DESCRIPTION OF GENE FUNCTION WITH CONTROLLED AND STRUCTURED VOCABULARY Traditionally, gene functions are described in natural languages that are difficult for computers to process. A standardized and computer-readable system for gene function description must be developed for automated annotation of the huge amounts of sequence and structure data produced by the genome sequencing projects and structural genomics projects. Gene ontology (GO) Gene Discovery for Disease Models, First Edition. Edited by Weikuan Gu, Yongjun Wang. © 2011 John Wiley & Sons, Inc. Published 2011 by John Wiley & Sons, Inc.
93
c06.indd 93
1/12/2011 9:44:06 AM
94
BIOINFORMATICS TOOLS FOR GENE FUNCTION PREDICTION
1
Molecular function
2
3
4
5
6
7
Binding
Catalytic activity
Hydrolase activity Nucleic acid binding
Peptidase activity GZMB (IEA)
Endopeptidase activity
DNA binding
Protein binding MYC (IPI)
Transcription regulator activity
Transcription factor activity MYBL2 (TAS) Serine-type peptidase activity MYC (TAS) SOX4 (TAS)
Serine-type endopeptidase activity
Chymotrypsin activity Granzyme B activity GZMB (IEA) GZMB (TAS)
Trypsin activity GZMB (IEA)
Figure 6.1. Gene function annotation with gene ontology.
(Ashburner et al., 2000) is the most widely used gene function classification system. It uses well-structured and -controlled vocabularies to describe gene function. Gene ontology includes three independent ontologies: biological process, molecular function, and cellular component. Each ontology has a hi